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The present study investigated the effects of five African medicinal plants (Alstonia boonei, Acalypha 
wilkesiana, Boerhaavia diffusa, Bridelia ferruginea, and Crassocephalum rubens) for their 
antioxidative and antidiabetic potentials by using several experimental protocols. The crude extracts 
(ethyl acetate, ethanol and aqueous) of the different parts (leaves, stem bark, root bark or aerial parts 
when applicable) were initially investigated for their detailed antioxidant and antidiabetic activity 
using in vitro, ex vivo and in silico experimental models. Then the most active crude extract from 
each plant was chosen for further fractionation with the solvents of increasing polarity. The solvent 
obtained fractions were then subjected to screening in terms of their antioxidant, -glucosidase, -
amylase and lipase inhibitory activity in vitro and intestinal glucose absorption and muscle glucose 
uptake ex vivo. Results from these assays revealed that the butanol and aqueous fractions of A. boonei, 
butanol fraction of B. ferruginea, ethanol extract of A. wilkesiana and B. diffusa and the aqueous 
extracts of C. rubens showed the best activities in terms of all the tested models. The most active 
crude extracts and fractions were consequently subjected to GC-MS and LC-MS analyses in order to 
identify their bioactive components. Then the structures of the most bioactive components were 
docked with the tested enzymes using in silico modelling. The anti-diabetic effect of the butanol 
fractions of A. boonei and B. ferruginea together with the aqueous extract of C. rubens were 
investigated in an in vivo intervention trial using a type 2 diabetes rat model. The in vivo experiment 
revealed that the fractions and extract exhibited potent in vivo hypoglycaemic activity. Interestingly, 
these fractions were also able to alleviate T2D-associated complications involving oxidative stress. 
Analysis of in vivo oxidative stress markers such as superoxide dismutase, catalase, glutathione and 
thiobarbituric acid reactive substances, in the serum, liver, kidney, heart and pancreas of the animals 
also suggested their strong antioxidative effects. The results of this study suggest that the different 
extracts/fractions of the above-mentioned plants have promising anti-diabetic potentials; however 
further clinical trials are required in order to justify the usefulness of these plants for the development 
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INTRODUCTION AND LITERATURE REVIEW 
1.1 Background of study 
The word Diabetes was derived from a Greek word around 1500 BC and means to siphon since it was 
earlier associated with excessive wasting of essential minerals of the body through urination 
(Lakhtakia, 2013). This urine was discovered to have a sweet taste which then led to the Latin name 
diabetes which means honey sweet (Zajac et al., 2010). Diabetes mellitus is a complicated metabolic 
disease which is brought about by high blood glucose levels (hyperglycaemia) due to defective insulin 
signalling and function (De Felice and Ferreira, 2014). Hyperglycaemia produces symptoms such as 
excessive thirst (polydipsia), habitual urination (polyuria), unexplained weight loss and frequent 
eating (polyphagia). Insulin is a hormone synthesized in the pancreatic β-cells and is required to 
effectively use glucose from digested food as an energy source (Chase et al., 1989). A spike in glucose 
levels due to postprandial digestion of food triggers insulin to transport the glucose to the needed 
peripheral organs for utilization (Geijselaers et al., 2017; Nolan et al., 2015). Insulin functions 
effectively by increasing glycogenesis and transport of glucose to the liver, muscle and adipose 
tissues. Insulin resistance leads to chronic hyperglycaemia generating anomalies in complex sugars, 
protein and fatty acid metabolism (Nolan et al., 2015).   
Diabetes can be controlled by different types of treatment modalities the most common of which is 
the use of synthetic drugs. These drugs though sometimes effective when used singly or in 
combination with other drugs, are not without side effects. Examples of these drugs are: metformin 
(a biguanide), insulin, rosiglitazone (a thiazolidinedione) with side effects such as nausea, weight 
gain/lost, high cost and lactic acidosis amongst others (Chaudhury et al., 2017). Interestingly 
traditional medicine could be effective in the treatment and control of diverse diseases. This is because 
plants contain phytochemicals which could render synergistic functions in the treatment of diseases 
such as diabetes. Several researches have mentioned the efficacy of medicinal plants in the 
management of diabetes (Choudhury et al., 2017; Mohammed et al., 2014). The vast array of 
medicinal plants gives more opportunities for researchers to carry out more studies with a view to 
harness the spread of diseases using medicinal plants. Many of these medicinal plants are currently 
being used by traditional healers for the treatment of diabetes but scientific evidence behind the use 
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of many of these medicinal plants is still unknown despite the rapidly growing prevalence of diabetes 
globally. 
1.2 Prevalence of diabetes 
Presently, over 422 million cases of diabetes have been recorded, which means 1 in 11 people in the 
world has diabetes and there will be an estimated increase by 2030 to 640 million cases i.e. 1 in 10 
people will have diabetes (Conway et al., 2018; WHO, 2016). This increase can be linked to factors 
such as change in diet, urbanization, sedentary lifestyles, aging and increasing population. There has 
been a global rise of diabetic cases as compared to the year 1980 where only 108 million cases were 
recorded as diabetic (IDF, 2015). This increase can be noticeable mostly in those in the age range of 
20-65 years (Conway et al., 2018).  
An increase in the number of deaths due to complications of diabetes has also been recorded: 3.96 
million deaths were recorded amongst adults aged 20 - 79 years in 2010. This number has risen to 5 
million in 2015; signifying a 26 % increase within the 5-year period (Zheng et al., 2018). Statistics 
also show that, as at 2017, 3.2 million deaths have been recorded for the  age range of 60 - 99 years 
(Cho et al., 2018) (Table 1.1). The rise in diabetes has a high impact on the economy globally. Factors 
like high cost of drugs, loss of productivity and premature deaths negatively impacts on a nation’s 
Gross Domestic Product (GDP) (Bouguerra et al., 2007; Edelman and Polonsky, 2017). 
Table 1.1: Global estimates of adults above 60 living with diabetes (IDF, 2017). 
 2017 2045 
Number of adults (65-99 years) 652.1 million 1.42 billion 
Incidence (65-99 years) 9.6% 17.9% 
Number of people living with diabetes (65-99 years) 122.8 million 253.4 million 
Number of deaths from diabetes (60-99 years) 3.2 million Not yet determined 
Total healthcare cost for diabetes (60-99 years) 527 billion 615 billion 
 
Africa has the most recorded number of undiagnosed cases of diabetes in the world, over 69.2% (two-
thirds) of people are living with diabetes without knowing (IDF, 2017).  Though the rate of diabetes 
is relatively low in Africa compared to other regions of the world (Figure 1.1), in 2017, the number 
of people living with diabetes was found to be 16 million, this number is estimated to rise to 41 
million by 2045 (IDF, 2017).  This shows a 156% increase which is the highest rate of increase 
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compared to other areas of the world. In South Africa, the prevalence of diabetes increased from 5.5% 
to 9% within 2000 to 2009, and also showed the second highest mean health care expenditure in the 
African region as a whole (Manyema et al., 2015). 
 
Figure 1.1: Estimate number of diabetes cases globally in 2017 and projected increase by 2045 
(Adapted without permission from IDF Diabetes Atlas, 2017). 
1.3 Etiologic categories of diabetes mellitus 
Classifying diabetes is broadly based on presumed etiology (risk factors), symptoms and causes. In 
1998, the WHO proposed a classification method based on the etiological factors presented, though 
many patients do not always fit into only a particular type of diabetes. For example, a pregnant woman 
diagnosed with Type 3 diabetes (gestational diabetes) may still be hyperglycemic after birth and later 
diagnosed with type 2 diabetes (ADA, 2016). Anyway, diabetes mellitus is mainly classified into two 
major classes: type 1 diabetes (T1D) or insulin dependent diabetes mellitus (IDDM) and type 2 
diabetes (T2D) or non-insulin dependent diabetes mellitus (NIDDM). Gestational diabetes mellitus 
(GDM) is also very common which normally occurs during pregnancy. 
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1.3.1 Type 1 diabetes (T1D) or insulin dependent diabetes mellitus (IDDM) 
Formally known as juvenile onset diabetes, this type of diabetes is a self-destroying (autoimmune) 
condition, whereby the body’s immune system attacks the pancreatic β-cells initiating insulin 
deficiency (Loghmani, 2005; Motala et al., 2003). Islet cell autoantibodies, autoantibodies to insulin 
and GAD (GAD65) and autoantibodies to the tyrosine phosphatases (1A-2 and 1A-2β) are identified 
as the markers for autoimmune destruction of the pancreatic β-cells (ADA, 2010). Most cases of T1D 
have exhibited presence of islet cells antibodies in the blood. These antibodies can be detected in 
human blood for several years before the onset of T1D. Children and babies are more prone to this 
disease because β-cell dysfunction occurs faster  young age compared to adults. Additionally, it is 
also suggested that environmental factors such as toxins, diets and enteroviruses can induce the 
generation of T-cell dependent autoimmunity in genetically susceptible individuals leading to T1D 
(Devendra et al., 2004). T1D holds the lowest prevalence (about 5%) of all diabetic cases (Fonseca, 
2009).  
Symptoms of T1D include polydipsia (excessive thirst), polyuria (increased urination), polyphagia 
(unexplained hunger) and persistent hyperglycaemia. The treatment for T1D usually involves the 
injection of insulin before complications of ketoacidosis and coma occurs and this usually spans 
through a lifetime (Atkinson, 2012). Unfortunately, no treatment to date has been able to prevent the 
onset or progression of T1D in those at risk (Siddiqui et al., 2013). 
1.3.2 Type 2 diabetes (T2D) or non-insulin dependent diabetes mellitus (NIDDM)  
This category of diabetes accounts for 90-95% of all diabetic cases. It presents in individuals with 
sustained insulin resistance followed by moderate insulin deficiency. T2D has recently been classified 
as a progressive disease since the function of pancreatic 𝛽-cells reduces over time (Fonseca, 2009). 
Conditions like increased serum low density lipoprotein (LDL), low serum high density lipoprotein 
(HDL) concentrations, hypertension and increased risk of cardiovascular diseases usually follow the 
detection of T2D if left unmanaged (Costacou et al., 2011; Stamler et al., 1993; Van Linthout et al., 
2010; von Eckardstein and Widmann, 2014). All of these diseases are defined together as metabolic 
syndrome (Alshehri, 2010; Ford, 2005). Diet, sedentary life style and urbanization are the main 





1.3.3 Gestational diabetes mellitus (GDM)  
This type of diabetes describes the signs of hyperglycemia experienced during pregnancy which 
disappear immediately after the termination of pregnancy (Bortolon et al., 2016; Qazi et al., 2016). 
In GDM, progesterone, chorionic somatomammotropin, stress and growth hormones induce insulin 
resistance which leads to maternal hyperglycemia and hyperinsulinemia in neonates (Kampmann et 
al., 2015). The existence of GDM during pregnancy is considered as one of the major risk factors of 
T2D in later life and about 90% of all pregnancies with GDM are complicated compared to non-
diabetic pregnancy (Leon et al., 2016). According to the International Diabetes Federation (IDF), 
16% of children born during 2013 had complications due to high blood glucose of their pregnant 
mothers (IDF, 2017). This number has been proposed to be increased due to the rise of obesity and 
sedentary lifestyle among adults (Kelley et al., 2015). The risk factors of GDM include, increased 
mothers’ age, visceral adiposity, polycystic ovarian syndrome, hereditary, hypertension and finally 
the delivery of larger babies. 
1.4 The role of insulin in the pathogenesis of T2D  
After food is ingested, carbohydrate in the food is broken down to glucose, when the insulin is 
responsible for carbohydrate homeostasis by inducing glucose transport to the muscle and adipose 
tissue for energy production and reducing the production of more glucose by the liver (Figure 1.2) 
(Porte, 2006). Insulin is produced in the β-cells of the pancreas and an anomaly in the secretion and 
action of this hormone has been implicated in the generation of diabetes (Cerf, 2013). 
High levels of glucose in the blood is the first trigger of insulin production. When glucose enters the 
cell, it is phosphorylated by glucokinase to glucose-6-phospahtase (G6P) to release energy in the form 




Figure 1.2: The Endocrine System. Source: Barnes (2015) 
When the channel is closed, it causes a depolarization and stretching of the cell membrane which 
leads to an influx of calcium ions. Fusion of the insulin vesicles cell membrane on the outer β-cell 
membrane thus causes the entry of insulin into the blood stream. Additionally, glucagon like peptide-
1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) might be able to activate protein kinase-
C and phospholipase through activation of adenyl cyclase activity and stimulation of β-cell protein 
kinase A which could account for the second phase synthesis of insulin (Wilcox, 2005).  
1.4.1 Insulin resistance 
This is a complex metabolic condition that occurs when the organs in the body becomes numb to the 
action of insulin. Prevailing insulin resistance happens when high blood glucose level does nothing 
to trigger insulin action. It is one of the two major reasons for the development of T2D (Taylor, 2012; 
Weyer et al., 2001). Normally, β-cells of the pancreas act on insulin resistance by intensifying the 
synthesis of insulin to act on the need of glucose by the tissues (Halban et al., 2014).  
The rise in blood glucose leads to induction of insulin secretion at the same time reducing the 
secretion of glucagon. This shows that low levels of blood glucose lead to reduction of insulin 
secretion and increase in glucagon synthesis.  Which indicates that these actions are all dependent on 
glucose and necessary to sustain glucose homeostasis (Guo, 2014). A number of conditions have been 




1.4.2 Mechanisms behind insulin resistance 
a. Dysfunction of pancreatic β-cell and insulin resistance 
The combinatorial action of β-cell dysfunction and insulin resistance results in persistent high glucose 
level, particularly in type 2 diabetic condition (Lorenzo et al., 2010). The pancreatic β-cell 
dysfunction causes more problems than insulin resistance due to the lack of insulin for glucose 
metabolism (Cerf, 2013). The β-cell must be in a healthy state in order to meet the metabolic demand 
for the production of insulin, when decrease β-cell mass has been reported in T2D (Butler et al., 
2003). However, hyperglycaemia has been attributed to the function but not the quantity of the β-
cells (Ashcroft and Rorsman, 2012).  
b. Impaired insulin-dependent PI3K activation 
In a high blood glucose state, the skeletal muscle is the main site for disposal of glucose by insulin 
hence resistance to the action of insulin in muscle is a key feature of either type 1 or T2D (DeFronzo, 
2015; Yki-Järvinen et al., 1990). The glucose transporter 4 (Glut 4) stimulates insulin action to 
effectively transport excess glucose to the skeletal muscle. There is normal occurrence of the Glut 4 
gene (Figure 1.3) in the skeletal muscle of normal subjects and an impairment of glucose uptake 
might occur as a result of impaired Glut 4 gene expression or impaired insulin signalling pathway 
(Choi and Kim, 2010; Garvey et al., 1988; Kim et al., 1999,). 
The signalling of insulin involves the binding of insulin to its required cell surface receptor through 
self-phosphorylation and induction of receptor tyrosine kinases which in turn results in tyrosine 




Figure 1.3: Insulin receptor and glucose transport (Adapted without permission from Nath, 2015). 
Phosphoinositide 3-kinase (PI3K) becomes activated through the binding to the IRS which in turn 
phosphorylates membranous phospholipids and phosphatidylinositol 4,5-bisphosphate (PIP2). This 
formed complex activates Akt/protein kinase B (PKB) and serine/threonine kinases C λ and ζ (PKC 
λ/ζ) through the activation of 3-phosphoinositide dependent protein kinase (Figure 1.3). Movement 
of insulin-activated GLUT 4 from the intracellular vesicles into the plasma membrane is favoured by 
the activated Akt phosphorylation (Farese et al., 2005; Sale and Sale, 2008).  
The insulin receptor can also be deactivated and dephosphorylated by the members of the protein 
tyrosine phosphatases and this can cause negative insulin action and glucose metabolism (Harley and 
Levens, 2003). Indeed, the PI3K pathway (Figure 1.4) is an important part of the insulin signalling 
cascade which is paramount to the correct action of insulin in transporting glucose to the needed 
organs. Therefore, an impairment in this pathway can lead to defective insulin signalling, thereby 




Figure 1.4: The insulin signalling pathway (Adapted without permission from Choi and Kim, 2010).  
c. Fatty acid-induced insulin resistance 
Consuming food high in dietary fat causes lipid overload and ultimately insulin resistance in organs 
(muscle and liver). Over time, overexposure of the skeletal muscle to high levels of saturated long 
chain fatty acids leads to insulin resistance, particularly in overweight and obese individuals. 
Abdominal obesity has also been implicated in sustained insulin resistance in T2D (Kahn and Flier, 
2000; Ye, 2013). This link comes from the theory that insulin stimulates the synthesis of fatty acids 
and glycogen but in some cases some obese individuals have been seen not to develop persistent 
hyperglycemia but insulin resistance (Kahn et al., 2006). The high prevalence of T2D among youths 
can be linked to obesity which is seen in the recent years. 
High intake of calories with little output of energy leads to increase in size of adipose tissue depots 
which results in obesity, availability of these depots varies from one person to another and that is why 
not all obese individuals are at risk of developing hyperglycemia (Lee et al., 2016). Obesity leads to 
an increased generation of proinflammatory cytokines, glycerol, leptin and adiponectin hormones 
which aid in loss of insulin sensitivity (Hardy et al., 2012). Hyperplasia in the adipose tissues induces 
the formation of inflammatory cytokines which might be involved in the induction of hyperglycemia 
and insulin resistance. On the other hand, high concentration of adipose tissue leads to increase in 
circulating non-esterified fatty acids (NEFAs) which in turn causes high fat storage in the muscle and 
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liver (Al-Goblan et al., 2014). The increase of NEFAs in the serum leads to a associated increase in 
insulin resistance. Interestingly, the use of antilipolytic agents leads to improved insulin function and 
glucose homeostasis. 
The function of insulin is not only limited to blood glucose regulation, storage and optimum utility, 
fat metabolism is also taken care of by insulin. This occurs by the inhibition of lipolysis through 
increased lipogenesis and induction of fatty acid uptake which leads to an abundance of energy in the 
fasting state (Poloz and Stambolic, 2015).  
Insulin exerts its aforementioned functions through the family of tyrosine kinase receptors and insulin 
growth factor-insulin receptor (IGF-IR). Insulin improves glucose homeostasis by increasing the 
levels of GLUT4 proteins in the plasma membrane (Furtado et al., 2002). Without the action of 
insulin, GLUT4 reclines within the plasma membrane and vesicular compartments of the cell. Insulin 
stimulates the movement of GLUT4 through exocytosis consequently reducing the endocytosis of 
GLUT4 (Jhun et al., 1992; Rea and James, 1997). 
1.5 Complications of diabetes 
1.5.1 Inflammation 
In 1998, a research proposed that inflammation as a result of persistent immune system activation 
could aggravate instead of attenuate complications of diseases such as T2D (Pickup and Crook, 1998). 
Over the years some study has backed up this assertion (Cefalu, 2009; Crook, 2004). Inflammation 
as a result of insulin resistance and impaired glucose tolerance can be said to be the first pathological 
feature in complications associated with T2D (King, 2008). The exact mechanism by which 
inflammation can evoke T2D is still not clear (Navarro and Mora, 2005). Inflammatory markers, pro-
inflammatory cytokines, tumour necrosis factor-alpha (TNF-α), interleukin-1 and interleukin-6 (IL-1 
and IL-6), immune cells (monocytes chemoattractant protein-1: MCP-1) produced by the adipose 
tissues are linked to the accumulation of body fat (Mahmoud and Al-Ozairi, 2013; Navarro and Mora, 
2005). The pro-inflammatory cytokines are associated with multiple pathways linked to insulin 
resistance and adipocyte function. The increase of these cytokines in the cell leads to the production 
of C-reactive proteins (CRP) which are acute phase proteins. Hyperglycemia and high fatty acids can 
also trigger inflammation by increasing glucose utilization and alterations in oxidative 
phosphorylation concomitantly (Zhou et al., 2010).  Oxidative stress and inflammation can lead to β-




1.5.2 Endothelial/mitochondrial dysfunction 
The mitochondria provide an avenue for the generation of ATP in other words energy for the cell 
hence they are called the power houses of the cell. ATP is necessary for the smooth running of the 
cell or metabolic processes and  dysfunction in the generation of ATP will lead to defects in the 
metabolic process. Mitochondrial malfunction has been associated with insulin resistance as well as 
the complications of T2D (Montgomery and Turner, 2015). This malfunction expresses itself by 
reduction in mitochondrial activity, decrease in mitochondrial oxidative phosphorylation processes 
or increase in production of reactive oxygen species (ROS) (Montgomery and Turner, 2015). Cells 
of patients with T2D have shown decreased mitochondrial quality and less ATP and mitochondrial 
RNA (mRNA) production (Leguisamo et al., 2012). Interestingly, mitochondria are the main site for 
the initiation of reactive oxygen species (ROS). 
1.5.3 ROS formation and oxidative stress in the complication of T2D 
Reactive oxygen species (ROS) are formed from the intermediates of oxygen obtained from the 
metabolism of the food we eat (Choe and Min, 2006). ROS refers to diverse chemicals with reactive 
properties which are capable of gaining or donating electrons (Tangvarasittichai, 2015). Complex I 
and III of the electron transport chain in the mitochondria routinely releases superoxide a form of 
ROS through oxidative phosphorylation (OXPHOS) (Choe and Min, 2006). At physiological pH, the 
superoxide gets catalysed by superoxide dismutase (SOD) to give hydrogen peroxide (H2O2), which 
is converted to water and oxygen by another anti-oxidative enzyme, catalase. The superoxide ions 
later lead to the production of hydroxyl radical through different steps where redox metals such as 
copper and iron are involved, and pancreatic beta cells are very vulnerable to hydroxyl radicals.  
Some other previous studies reported that the polyol is responsible for the generation of ROS followed 
by the generation of advanced glycation end products (AGE) and high expression of their receptors 
and ligands, protein kinase C activation and increased activity of the hexosamine pathway (Figure 





Figure 1.5: Pathways necessary for production of reactive oxygen species (ROS) (Adapted without 
permission from Tang et al., 2012). 
The increased production of ROS through these pathways leads to insulin resistance and β-cell 
dysfunction.  
a. The polyol pathway 
Under normal conditions in the cell, the glycolytic pathway is activated by the phosphorylation of 
glucose to glucose 6-phosphate by hexokinase and a small amount of the un-phosphorylated glucose 
enters into the polyol pathway (Tang et al., 2012). However, hyperglycemic conditions present with 
an increased influx of sugars through the polyol pathway of which rate limiting step is the 
transformation of glucose to sorbitol through the aldose reductase enzyme with reduced nicotinamide 
adenosine dinucleotide (NADPH) as a cofactor (González et al., 1984). The increased utilization of 
NADPH then leads to an increased redox stress since NADPH is required to also generate GSH, a 
potent antioxidant. Studies have shown that increased expression of aldose reductase in diabetic mice 
influenced a higher risk of complications of diabetes by reducing the necessary genes which are 




b. Increased formation of AGE 
AGEs are formed when the glycation of plasma proteins and collagen occurs through increased 
concentration of glucose in the cell (Singh et al., 2014). This non-enzymatic alteration of plasma 
proteins could lead to cell damage since  AGEs interact abnormally with mitochondrial matrix 
receptor,  consequently leading to the formation of ROS (Goldin et al., 2006). Free radicals produced 
from glycation can cause protein fragmentation and nucleic acids and lipid peroxidation (Baynes, 
1991). Hyperglycemia can increase the formation of AGEs in animal models and AGEs have also 
been linked to the formation of diabetic retinopathy (Kandarakis et al., 2014).  
c. Activation of PKC isoforms 
Another pathway actively involved in the generation of ROS in type 2 diabetic condition is the 
increased isoforms of activated protein kinase C (PKC). This could be as a result of the 
interrelationship between AGEs and their cell surface receptors (Derubertis and Craven, 1994).  
Dihydroxyacetone phosphate a glycolytic intermediate, is reduced to glycerol-3-phosphate which 
leads to the formation of diacylglycerol (DAG). High levels of DAG promote the activation of protein 
kinase C. In diabetic retinopathy, high blood glucose causes PKC and p38α mitogen-activated protein 
kinase (MAPK) induction which leads to the expression of Src homology-2 domain-containing 
phosphatase-1 (SHP-1) (Geraldes et al., 2009). This cascade leads to a decrease in downstream 
signalling resulting in cell death and increased risks of diabetic complications like atherosclerosis and 
heart disease.  
d. Increased hexosamine pathway 
Sustained hyperglycemia causes an increased influx of fructose 6-phospahte through the hexosamine 
pathway. Glutamine fructose 6-phosphate amidotransferase (GFAT) is the rate-limiting enzyme for 
the hexosamine pathway and it is powered by the fructose 6-phosphate shifted from glycolysis (Du 
et al., 2000). Fructose 6-phosphate is transformed to Glucosamine 6-phosphate by GFAT and then to 
Uridine Diphosphate N-acetylglucosamine (UDP-GlcNAc) a major end product and a substrate for 
alteration of target proteins. This alteration is done through post-translational modification of serine 
and threonine residues located on cytoplasmic and nuclear proteins (Giacco and Brownlee, 2010). It 
has been reported that overexpression of GFAT causes increased expression of TGF-β and TNF-α by 
increasing the appearance of upstream stimulatory factors 1 and 2 (USF1 and 2) (Weigert et al., 2004). 
The serine modification caused by UDP-GlcNAc in hyperglycemic conditions could also endothelial 




Figure 1.6: ROS production by the Electron transport chain. (Adapted without permission from 
Giacco and Brownlee, 2010). 
However, these proposed pathways responsible for the generation of ROS are all initiated from one 
source, mitochondria (Giacco and Brownlee, 2010). The mitochondria drive the overproduction of 
superoxide by the electron transport chain and this is the foundation of ROS production. This is not 
farfetched since the superoxide ion is the first oxygen free radical produced by the mitochondria and 
it is sporadically converted to more deleterious free radicals if left uncontrolled (Wallace, 1992). High 
blood glucose in diabetic cells causes increase in oxidation of pyruvate in the TCA cycle leading to 
the flow of NADH and FADH2 (electron donors) into the ETC. This influx then leads to blockage of 
electron transfer in complex III due to increase in voltage gradient in the mitochondrial membrane. 
Superoxide is then generated by the donation of electrons by the coenzyme Q to molecular oxygen 
(Figure 1.6). In cultured endothelial cells, hyperglycemia has been discovered to increase the 
mitochondrial membrane voltage and ultimately increase the generation of ROS (Korshunov et al., 
1997).  
Since we have understood the different mechanisms through which ROS can be generated in 
complications of T2D, it is now time to highlight the different complications seen in prolonged T2D. 
These complications are divided into short-term and long-term complications depending on the 





1.6 Short-term complications of T2D 
Upon immediate diagnosis of T2D, the complications of diabetes are still mild and can be reversed 
to normal if managed effectively. These short-term complications are: 
1.6.1 Hypoglycemia 
This occurs as a result of the blood sugar becoming too low (≤ 63 mg/dL or 3.5 mmol/L), which 
usually happens after the treatment of T2D with oral hypoglycemic drugs or insulin (Pober, 2010). 
The physical presentation of hypoglycemia includes sweating, fast heartbeat, anxiety, lack of feelings 
in fingers, toes and lips, sleepiness, confusion, headaches and babbled speech. Drinking orange juice 
and eating sugar can be used to manage hypoglycemia. It is usually associated with ‘dead in bed 
syndrome’. 
1.6.2 Hyperosmolar Hyperglycaemic Nonketotic Syndrome (HHNS) 
Hyperosmolar hyperglycaemic nonketotic syndrome is a very rare (< 1% of hospital admitted diabetic 
cases) short-term complication of T2D which occurs as a result of very high blood glucose levels (> 
600 mg/dL) and glucosuria (Pasquel and Umpierrez, 2014). In HHNS, there is little or no production 
of ketone bodies unlike ketoacidosis. If HHNS is left unmanaged  it can result in hyperosmolar 
nonketotic coma in old aged patients.  
1.6.3 Diabetic ketoacidosis (DKA) 
This occurs due to unmanaged high blood glucose and is also very rare among patients with T2D (Lin 
et al., 2010). Insulin deficiency is a lead cause of DKA. In the absence of insulin, the body will use 
energy from ketones produced by breakdown of fats. However, a high level of ketones in the body 
will lead to DKA which will become a complication of T2D. The outward signs of DKA include 
vomiting, dehydration and can even lead to coma if left untreated (Welch and Zib, 2004).  
1.7 Long-term complications of T2D 
These long-term complications last a lifetime in patients with T2D. Those diabetic patients  who do 
not manage their blood glucose level effectively are at high risk of developing long-term diabetic 
complications (Stratton et al., 2000). These occur due to persistent hyperglycemia which results in 
thickening of the blood vessels. They are broadly classified into two types: damage to small blood 
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vessels (microvascular complications) and damage to large blood vessels (macrovascular 
complications). 
1.7.1 Microvascular complications 
a. Diabetic retinopathy (DR) 
This is possibly the most prevalent microvascular complication of T2D, and in combination with 
diabetic muscular edema are the prime cause of blindness among working-class populace in the world 
(López et al., 2017). In South Africa, the prevalence of DR is between 5 to 10% and it is the fourth 
leading cause of blindness (Thomas et al., 2015).  It occurs by the blockage of the small blood vessels 
of the eye by high blood glucose levels. The damage by diabetic retinopathy can be prevented by 
early detection and effective management. Albuminuria, obesity and duration of diabetes have been 
considered as risk factors for DR. Oxidative stress and growth factors have been postulated to play a 
major role in this regard as well. DR can be characterized by proliferative retinopathy which leads to 
the formation of thick blood vessels on the retina. If left untreated blindness occurs through separation 
of traction retina as well as haemorrhage.   
b. Diabetic nephropathy 
Diabetic nephropathy accounts for more than half of all cases of kidney failure (Gheith et al., 2016). 
The kidney is a major organ responsible for filtering and removal of waste products from the body 
and also for maintaining the levels of water and salt in the blood (UKPDS, 1998). In T2D, excess 
glucose in the blood causes a lot of stress on the kidneys which leads to organ damage. The symptoms 
of DN include persistent proteinuria (proteins in the urine i.e. > 500 mg in 24 hours). In DN, the 
kidneys experience changes such as thickness of the glomerular basement membrane, formation of 
micro aneurysm and Kimmelsteil-Wilson bodies (Gheith et al., 2016).  
c. Diabetic neuropathy  
Neuropathy is the disease of the nerve (nerve damage) and it occurs in long-term conditions of T2D 
(Jaiswal et al., 2017). This damage can cause loss of feeling or movement in the legs, feet, hands, 
arms, chest and stomach. This nerve damage can also make it difficult for a man to sustain an erection. 
The most common manifestation of diabetic neuropathy in T2D is chronic sensorimotor distal 
symmetric polyneuropathy (Tesfaye et al., 2013). In this case, patients notice numbness with burning 
and tingling pain. In the feet this can cause sores and if left untreated can lead to amputation of the 
feet. A high number of amputations have been done so far as a result of T2D (Rodrigues et al., 2016).  
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1.7.2 Macrovascular complications 
These types of complications affect the large blood vessels and they are: 
a. Atherosclerosis 
Atherosclerosis occurs from inflammation and damage to the arterial wall in the peripheral or 
coronary vascular system (Pithová et al., 2016). In response to this, oxidized lipids from low density 
lipoproteins (LDL) gather in the endothelial wall of the arteries. These accumulated lipids form foam 
cells through the infiltration of the arterial wall by monocytes. Foam cells stimulate the proliferation 
of macrophage and T-lymphocyte attraction. Collagen accumulation and proliferation of smooth 
muscle in the arterial wall is induced by the T-lymphocyte, the result of all these processes is the 
production of a lipid-rich atherosclerotic region which then leads to complications such as 
atherosclerosis in T2D (Kalofoutis et al., 2007).  
b. Cardiovascular disease (CVD) 
CVD is the main cause of death of patients with T2D,  accounting for the largest part of health care 
expenditure in people living with T2D (Ahmed et al., 2010).  Obesity is associated with an increased 
risk of CVD in T2D patients. As explained earlier, a possible link between obesity and the 
complications of diabetes could be low grade inflammation. Patients with diabetes have greater 
cardiac mass compared to those without diabetes, which might be as a result of raised release of 
adipocytes (resistin and leptin) leading to hypertrophic effects on the heart cells (Barouch et al., 2003; 
Leon and Maddox, 2015).  
Africa is suffering from the burden of diabetes due to huge cost and expenditure spent of treating and 
managing diabetes (Mutyambizi et al., 2018). Thus, the management and control of T2D is of 
paramount importance to the population at large.  
1.8 Management of T2D 
Different measures and modalities have been proposed to manage diabetes. These measures aim to 
control blood glucose levels to tolerable points.  
1.8.1 Exercise and physical activity 
Exercise is the first advice a physician will give to a diabetic patient. Staying fit is a good way to keep 
blood glucose level at tolerable levels. During exercise the muscle cells becomes more sensitive to 
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insulin, and the contraction of the muscles leads to increase uptake of glucose even in the absence of 
insulin (Riddell and Perkins, 2009). Exercise helps T2D patients avoid the long-term complications 
of T2D.  
1.8.2 Dietary modifications 
The power of food over diabetes is amazing; a healthy diet can help normalize blood sugar levels, 
weight and blood pressure and reduce risks of complications of T2D. Foods such as white flour, table 
sugar and fruit juice are termed high-glycemic foods as they stimulate increase in blood sugar 
(Inzucchi et al., 2015). Low glycemic foods such as whole grains, nuts and legumes are high in fibre 
which helps control appetite (Chiu and Taylor, 2011). Counting carbs and eating a balanced diet are 
effective ways of reducing blood sugar levels to normoglycemic level. 
1.8.3 Pharmacologic management of T2D 
Therapeutic drugs are usually employed with the action of exercise and diet to help control high blood 
sugar levels. The need for better treatment modalities of T2D has led to the discovery and manufacture 
of different types of anti-diabetic drugs. These drugs target what is known as the ‘ominous octet’ that 
causes T2D. This section will shed more light on the mechanism of action of anti-diabetic drugs and 
possible side effects. 
a. Insulin secretagogues 
Impaired insulin secretion in T2D can be tackled using insulin secretagogues. These drugs trigger the 
release of insulin by blocking the KATP channel in the pancreatic β-cell which leads to depolarization 
of the membrane, increase in intracellular Ca2+ and insulin granule exocytosis (Cobb and Dukes, 
1998). Examples of this class of drugs includes sulfonylureas which bind to plasma proteins and 
cannot be used by type 1 diabetic patients or pregnant women. Another class of secretagogue is non-
sulfonylurea secretagogue, an example of which is meglitinides (also known as short acting insulin 
secretagogue). They act on the same channels as sulfonylureas but on different binding sites. The side 
effects of insulin secretagogues include hypoglycemia and weight gain.  
b. GLP-1 receptor agonists 
Glucagon like polypeptide-1 (GLP-1), DPP-4 (dipeptidyl peptidase-4) inhibitors and amylin agonist 
pramlintide are the classes of drugs available for addressing abnormalities in glucagon secretion 
(Godoy-Matos, 2014). The currently used GLP-1 agonists used are exenatide and liraglutide which 
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help improve weight loss and metabolic dysfunction. Their adverse effects include gastrointestinal 
disturbances, nausea and mild hypoglycemia. 
c. Drugs that increase glucose uptake 
Biguanides such as metformin help to reduce hyperglycemia by inhibiting hepatic glucose output and 
increasing the uptake of glucose by the muscle. Amongst the common antidiabetic drugs, metformin 
remains the only drug that does not encourage weight gain and it is used as a first line treatment in 
managing T2D. Thiazolidinediones also improve better use of glucose in the cells by binding to 
PPARγ (a nuclear protein responsible for transcription of genes involved in glucose and fat 
utilization) (Jerry and Chisholm, 2004). Insulin injections are also prescribed for the better utilization 
of glucose in the cells. Apart from cost, the side effects of these classes of drugs include 
hypoglycemia, and pain associated with needle prick (in the case of insulin injections). 
d. Incretin therapies 
Enhancing insulin action in response to oral glucose overload compared to intravenous glucose level 
is known as the ‘incretin effect’. Incretin is a hormone that has been proposed to be responsible for 
satiety (i.e. not feeling hungry). The GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) 
are the peptide hormones in charge of the incretin effect (Pratley, 2010, Cernea, 2011). They act by 
stimulating the release of insulin from pancreatic β-cells, suppressing glucagon secretion, reducing 
gastric emptying and regulating appetite (Pratley, 2010). These incretin memetics are widely used in 
addition to metformin to aid efficient glycemic control and their side effects include nausea and 
weight loss.  
e. Alpha glucosidase inhibitors 
Alpha glucosidase inhibitors such as acarbose act on hyperglycemia by inhibiting the digestion of 
carbohydrates in food to glucose by inhibiting carbohydrate digesting enzymes such as alpha-amylase 
and alpha-glucosidase (McCulloch, 2007). The limitations associated with the use of this drug 
includes cost, gastrointestinal problems, less effective in reducing the amount of glycated hemoglobin 
in the blood. Most commonly used alpha-glucosidase inhibitors are acarbose, miglitol etc. 
f. Sodium glucose transporters 
These transporters are located in the kidney and they help to tackle the reabsorption of glucose by the 
kidney (Kalra, 2013). SGL2 inhibitors such as dapaglifoxin, empaglifoxin and canaglifoxin aid in 
reducing reabsorption of glucose though this causes glucosuria it reduces hyperglycemia in T2D 
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patients. The mechanism of action of these drugs highlight their side effects (ketoacidosis, urinary 
tract infections and hypoglycemia). 
g. Drugs that improve neurotransmitter dysfunction 
Dopamine is a neurotransmitter in the brain which has been shown to be affected by hyperglycemia. 
The administration of bromocriptine (a systemic and intracerebral dopamine agonist) to insulin 
resistant animals caused a reduction in increased ventromedial hypothalamus noradrenergic and 
serotonergic levels through a reduction in gluconeogenesis, adipose tissue lipolysis and improved 
insulin sensitivity (DeFronzo, 2011).  
Considering the numerous side effects of the different classes of conventional antidiabetic drugs, 
there is a need to develop alternative therapies for the treatment of T2D, particularly from natural 
products, which are widely available, low cost and with no or less side effects.  
1.8.4 The importance of medicinal plants in drug discovery 
Plants have since been successfully used in the treatment of diseases such as diabetes. Over 5000 
years ago, Sumerian clay tablets were engraved with herbal prescriptions for diseases (Petrovska, 
2012).  Traditional healers have found the use of dietary modifications with medicinal plants and 
minerals to be an effective approach for the management of diseases such as T2D, cancer and others 
(Farag et al., 2016). In 2600 BC, in the area of Mesopotamia, traditional approach has been employed 
in the treatment and cure of diseases (Choudhury et al., 2017). The use of medicinal plants is even 
more common in different low-income areas of Africa.  Some patients prefer the use of traditional 
medicine over synthetic drugs because of the cost, numerous side effects and frequent unavailability 
of synthetic drugs. The WHO has encouraged African countries to embrace the practice of traditional 
medicine since Africa is filled with an abundance of different varieties of medicinal plants 
(Mahomoodally, 2013).   
Interestingly, the use of traditional medicine is on the rise even in developed countries like America, 
Australia, Netherlands and France. Factors responsible for this could be linked to curiosity, 
prevention of sickness, inability to get well with conventional drugs, and believing that a combination 
of herbs and conventional drugs will bring about faster healing (van Andel and Carvalheiro, 2013).  
In this present era, the use of medicinal plants still prevails as 11% of 252 basic prescription drugs 
are derived from plant sources (Veeresham, 2012), making plants effective in drug delivery and 
production. The availability of compounds of natural origin in different stages of clinical development 
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emphasizes the value of natural products as basis for novel drugs. Apart from natural products in 
direct use as drugs, some products can be used to model and manufacture new drugs for treating 
diverse diseases.  
A recent study showed that about 50% of cancer drugs approved within 30 years (1981 to 
2010) are from plant sources either directly or indirectly (Newman and Cragg, 2012). The 
world’s first anti-malarial drug quinine was derived from the bark of the native cinchona tree 
(Achan et al., 2011). The drug aspirin used in the treatment of fever and headaches was discovered 
from Salix alba known as the willow plant (Mahdi, 2010). Quinine, morphine, digoxin, ergomentrine 
and reserpine are examples of popular orthodox drugs with plant sources (Ulrich-Merzenich, 2014).  
Metformin, a widely used anti-diabetic drug originates from the plant Galega officinalis commonly 
known as French lilac (Bailey and Day, 2004). The potential of drugs from natural origin has 
generated the motive to further identify and investigate novel phytochemicals from plant sources with  
the sole aim of drug discovery for the management of diseases. 
1.9 African medicinal plants in the treatment of T2D  
Africa is blessed with a rich diversity of medicinal plants, and this marks our socio-economic and 
cultural heritage. Africa contains over 45,000 unexploited plant species.  In East and Central African 
region, the use of plants is widespread in the treatment of diseases and the common plants include 
Azadirachta indica, Morinda citrifolia, Zanthoxylum zanthoxyloides and different species of Cactus 
(EL-Kamali, 2009).  
Research carried out in 2013 explained the medicinal value and distribution of 10 commonly used 
African medicinal plants. These plants include Momordica charantia, Aloe ferox, Catharanthus 
roseus, Acacia Senegal, Cyclopia genistoides, Pelargonium sidoides, Artemisia herba-alba, 
Harpagophytum procumbens, Centella asiatica and Aspalathus linearis. The plants were selected 
because they have their origin from African roots and are widely used in the management and 
development of drugs for curing diseases (Mahomoodally, 2013).  
Over 400 plants and compounds have been discovered to show antidiabetic activities both in vitro 
and ex vivo and research is still on going in this regard (Chang et al., 2013). Cinammon (Cinnamomum 
verum and C. zeylanicum) commonly used as spice and flavorings in food is traditionally being used 
in treatments of diarrhea, colds and headaches (Khan et al., 2003). Studies have shown the efficacy 
of cinnamon as an antidiabetic agent. The blood glucose reducing ability of this plant was reported 
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and was achieved through lowering insulin resistance and increasing liver glycogenesis (Rao and 
Gan, 2014, Ulbricht et al., 2011).  
1.10 Justification of the research 
Discussions above show the importance of medicinal plants in the treatment of different diseases, 
especially T2D. With the staggering need for the discovery of alternate therapies due to the 
deficiencies found in synthetic drugs, there is need to conduct more research with plants with the 
hope of drug discovery, since these plants are widely available.  
1.11 Scope and limitations of the study 
The focus of this study was to screen some African medicinal plants with a view to identify the anti-
diabetic potential of the plant parts. 
This study extensively covered the antioxidant and anti-diabetic screening of Alstonia boonei, 
Bridelia ferruginea and Crassocephalens rubens using various in vitro, ex vivo, in silico and 
ultimately in vivo experiments. Some bioactive components were also identified from the above-
mentioned plants and also from Boerhaavia diffusa and Acalypha wilkesiana using GC-MS and LC-
MS analysis.  
This study did not investigate the in vivo antidiabetic potential of Boerhaavia diffusa and Acalypha 
wilkesiana due to unavailability of plant samples. It also did not exhaustively screen the bioactive 
components from all the plants using HPLC, or HPLC coupled with nuclear magnetic resonance 
(LC/NMR) techniques. 
1.12 Aims and objectives 
This study aims to conduct a detailed investigation on the antioxidant, anti-diabetic and anti-
obesogenic potentials with possible toxicological effects of five African medicinal plants namely; 
Alstonia boonei, Acalypha wilkesiana, Bridelia ferruginea, Boerhaavia diffusa and Crassocephalens 
rubens employing different in vitro, ex vivo and in vivo models with the identification of the possible 
bioactive anti-T2D agents as well as detecting their mechanism of action. 
The specific objectives of this research are: 
1. To assess the in vitro and ex vivo antioxidant activities of the aqueous, ethanol and ethyl 
acetate crude extracts of various parts (stem barks, roots and leaves) of the plants. 
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2. To examine the abilities of the extracts of these plant parts to inhibit key carbohydrate (α-
glucosidase and α-amylase) and lipid (lipase) digesting enzymes in vitro.  
3. Based on the above results, the best extract from the plant parts was subjected to solvent 
based fractionation to yield the fractions.  The obtained fractions were further examined for 
their antidiabetic potentials via using in vitro and ex vivo experimental models. 
4. The best fractions from the plants were subjected to study of the in vivo anti-diabetic abilities 
using a T2D model. The molecular mechanism behind insulin-mediated muscle glucose 
uptake potential of the most effective plant was also investigated. 
5. Possible bioactive agents in the extracts and fractions were identified from each plant using 
Gas chromatography-mass spectrometry (GC-MS).  
1.13 Thesis overview 
This thesis is organized into 8 chapters. The general structure of the thesis and the focal point of each 
chapter is described as follows: 
CHAPTER 1: Introduction 
A general background of the entire study is given in this chapter. It explains the problem (type 2 
diabetes), the prevalence, pathological features, and different treatment modalities of this disease. 
This chapter also pinpoints the rationale, objectives of the study and structure of the thesis.     
CHAPTER 2: Materials and methods 
This chapter provides a detailed explanation of all the materials and methods used during the entire 
study. 
CHAPTER 3: Alstonia boonei 
This chapter provides a compact background, ethnopharmacological and biological importance of A. 
boonei. The chapter outlines the in vitro, ex vivo, in silico and in vivo antioxidant and anti-diabetic 
screening of the different parts of this plant with their extracts or fractions. It also explains the 
identified bioactive constituents present in the plant extract/fraction using different solvents.  
CHAPTER  4: Acalypha wilkesiana 
This chapter explains the in vitro anti-oxidant activity of the plant. The effect of extracts from the 
plant parts on ameliorating iron-induced oxidative pancreatic injury was also investigated ex vivo. 
This chapter also went further to identify the present bioactive components in the plant parts using 
GC-MS analysis.  
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CHAPTER 5: Crassocephalum rubens 
The in vitro, ex vivo and in silico antioxidant and anti-diabetic screening of C. rubens was explained 
in this chapter. The chapter also went further to explain the effect of the aqueous the plant on type 2 
diabetes using a potent animal model of type 2 diabetes. The identified phytochemicals mainly 
phenols, might render synergistic effects to the observable promising anti-diabetic activity.    
CHAPTER 6: Bridelia ferruginea 
This chapter reports the detailed in vitro antioxidant and anti-diabetic of the leaves, stem and rootbark 
extracts of B. ferruginea. The effect of the most active fraction on inhibition of glucose absorption in 
small intestinal tissues were examined ex vivo together with the induction of muscle glucose uptake 
by the muscle tissue. The most active fraction was then used for in vivo animal study where the 
fraction was able to reduce blood sugar levels. The identified bioactive constituents from the extracts 
and fractions might be responsible for the promising antioxidant and anti-diabetic activity of this 
plant.  
CHAPTER 7: Boerhavia diffusa 
This chapter reports the in vitro, ex vivo and in silico antioxidant and anti-diabetic activity of solvent 
extracts from the aerial parts of B. diffusa.  
CHAPTER 8: General conclusions and recommendation  
This chapter presents a general summary based on the results of the previous chapters. It also provides 
suggestions and recommendations for future research. This thesis represents a compilation of 
manuscripts where each chapter is an individual entity and therefore some repetitions between 
chapters are unavoidable. The last part of the thesis contains a detailed bibliography of all the cited 




MATERIALS AND METHODS 
2.1 Experimental design 
 
Figure 2.1: Flowchart showing the entire experimental approach 
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2.1.1 Chemicals and reagents  
Absolute ethanol, ascorbic acid, calcium chloride di-hydrate, chloroform, dinitrosalicylic acid (DNS), 
disodium EDTA, ethyl acetate, ferric chloride, ferrous sulphate heptahydrate, Folin ciocalteau 
reagent, glucose-6-phosphate dehydrogenase, D-glucose 6-phosphate sodium salt, Griess reagent, 
hydrogen peroxide, isopropanol, maltose, magnesium chloride, magnesium sulphate, mono-basic 
potassium phosphate, phenol red,  sodium chloride, sodium bicarbonate, sodium citrate, sodium 
hydroxide, sodium hydrogen carbonate, sodium phosphate, sodium nitroprusside, starch, sulphuric 
acid, trichloroacetic acid, reduced glutathione, thiobarbituric acid, deuterated chloroform and 
deuterated methanol were purchased from Merck Chemical Company, Durban, South Africa. 
Acarbose, ammonium molybdate tetrahydrate, citric acid, 2 deoxy-D-ribose, di-basic sodium 
phosphate, diethylenetriaminepentaacetic acid (DETAPAC), 5,5′-dithiobisnitrobenzoic acid 
(DTNB), 1,1-diphenyl-2-picrylhydrazyl radical (DPPH), gallic acid, 6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid (trolox), 6-hydroxydopamine, p-nitrophenyl-α-D-
glucopyranoside (pNPG), 3-(N-morpholino) propanesulfonic acid (MOPS)p-nitrophenol, porcine 
pancreatic amylase, potassium ferricyanide, sodium acetate, streptozotocin and yeast α-glucosidase, 
were obtained from Sigma-Aldrich through Capital Lab Supplies, New Germany, South Africa.  
Glucose and fructose were bought from Associated Chemical Enterprise (ACE), South Africa, while 
metformin and Novo rapid insulin were bought from a local pharmacy (Pharmed) in Durban, South 
Africa. 
A specific ultra-sensitive rat insulin ELISA kit was procured from Mercodia AB, Uppsala, Sweden. 
Other reagents used for investigating the remaining serum parameters were purchased from Labtest 
Diagnostics (Lagoa Santa, Brazil) purchased through Replamed Company Ltd., Centurion, located in 
South Africa.  
2.1.2 Equipment  
Buchi Rotavapor II, Buchi, Germany, Shimadzu UV mini 1240 spectrophotometer (Shimadzu 
Corporation, Kyoto, Japan), Steri-Cult CO2 incubator (Labotec, South Africa), An Automated 
Chemistry Analyzer (Labmax Plenno, Labtest Inc., Lagoa Santa, Brazil), Glucometer (Glucoplus 
Inc., Saint-Laurent, Quebec, Canada), Ultra Turrax Tube Drive Work Station Homogenizer (IKA-
Works, Staufenim Breisgau, Germany), Hettich Mikro 200 Microcentrifuge (Hettich Lab 
Technology, Tuttlingen, Germany), Synergy HTX Multi-mode Reader (BioTek Instruments Inc, 
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Winooski, USA), Microfuge 20R Centrifuge (Beckman Coulter, Inc., Germany), Eppendorf™ 5810R 
Centrifuge (Fisher Scientific, UK).   
2.1.3 Collection and preparation of plant materials 
The leaf, stem and root bark samples of Alstonia boonei, Acalypha wilkesiana, Bridelia ferruginea, 
aerial parts of Boerhavia diffusa, and Crassocephalum rubens were collected in November 2015 from 
the city of Ibadan, Oyo state, Nigeria. The plant materials of A. boonei, B. ferruginea and B. diffusa 
were validated at the herbarium unit of the Department of Pharmacognosy, University of Ibadan, 
Nigeria where their designated voucher specimen numbers DPHI Nos. 1379, 1380 and 1650 were 
deposited respectively. The authenticity of C. rubens and A. wilkesiana plant samples were verified 
at the herbarium section of the Forest Research Institute of Nigeria (FRIN), where a voucher specimen 
number FHI. 110605 and FHI. 110606 was preserved, respectively. 
Dirt and sand stains were promptly removed from the plant materials followed by shade drying for 3-
4 weeks till they reached constant weights. When dried, the samples were then ground to powdery 
form with a mill blender and packaged as a unit in air-tight bags for transportation to the University 
of KwaZulu-Natal, Durban, South Africa for further analysis.  
2.1.4 Preparation of the crude extracts  
Individually, 100 g of the samples from each part of plant was defatted with hexane. Defatted samples 
were soaked with 200 mL of ethyl acetate, ethanol and water for 48 hours respectively followed by 
consistent shaking for 2 h at 200 rpm. The samples were then sieved using a Whatmann filter paper 
(No. 1) and the filtrates were dried in vacuum using a rotary evaporator at 40°C with reduced pressure 
to acquire the crude extracts. The aqueous extracts were dried at 50°C overnight by using a water 
bath (Figure 2.2). The weights of the resulting extracts in all cases were determined, then they were 




Figure 2.2: Flowchart to describe the sequential extraction of plant samples 
2.2 Analytical methods 
2.2.1 In vitro antioxidant activities of the isolated crude extracts   
i. Evaluation of total phenol content (TPC) 
The estimation of TPC (as equivalent of gallic acid) of the extracts were determined using a 
previously described method (McDonald et al., 2001) with little modifications. Concisely, a volume 
of 200 μL of the extract (at a concentration of 240 μg/mL) was mixed with 1000 μL of Folin ciocalteau 
reagent (diluted 10 times) and 800 μL of 0.7 M Na2CO3 and incubated at 25°C for 30 min. A 
Shimadzu UV mini 1240 spectrophotometer set at 765 nm was used to determine their absorbance. 
All measurements were reproduced 3 times.  
ii. Determination of Ferric (Fe3+) reducing antioxidant power (FRAP)  
The reducing capacity of these extracts was determined by potassium ferricyanide method. Briefly, 
50 µL of extract in increasing concentrations (50-250 µg/mL) was incubated with a 50 µL of 0.2 M 
sodium phosphate buffer (pH 6.6) with 50 µL of 1% potassium ferricyanide for 30 min at 50°C. 
Acidification of the reaction was achieved using 50 µL of 10% TCA. Then 50 µL of the acidified 
mixture was added to 50 µL of distilled water (d.H2O) and 40 μL of FeCl3 (0.1%) and its absorbance 
was recorded at 700 nm in a 96 well plate reader in triplicates. High reducing activity of the extracts 
29 
 
is seen in increasing absorbance (Oyaizu, 1986). The result was reported as GAE using this 
expression: 
Ferric reducing antioxidant power (%) = 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑆𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝐺𝑎𝑙𝑙𝑖𝑐 𝑎𝑐𝑖𝑑
 𝑋 100  
iii. Free radical scavenging activity using DPPH   
The antioxidant capacity of the extracts was investigated based on their capacity to mop up the non-
transient 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical (Ak and Gülçin, 2008). The standards 
used were ascorbic acid, trolox and gallic acid and absorbance was read at 517 nm. Briefly, 100 µL 
of 0.3 mM DPPH in methanol was added to 200 µL of extracts (50-250 µg/mL), this was then mixed 
and incubated in pitch-dark conditions at room temperature for 30 min. Thereafter, the absorbance 
was recorded at 517 nm in triplicates, and the result was extracted as a proportion of the blank using 
this expression: 




iv. Non-site-specific .OH radical mediated 2-deoxy-D-ribose degradation assay  
The Fenton reaction made up of Ascorbate–EDTA and H2O2 generate hydroxyl (.OH) radicals which 
could degrade deoxyribose and it is measured as a product degradation reaction. The .OH radical 
inhibiting ability of the extracts were determined by investigating the tussle for the released hydroxyl 
radicals within the extracts and deoxyribose as reported by Hinneburg et al. (2006). The experiment 
was done by adding 200 μL of already mixed 100 μM FeCl3 and 100 μM EDTA (1:1 v/v) solution, 
100 μL of 10 mM H2O2, 360 μL of 10 mM 2-deoxy-D-ribose, 1 mL of varying concentrations of the 
extract (50–250 μg/mL), 400 μL of phosphate buffer (50 mM, pH 7.4) and 100 μL of 1 mM ascorbic 
acid in progression. The resulting mixture was quickly incubated for 2 hours at 50°C. Then, 1 mL of 
TCA (2.8%) and 1 mL of 1.0% thiobarbituric acid (in 25 mM NaOH) were added to the reaction 
tubes. Further incubation in a H2O bath at 50°C for 30 min was required for the samples to develop a 
pink colour. The absorbance at 532 nm was used to determine the level of oxidation of the samples 
and the OH. radical scavenging capacity of the extract was recorded as percent inhibition of 
deoxyribose using this expression: 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) = 1 − (
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙




v. Nitric oxide (NO) radical inhibition assay  
The ability of aqueous solution of sodium nitroprusside at physiologic pH to aggressively emit nitric 
oxide (NO) that might interact with oxygen to generate nitrite ions forms the basis of this assay 
(Kurian et al., 2010). These nitrite ions could be determined using Griess reagent. The experiment 
was done by briefly incubating 500 μL of 10 mM sodium nitroprusside in sodium phosphate buffer 
(pH 7.4) and 500 μL of the extract at different concentrations (50-250 μg/mL) for 2 h at 37°C. A 500 
μL of Griess reagent was then added to the reaction mixture. A chromophore produced by the 
coupling of nitrite with sulphanilamide was determined at 546 nm. The percentage inhibition of the 
NO emitted was calculated by comparison with the absorbance of a prepared control (10 mM sodium 
nitroprusside in phosphate buffer). The assay was done three times and the scavenging capacities of 
the plant was estimated using the expression below:  
𝑆𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (%) = 1 − (
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
) 𝑋 100 
2.2.2 In vitro key anti-diabetic and anti-obesogenic enzymes inhibitory assays   
a) Inhibitory of -glucosidase activity   
The α-glucosidase inhibitory potential of the extracts was determined based on a slightly modified 
version of a previously published method (Ademiluyi and Oboh, 2013). Briefly, a 250 µL of acarbose 
(standard) or extract at varying concentrations (50-250 µg/mL) was incubated with 500 µL of -
glucosidase (1.0 U/mL) in phosphate buffer (with a concentration of 100 mM, pH 6.8) for 15 min at 
37°C. Then, a 250 µL of 5 mM p-Nitrophenyl-α-D-glucopyranoside (pNPG) solution mixed in the 
phosphate buffer was added to the mixture and further incubated for 20 min at 37°C. The substrate 
was pNPG and the absorbance of the released p-nitrophenol was noted at 405 nm. The inhibitory 
activity was reported as a proportion of the control devoid of inhibitors using this expression: 
         𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) = 1 − (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓
𝑠𝑎𝑚𝑝𝑙𝑒
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 ) X 100 
b) -amylase inhibitory activity 
The -amylase inhibitory potential of the extracts were investigated using a previously reported 
procedure (Shai et al., 2010) with moderate modifications. Briefly, 250 μL of each extract or standard 
(acarbose) at varying doses (50-250 μg/mL) was incubated with a 500 μL of porcine pancreatic 
amylase (2 U/mL) in phosphate buffer (100 mM, pH 6.8) for 20 min at 37°C. Then, a 250 μL of starch 
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(1%) was suspended in 100 mM phosphate buffer (pH 6.8) and was subsequently added to the reaction 
and incubated for 1 h at 37°C. A dinitrosalicylate (DNS) colour reagent (1 mL) was thereafter added 
and boiling was initiated for 10 min. The absorbance of the resulting mixture was recorded at 540 nm 
and the inhibitory activity was expressed as proportion of a control lacking inhibitors. 
𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 (%) = 1 − (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓
𝑠𝑎𝑚𝑝𝑙𝑒
𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 )  𝑋 100 
c) Estimation of pancreatic lipase inhibitory activity 
Pancreatic lipase inhibitory potential of plant extracts was determined using a slightly modified 
procedure from its originally published form (Kim et al., 2010), here, the substrate used was p-NPB 
(p-nitrophenyl butyrate) in dimethyl formamide. The lipase inhibitory activity was extrapolated by 
recording the hydrolysis of p-NPB to p-nitrophenol by measuring absorbance at a wavelength of 405 
nm. The inhibition rate of lipase by the plant extract was calculated using the following expression: 
% Inhibition = (1 −
𝐴𝑠
𝐴𝑐
) 𝑋 100 
As: absorbance in the presence of the sample and Ac: absorbance of the control. 
2.2.3 Ex vivo antioxidant assays 
A 100 µL of pancreatic and hepatic tissue homogenates from rats was pipetted into a reaction mixture 
containing 100 µL of each extract with 30 µL of pro-oxidant (0.1 mM FeSO4). This was then 
incubated in 5% CO2 for 30 min, a reaction containing no extract served as negative control i.e. 
untreated. 
This sample was then immediately assayed for Catalase (Chance and Maehly, 1955), Superoxide 
Dismutase (SOD) (Kakkar et al., 1984), reduced glutathione (GSH) level (Ellman, 1959), and lipid 
peroxidation (LPO) level (Chowdhury and Soulsby, 2002). The Folin–phenol method was used in 
estimating the total protein content of the tissue homogenates (Lowry et al., 1951).    
i. Catalase activity   
The catalase activity was estimated by a spectrophotometric molybdate procedure (Hadwan and 
Abed, 2016). Concisely, 100 µL of the incubated homogenate was added to 1 mL of H2O2 (65 µM) 
in sodium phosphate buffer (6.0 mM, pH 7.4) for 3 min. The reaction was ended by adding 4 mL of 
ammonium molybdate (32.4 mM) and the alterations in the yellow-coloured molybdate/H2O2 
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complex was recorded at a wavelength of 347 nm compared to the blank containing H2O2 alone. The 











t = time; S° = Abs. of standard tube (containing all reagents except tissue sample); S = Abs. of test 
samples; M = Abs. of control test sample (contains all reagents except H2O2); Vt = summation of 
volume of total reagents in test tube; Vs = test sample volume; Abs. = Absorbance at 340 nm 
ii. Superoxide dismutase (SOD) enzyme activity    
This assay was performed according the procedure of Kakkar et al. (1984) with slight modifications. 
Concisely, 170 μL of a 0.1 mM diethylenetriaminepentaacetic acid (DETAPAC) and 15 μL of the 
incubated homogenate were platted in a 96-well plate. Immediately, 15 μL of a 1.6 mM 6-
hydroxydopamine (6-HD) was put in the mixture followed by gentle mixing by carefully patting the 
sides of the 96-well plates. Absorbance was measured at 492 nm for 3 minutes at 1 min interval. The 
activity of the present SOD enzyme was determined by exploiting this formula: 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
(𝐴1 − 𝐴𝑏)𝑋 𝑅𝑣 𝑋 𝐷𝑓
490 𝑋 𝑆𝑣
 
 ε490 is the standard molar absorptivity at 490 nm wavelength given as 1.742/mM/cm, A1 and Ab 
are rates of reaction rate for sample and blank. Rv is the volume of the entire reaction, Df is the used 
dilution factor and Sv is the volume of the sample. 
iii. Reduced glutathione (GSH) assay 
This assay relies on the rapid oxidation of GSH by 5,5’-dithio-bis (2-nitrobenzoic acid) to generate 
5’-thio-2-nitrobenzoic acid (TNB) a yellow formation measurable at 415 nm. The formed oxidised 
glutathione (GSSG) can be converted to GSH by glutathione reductase in a reaction containing the 
cofactor NADPH (Rahman et al., 2006). Briefly, 150 µL of incubated sample was precipitated with 
equal volume of TCA (10%) and then centrifuged at 2000 rpm for 10 min at 25°C. A 80 µL of the 
supernatant, with 40 µL of 0.5 mM DTNB and a 200 µL of sodium phosphate buffer (0.2 M, pH 7.8) 
was plated in a 96-well plate. The mixture was then incubated at 25°C for 15 min and its absorbance 
measured at 415 nm. A standard curve was plotted using varying GSH concentrations as standard and 




iv. Determination of lipid peroxidation 
This was carried out using a slightly modified previously reported method (Oboh et al., 2012). Lipid   
peroxidation was initiated by incubating 30 μL of ferrous sulphate (15mM) with 100 μL of varying 
concentration of the extract (50-250 μg/mL) in water and the pancreatic homogenate for 30 min at 
37°C. Then, 200 μL of SDS (8.1%) solution, 750 μL of acetic acid (20%), 2 ml of TBA (0.25%) 
solution and 850 μL of miliQ H2O and further boiled with the 200 μL of the incubated samples for 
one hour. After cooling, the absorbance was recorded at 532nm. The MDA concentrations of the 
tested samples were extrapolated from the MDA standard curve.   
v. Determination of glutathione reductase activity 
This assay relies on measuring the glutathione reductase activity spectrophotometrically by recording 
reduction in absorbance of the NADPH at 340 nm (Smith et al., 1988). Briefly, 10 µL of sample or 
glutathione reductase buffer (at a concentration of 50 mM Tris.HCl and 1 mM EDTA solution, pH 
8.0) for blank was mixed in a 96-well plate and a 221 µL of the assay buffer with 38 µL of GSSG 
solution (8 mM) was added consecutively. Thereafter, 10 µL of NADPH was put in the reaction 
followed by immediate mixing by gently patting the four sides of the 96-well plate. The linear 
decrease in absorbance at 340 nm was quickly noted for 8 min at a 2 min interval using a multi-plate 
reader. The activity of the glutathione reductase enzyme was calculated using this expression:  
Activity = 1000 𝑋 [
𝐴1−𝐴𝑏
340
] 𝑋 0.5 µmol/min/µg of protein 
Where: 340 is the molar absorptivity at 340 nm which is 6.22 mM/cm, A1 and Ab represents rate of 
the sample and blank reactions.    
vi. Estimation of glutathione peroxidase activity 
This reaction is based on the oxidation of GSH to GSSG through the glutathione peroxidase enzyme 
in the presence of H2O2:an antioxidant. Briefly, sample homogenates and serum samples were diluted 
to a concentration range of 5-10 mg/mL (based on their protein concentration) using the assay buffer. 
A 5 µL of the diluted sample or homogenization buffer (blank) was platted in a UV disposable 96-
well plate, then a 210 µL of assay buffer, 2.5 µL of GSH solution (100 mM), 2.5 µL of glutathione 
reductase (0.1 U/mL), 2.5 µL of sodium azide solution (100 mM) (added to diluted hepatic 
homogenates to inhibit catalase activity) or 5 µL of distilled H2O (to other samples or blank). 
Thereafter, 2.5 µL of NADPH (15 mM) was added and the t-BHP-independent NADPH oxidation 
was recorded at 340 nm (reaction 1) for 8 min at 2-min intervals for both the sample (A1) and blank 
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(A1b) using a multi-plate reader. The reaction was initiated by adding 25 μL of either 12 mM t-BHP 
or 1.5 mM H2O2 solution (for liver sample homogenates) and the hydroperoxide-dependent linear 
NADPH oxidation at absorbance of 340 nm (reaction 2) was recorded for 6 min at 2 min intervals for 
both the samples (A1) and the blank (A2) using a multi-plate reader. 
The following expression was used to calculate the activity of glutathione peroxidase enzyme: 
Activity = 1000 × ((A2 -A1) - (A2b-A1b))/ є340 × 𝟎. 𝟓 μmol/min/μg of protein 
є340 is the Molar absorptivity at 340 nm which is 6.22/mM/cm, A1 and A2 is the rate of reaction 1 
and 2 for the samples, A1b and A2b is the rate of reaction for blank reaction 1 and 2. 
2.2.4 Gas chromatography-mass spectrometric (GC-MS) analysis of most effective extracts 
and fractions 
Based on the results of the experiments carried out so far, the most active extracts from the plant were 
put through GC-MS analysis. GC-MS analysis was carried out on an Agilent Technologies 6890 
Series GC coupled with an Agilent 5973 mass selective detector equipped with Agilent Chemstation 
software.  A HP-5MS capillary column was used (30 m × 0.25 mm ID, 0.25 μm film thickness, 5% 
phenylmethylsiloxane).  Helium was used as the carrier gas at a flow rate of 1.0 mL min-1 and linear 
velocity of 37 cm/s. The injector temperature was set at 250°C.  The oven temperature was 
programmed to reach 280C from initial 60°C at a rate of 10°C/min. A 1 μL injection was made in 
the split mode with a split ratio of 20:1. The MS was operated in the electron ionization mode at 70 
eV and electron multiplier voltage at 1859 V.  The operating parameters for the instrument were: ion 
source temp. 230°C, quadrupole temp. 150°C, solvent delay 4 min and scan range 50-70 amu. 
Compounds were identified using the NIST library by direct comparison to the mass spectral data of 
known compounds. 
2.2.5 Liquid Chromatography-Mass Spectroscopy (LC-MS) profiling 
The aqueous extract and fractions were subjected to LC-MS analysis (Shimadzu LCMS-2020 Single 
Quadrupole) by direct injection into the machine via a loop, with the stop time set at 4 mins. The 
operating parameters were: 
Photodiode Array (PDA) sampling frequency: 1.5625 Hz; Operating mode: low pressure 
gradient; Pump A: LC-2030 Pump; Mobile Phase A and B: water and methanol respectively; Flow 
rate: 0.200 ml/min; Start and End wavelengths: 190 and 800 nm respectively; Cell Temp.: 
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40°C; Start and End time: 0.00 and 4.00 mins respectively; Acquisition mode: Scan; Scan Speed: 
1667 u/s; Polarity: Positive; Event Time: 1.00 s; Detector Voltage: +1.00 kV; Threshold: 0; Start 
and End m/z: 50.00 and 1700.00 respectively. Compounds were identified directly by comparing 
their mass spectral data with those in the NIST library online and Food Database [FooDB 
Version 1.0] (FoodDB, 2017). 
2.2.6 Fourier transform infrared spectroscopy (FT-IR) analysis 
The chemical functional groups of the extracts and fractions were determined by direct scanning at a 
spectral range of 380 – 4000 cm–1 on a FT infrared spectrophotometer. The functional groups were 
determined by comparing the peak frequencies to an IR spectroscopy correlation table. 
2.2.7 Molecular docking 
The docking studies for antioxidant and anti-diabetic enzymes were performed using AutoDock Vina 
software (Trott and Olson, 2010). The crystal structure of the antioxidant enzymes was downloaded 
from the protein data bank (PDB). The human SOD (PDB ID: 2C9V, resolution 1.07 Å) (Strange et 
al., 2006), human erythrocyte catalase (PDB ID: 1QQW, resolution 2.75 Å) (Ko et al., 2000) and 
human glutathione reductase (PDB ID: 1XAN, resolution 2 Å) (Savvides and Karplus, 1996) were 
selected as suitable structures for docking of catalase, SOD and glutathione reductase respectively. 
PDB structures with access code: 1UOK (Watanabe et al., 1997) (resolution 2.4 Å), 1LPB (Egloff et 
al., 1995) (resolution 2.46 Å) was used for α-glucosidase and lipase respectively. The active binding 
site of catalase, SOD and glutathione reductase was defined using AutoDock tools (Sanner, 1999) 
within the grid size of (54x48x46), (64x62x60), (28x26x24) respectively while 44x42x40 dimensions 
was used for α-glucosidase and lipase with 1.00 Å as the grid spacing. AutoDock tools graphical user 
interface by MGL Tools (Morris et al., 2009) was applied to add Gasteiger charges. All the ligand 
structures were retrieved from PubChem compound database and optimized using Gaussian 09, prior 
to docking to obtain the global minimal structures (Makatini et al., 2013, Oyebode et al., 2018). 
2.3 In vitro and ex vivo antioxidant and anti-diabetic activities of solvent fractions derived 
from the crude extracts  
2.3.1 Solvent fractionation of the most active crude extracts from each plant  
From the results of the preliminary antioxidant assays (earlier described), the most promising crude 
extract from each plant was picked for further fractionation (Figure 2.3). The selection was made 
within crude extracts obtained from the same plant.  
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The preferred extracts for fractionation were the ethanol extract of leaves (A. boonei and B. 
ferruginea). Ten g of these crude extracts was dissolved totally in 100 mL of distilled water: methanol 
(1:9) and then partitioned successively with hexane (200 mL twice), dichloromethane (200 mL twice), 
ethyl acetate (200 mL twice) and n-butanol (200 mL twice) (Figure 2.3). All the resulting fractions 
were evaporated to dryness at 40°C under reduced pressure and the remaining aqueous fraction was 
dried on a water bath. The fractions were then weighed, put in glass vials and refrigerated at 4°C until 
needed.  
 
Figure 2.3: Flowchart showing the step by step fractionation of the crude extracts 
All the fractions were investigated for in vitro, ex vivo antioxidant and anti-diabetic activities using 
the procedures earlier described. 
2.4 Ex vivo glucose absorption and glucose uptake study 
a. Animals  
Five male Sprague-Dawley rats weighing 180 ± 10.12 g (average body weight) were received from 
the Biomedical Resource Unit (BRU) located in the Westville Campus of the University of KwaZulu-
Natal, Durban, South Africa. The animals were momentarily (12 h) denied food but not water and 
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euthanized using isofor anaesthesia. Then the entire gastrointestinal tract (GIT) and parts of the psoas 
muscle were harvested after dissection and instantly used for small intestinal glucose absorption and 
muscle glucose uptake study, respectively. The animals were handled in cognisance to the rules and 
regulations of the Animal Research Ethics Committee of the University of KwaZulu-Natal, Durban, 
South Africa (Ethical approval number: AREC/003/017D). 
b. Determination of glucose absorption in isolated rat small intestine 
The effects of the varying concentrations (100-250 mg/dL) of extracts/fractions on small intestinal 
glucose absorption was measured in harvested rat jejunum. In this regard, the concentrations of 
glucose level in an incubation mixture consisting the pre-cut rat jejunum and test samples was 
recorded according to a previously published method (Hassan et al., 2010) as modified by Chukwuma 
et al. (2017). Briefly, jejunal segments of the harvested small intestine were sliced into smaller pieces 
of 5 cm and the inner jejunal lumen was cleaned with 2 mL of Krebs buffer (118 mM NaCl, 5 mM 
KCl, 1.328 mM CaCl2·2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 and 25 mM NaHCO3) by an 
antiseptic syringe. The pieces were initially inverted to show the villi, and then placed in an incubation 
tube with 8 mL of Krebs buffer and 11.1 mM glucose and varying concentrations of extract when 
glucose with Krebs buffer was used as a control. Then 1 mL mixture was taken from each incubation 
tube before and after the 2 h incubation time in a Steri-Cult CO2 incubator (Labotec, South Africa) 
with 5% CO2, 95% oxygen and 37°C settings. The amount of glucose in the samples was determined 
using an Automated Chemistry Analyzer (Labmax Plenno, Labtest Inc., Costa Brava, Brazil). The 
small intestinal absorption of glucose was extrapolated as the quantity of glucose absorbed per 
centimetre of rat jejunum using following formula: 
Abdominal glucose absorption = 
𝐺𝐶1− 𝐺𝐶2
𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑗𝑒𝑗𝑢𝑛𝑢𝑚 (𝑐𝑚)
   
Where GC1 & GC2 are the glucose concentrations (mg/dL) before and after the incubation 
respectively. 
Percentage inhibition of glucose intake from the jejunum of small intestine was recorded as per 
following expression:  
  %Inhibition = 
Δ𝐺𝐶 𝑐𝑜𝑛𝑡𝑟𝑜𝑙− ΔGC sample)
ΔGC control
 X 100      




c. Determination of glucose uptake in harvested rat psoas muscle 
The effect of the different concentrations (100-250 mg/dL) of the plant extracts/fractions on muscle 
glucose uptake was measured in harvested rat psoas muscle according to the procedure explained in 
a previous study (Hassan et al., 2010) as modified by Chukwuma et al. (2017). The harvested psoas 
muscle was briefly cleaned with Krebs buffer and diced into small chunks of the same weight (500 
mg). Each chunk was then incubated in 8 ml of Krebs buffer, pre-mixed with 11.1 mM glucose 
(control) and varying concentration of the extract. A 0.5 mg/mL metformin solution was used as a 
positive control. The incubation time lasted for an hour in a CO2 incubator (as mentioned earlier) with 
5% CO2, 95% oxygen and 37°C temperature settings. Before and after the incubation period, 1 mL 
sample was collected from each incubation tube and the glucose concentration was measured using a 
Chemistry Analyzer as mentioned earlier. The uptake of glucose by the muscle was extrapolated as 
the quantity of glucose (mg) used up by each gram of muscle tissue using following formula: 
Muscle glucose = 
(𝐺𝐶1−𝐺𝐶2)
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑢𝑠𝑐𝑙𝑒 𝑡𝑖𝑠𝑠𝑢𝑒 (𝑔)
       
Where GC1 and GC2 are glucose concentrations before and after incubation respectively. 
2.5 In vivo antidiabetic activity of the most active fractions in a type 2 diabetes rat model  
From the results of all the experiments carried out, the best fraction/extract from each plant was chosen 
for the in vivo studies. The aqueous fraction of B. ferruginea leaves, the butanol fraction of A. boonei 
leaves and the aqueous crude extract of C. rubens were selected for in vivo study since they showed the 
best activities in the antioxidant and antidiabetic models used during in vitro and ex vivo studies.  
a.  Animals 
Seven-week-old male Sprague-Dawley rats were procured from the Biomedical Resource Centre located 
at the Westville Campus of the University of KwaZulu-Natal, Durban, South Africa. Animals were 
randomly grouped into seven (7) groups as follows, with five (5) rats each in the normal or non-diabetic 
groups and seven (7) rats each in the diabetic groups: 
Normal Control (NC) = Normal male SD rats (non-diabetic/not treated)  
Non-diabetic fraction control (NFC) = non-diabetic rats administered 300 mg/kg body weight fraction 
Diabetic Control (DC) = diabetic and untreated rats 
Diabetic & fraction Low dose (DFL) = diabetic rats administered 150 mg/kg body weight fraction 
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Diabetic & fraction High dose (DFH) = diabetic rats administered 300 mg/kg body weight fraction 
Diabetic & Standard drug; Metformin and glibenclamide (DBM & DBG) = diabetic rats administered 300 
mg/kg body weight metformin and 5 mg/kg body weight glibenclamide. 







Figure 2.4: Flow diagram describing comprehensive in vivo experiment 
The animals were bred in a maximum of seven-in-one large poly carbonate cages and in a temperature 
and humidity-controlled room with a 12-hour light-dark cycle. The entire animals were fed with a 
commercial rat pellet diet ad libitum all through the experimental period. Animals were maintained 
according to the rules and regulations of the Experimental Animal Ethics Committee of the University of 
KwaZulu-Natal, South Africa (Animal ethics approval number: AREC/003/017D). 
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b.  Induction of diabetes 
The animals were left to acclimatize for one week. During the first 2 weeks of the experiment, the animals 
in the diabetic groups were supplied with a 10% fructose solution to induce insulin resistance (Wilson 
and Islam, 2012) while the animals in the normal or non-diabetic groups were supplied with normal 
drinking water. Thereafter, animals in the diabetic groups were intraperitoneally injected with a low dose 
of streptozotocin (40 mg/kg body weight)dissolved in a citrate buffer (pH 4.5) to induce partial pancreatic 
β-cell dysfunction, while animals in the normal or non-diabetic groups were injected with the same 
volume of citrate buffer alone. A week after the streptozotocin injection, the Non-fasting blood glucose 
levels of all animals were measured using the whole blood extracted from the tail vein tested with a handy 
glucometer, and animals with a NFBG level > 200 mg/dL were considered as diabetic. However, animals 
with a NFBG level < 200 mg/dL were removed from the experiment. 
c.  Intervention trial 
 After induction of diabetes, all animals had unlimited access to drinking water and commercial rat chow 
and the animals in plant fraction/extract groups were given a single oral dose of respective plant 
fraction/extract (150 or 300 mg/kg body weight) then the animals in the DBM and DBG groups were 
administered with a single oral dose of metformin (300 mg/kg body weight), glibenclamide (5 mg/kg 
body weight), respectively. The animals in the NC and DBC groups were supplied with equivalent volume 
of normal drinking water via the same route.   
d.  Oral Glucose Tolerance Test (OGTT) 
The OGTT was done in the last week of the 5-week intervention period. This was done after an overnight 
fast, then glucose was orally administered to each animal at a dose of 2.0 g/kg body weight and blood 
samples were collected from the tail vein at 0 (just before glucose ingestion), 30, 60, 90 and 120 min. 
Glucose levels were estimated by using a portable Glucometer (Glucoplus, Quebec, Canada). 
e.  Determination of food and fluid intake, body weight and sampling 
All through the study, the body weights of rats were measured weekly and the food and fluid intake was 
measured daily. The study was concluded with an overnight fasting (12 h) of all animals and consequently 
anesthetizing using isofor. The blood was collected via cardiac puncture and organs (liver, kidney, heart, 
muscle and pancreas) were collected, rinsed, weighed and preserved at a temperature of -30°C for 
subsequent analysis. Sterile centrifuge tubes were used for blood collection and the samples were stored 
on ice for 2-3 h. Separation of the serum was done by centrifugation at 3000 rpm for 15 min and stored at 
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-30°C for further usage. A small part of the pancreas from each rat was cut and submerged into a 10% 
neutral buffered formalin and then stored at room temperature for histopathological analysis.   
2.6 Serum analysis 
Serum insulin concentration was measured using an enzyme-linked immunosorbent assay (ELISA) 
procedure done with an ultrasensitive rat insulin ELISA kit (purchased through Mercodia, Uppsala, 
Sweden) with absorbance read in a multi-plate reader. The total cholesterol, HDL- and LDL-
cholesterols, with triglycerides, fructosamine, urea, and uric acid concentrations including liver 
function enzymes; aspartate and alanine aminotransferases (AST and ALT) and alkaline phosphatase 
(ALP) were determined with an Automated Chemistry Analyzer (Labmax Plenno, Labtest Co. Ltd., 
Lagoa Santa, Brazil) using standard assay kits for these analyses purchased from the same production 
company.  Homeostatic model assessment (HOMA-IR and HOMA-β) were estimated using serum 
insulin levels and FBG concentrations taken at the end of the experiment using the following 
expression:  
  HOMA – IR = 
Serum insulin (U/L) X Blood glucose (mg/dL)
22.5
 
  HOMA – β cell function = 
20 X Serum insulin in U/L 
Blood glucose in mg/dL− 3.5  
 
The conversion factor for insulin = 1 U/L = 7.174 pmol/L 
2.7 Hepatic glycogen content 
Estimation of the levels of hepatic glycogen concentrations was done by using a phenol-sulfuric acid 
method (Lo et al., 1970). One gram of the excised liver was digested with 1.5 mL of 30% KOH 
saturated in Na2SO4. This was put in a test tube completely immersed in ice, later it was boiled for 30 
mins. Then 2 mL of 95% ethanol was added to the sample followed by cold centrifugation for 30 
mins at 840 g twice to properly precipitate the glycogen content. Thereafter the supernatant was 
aspirated, and the precipitate dissolved in 3 mL of distilled water. A 1 mL of 5% phenol was added 
to the dissolved glycogen and 5 mL of concentrated H2SO4 was rapidly and carefully added. The 
mixture was mixed thoroughly and boiled for 20 mins, followed by cooling and the absorbance was 
read using a 96-well plate at 600 nm. The glycogen content of the samples was extrapolated from a 




2.8 Histopathology analysis of the excised pancreas  
The formalin-preserved pancreatic tissue was subjected to standard laboratory procedures for paraffin 
fixing/embedding. Tiny sections were cut to a size of approximately 4 μm, followed by deparaffination 
of the slides using p-xylene. This was consequently rehydrated using ethanol at different concentrations 
(100%, 80%, 70%, 50%) and cleansed with running water. Subsequently, the hematoxylin was used to 
stain the slides for 5 mins and then cleansed with running water. Next was counterstaining using eosin, 
Finally, the stained slides were arranged and mounted in DPX, with a sterile cover-slip and viewed with 
Leica slide scanner (SCN 4000, Leica Bio-systems, Germany). 
2.9 In vivo antioxidant studies  
To fully understand the likely role of antioxidant activity in combination to the observed anti-diabetic 
activity, the in vivo antioxidant potentials of the fractions/extract were investigated in the serum and 
tissues of the animals using six in vivo oxidative stress markers namely; reduced glutathione (GSH), 
thiobarbituric acid reactive substances (TBARS) levels, catalase, superoxide dismutase (SOD), 
glutathione reductase (GR) and glutathione peroxidase (GPx) assays.  
To perform these assays, centrifuged homogenates of the excised tissues (liver, kidney, heart and 
pancreas) were initially prepared by homogenising 0.5 g of the organ tissue sample in 4000 µL of 
homogenization buffer (50 mM sodium phosphate buffer with triton X-100, pH 7.5) with an Ultra 
Turrax Tube Drive Work Station Homogenizer (IKA-Works, Staufenim Breisgau, Germany). Soon 
after, the solution was transferred to a microtube and centrifuged for 15 min at 15000 rpm in a Hettich 
Mikro 200 Microcentrifuge (Hettich Lab Technology, Tuttlingen, Germany). The supernatant was 





THE ANTIOXIDANT AND ANTIDIABETIC ACTIVITIES OF 
ALSTONIA BOONEI IN VITRO AND IN VIVO 
3.1 Background 
Alstonia boonei is a large deciduous tree, which grows up to 35 meters high (Figure 3.1) and is widely 
distributed in Africa: Cameroon, Nigeria, Egypt, Ghana, Code D’Ivoire and Central African Republic. 
It belongs to the Apocynacea family and its species are scattered all over the African continent 
(Adotey et al., 2012). At the nodes, the leaves of A. boonei are in whorls of 5-8 oblanceolate parts 
with the lateral vein prominent at right angles to the midrib. The bark of the tree contains an abundant 
latex supply. The fruits are joined to thin follicles as long as 16 cm with brown floss at each end 
(Olajide et al., 2000). 
 
Figure 3.1: Alstonia boonei (Apocynaceae); Common names: cheese wood (English), emien 
(French), Awun (Yoruba, Nigeria), Egbu (Igbo, Nigeria), Ekuk (Ewondo, Cameroon). Adapted 




3.1.1 Ethnobotanical uses 
The stem bark remains the most commonly used part for therapeutic purposes; though more effective 
when used fresh, the dried part is also frequently used (Olajide et al., 2000). The bark has been found 
to contain anti-inflammatory, analgesic, antipyretic, antidiabetic, anti-helminthic and antimicrobial 
activities (Akinmoladun et al., 2007; Gupta et al., 2005; Okoye et al., 2014; Opoku and Akoto, 2015). 
A decoction of the stem bark is usually mixed in honey and taken four times a day as painkiller for 
dysmenorrhea, lower abdominal pain and pains as a result of malaria (Majekodunmi et al., 2008). 
Cold infusion from the stem bark (fresh or dry) is effective as a hypoglycaemic agent. This is also 
effective as a good deworming liquid (Adotey et al., 2012; Olajide et al., 2000). A mixture of the 
decoction of the stem bark of A. boonei with other plants can be used in treatment of asthma, fractures, 
jaundice and breastmilk induction. The leaves and latex are also used in the treatment of rheumatism, 
hypertension and muscular pain (Iniaghe et al., 2012).   
3.1.2 Biological activities 
Much attention has been given to the analgesic and anti-malaria effect of A. boonei and until recently 
little has been known on its anti-diabetic effects.  
The analgesic property of the methanol leaf extract was investigated, and it was discovered that the 
analgesic effects of A. boonei could be mediated through both central and peripheral mechanisms 
(Iniaghe et al., 2012). In order to validate the anti-microbial activity of A. boonei, the ethanol and 
aqueous extract of the root was assayed for microbial susceptibility using the agar well diffusion 
procedure (Opoku and Akoto, 2015). Some gram-positive and gram-negative bacteria such as 
Staphylococcus aureus, Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa and a fungus 
(Candida albicans) were used for this study and the result revealed that the ethanol extract exhibited 
better antimicrobial ability than the aqueous counterpart. An isolate obtained from the petroleum ether 
fraction of A. boonei lupeol acetate was investigated for its anti-arthritic activity in an arthritic animal 
model. Lupeol acetate reversed the increase in spleen weight and serum alkaline phosphatase which 
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Preface: This article reports in detail the in vitro antioxidant and anti-diabetic studies of the crude 
extracts from A. boonei;, it is currently under review in Journal of Natural Products Research.    
3.2.1 Abstract 
This study investigated the antioxidant activities of extracts from three parts of Alstonia boonei. 
Sequential extraction was done on the leaves, stem and root bark samples with solvents of increasing 
polarity and these extracts were assayed for total phenolic content and in vitro antioxidant and 
antidiabetic activities using different experimental models. The electron donating, 1,1-diphenyl-2-
picryl-hydrazyl (DPPH) and nitric oxide radical scavenging capacity of all the extracts was 
investigated in this study. The ability of these extracts to inhibit α-glucosidase and α-amylase were 
also examined in vitro. The ethanol extract of the leaves showed the highest total phenolic content 
compared to other extracts. All extracts showed free radical scavenging abilities in the different 
models. The ethanol and aqueous extracts significantly (p < 0.05) inhibited the key anti-diabetic 
enzymes tested. GC-MS analysis of the different plant parts revealed the presence of sterols, 
aromatics, aliphatic acids and esters, which when docked with α-glucosidase and α-amylase enzymes 
revealed a high binding affinity. Data from this study suggest that the different parts of A. boonei, 
especially the ethanol and aqueous extracts, possess potent anti-oxidant activities that points to further 
studies to identify the active agents. 




Medicinal plants have been widely accepted in Africa in the treatment and management of diverse 
ailments. Fortunately, Africa is a land flourishing with a diversity of plant species. According to 
World Health Organization (WHO), between 65% and 80% of the population of developing countries 
depend on medicinal plants (Palhares et al., 2015). Development of drugs from natural sources is well 
encouraged because only 15% of this has been fully exploited to determine their therapeutic potentials 
out of over 300 000 species of plants in the world (De Luca et al., 2012). Since the last century, the 
sporadic change in life styles and eating habits of the humans has led to unfolding of different types 
of chronic diseases such as diabetes (Eddouks et al., 2012).  
Diabetes is characterized under the category of non-communicable diseases (NCD) and is rapidly 
emerging as a global health challenge (Arredondo et al., 2018). The global prevalence of adults over 
18 years with diabetes has doubled over the past 20 years (Cho et al., 2018).  Data from the 
International Diabetes Federation (IDF) suggest that over 425 million people are currently diagnosed 
to be living with diabetes and this number has been proposed to increase by over 50% in 2040 (IDF, 
2017). Among all cases of diabetes, the most prevalent of all still remains type 2 diabetes (T2D) 
which is predominant in 95% of all diabetic cases (Fuchsberger et al., 2016). 
T2D is characterised by insulin resistance, partial β-cell dysfunction, which leads to and consequently 
if left unmanaged hyperglycaemia (Fuchsberger et al., 2016). Persistent hyperglycaemia has been 
implicated in the generation of free radicals through diverse pathways caused by auto-oxidation of 
the excess glucose in the blood stream (Asmat et al., 2016). The continuous build-up of free radicals 
which limits the antioxidant supply in the body leads to a condition known as oxidative stress (Asmat 
et al., 2016).  Oxidative stress has been linked to T2D-associated macro- and micro-vascular 
complications (Matough et al., 2012). 
The available synthetic drugs (such as metformin, glibenclamide, thiazolidinedione and others) have 
not been able to fully manage these T2D associated complications since their efficacy reduces slowly 
while they have some short- and long-term side effects. These side effects range from nausea, 
hypoglycaemia, heart problems, and body weight gain. Apart from these, the high cost and availability 
of these drugs also pose some drawbacks which leads to the need for alternate therapies from 
medicinal plants among which is Alstonia boonei.  
Alstonia boonei De Wild (family: Apocynaceae) is a towering tree which has species scattered all 
over Africa. In some parts of Africa, it is referred to as “sacred tree” and is worshiped in these areas. 
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Traditionally, decoctions from the stem bark is used to treat ailments such as fever, inflammations 
and joint pains (Akinnawo et al., 2017; Majekodunmi et al., 2008). The latex obtained from the stem 
bark is also used as an analgesic in some parts of Africa (Adotey et al., 2012). Formulations from the 
stem bark is currently being used in some parts of Nigeria in the effective treatment of malaria (Chime 
et al., 2013). The crude ethanol leaves extract of A. boonei has been shown to have potent high blood 
glucose reducing activity in an alloxan-induced rabbit model of diabetes (Akinloye et al., 2013; 
Osadolor et al., 2015). However, the detailed antidiabetic activity of the various parts of this plant are 
investigated yet and the mechanisms behind its antidiabetic activity are still unknown. 
This study was conducted to examine the detailed antidiabetic activity as well as mechanisms behind 
the antidiabetic effects of the different parts of this plant and thereafter, identify potential bioactive 
compounds which could render synergistic effects to its activity. In silico molecular docking was also 
performed with the compounds to estimate binding affinities of the identified compounds to α-
glucosidase and α-amylase which are potent carbohydrate hydrolyzing enzymes. 
3.2.3 Materials and methods  
Please refer to Chapter 2 for the detailed methods used for A. boonei. 
3.2.4 Results 
The ethanol extract of the leaves of A. boonei contained a significantly (p < 0.05) greater amount of 
total phenol compared to all the other extracts from the different parts of this plant. 
The total reducing power (reported as percentage gallic acid equivalent) of the different extracts of 
A. boonei in comparison to ascorbic acid and Trolox is shown in Figure 3.2.1. The result showed that 
the total reducing power of all extracts was increased with increasing concentrations. However, the 
ethanol and aqueous extracts of the leaves, stem- and root barks showed significantly (p < 0.05) higher 








Table 3.2.1: Total phenolic content of various extracts of A. boonei parts 




Ethyl acetate 50.04 ± 0.54d 
Ethanol 58.14 ± 1.66d 
Aqueous 26.71 ± 1.51a 
Stem bark 
 
Ethyl acetate 42.79 ± 0.057c 
Ethanol 31.9 ± 0.384ᵇ 
Aqueous 30.82 ± 0.85ab 
Root bark 
 
Ethyl acetate 33.00 ± 0.86ab 
Ethanol 34.09 ± 1.02ab 
Aqueous 34.82 ± 0.73ᵇ 
Results are reported as mean ± SD of three replicas. a-dDifferent superscripts alphabets within a column are significantly 
different from one another (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
Figure 3.2.2 shows the DPPH radical scavenging activities of A. boonei leaves, stem bark and root 
bark extracts. All extracts were able to scavenge the DPPH free radical in a dose-dependent manner 
however, the ethanol extract of the leaves and the aqueous extract of the stem- and root barks 
demonstrated a more potent DPPH inhibiting activity which was almost similar to the standard 
antioxidants (Trolox and Ascorbic acid) used. The IC50 values on Table 3.2.2 also for the ethanol 
extract of the leaves and stem bark and the aqueous extract of the root bark. 
The nitric oxide (NO) radical scavenging activities of the different extracts of A. boonei is shown in 
Figure 3.2.3. Compared to other parts, only the stem bark extracts showed a concentration-dependent 
inhibition of nitric oxide. The aqueous extract of the stem bark showed the lowest IC50 values (Table 








Figure 3.2.1: Total reducing power (relative to gallic acid) of leaves, stem bark and root bark extracts 
of A. boonei. Results are reported as mean ± SD of three replicas. a-dDifferent alphabets presented for a given 
concentration for each extract indicate significant difference (Tukey’s-HSD multiple range post hoc test, p < 0.05) EtAc: 
Ethyl acetate, EtOH: Ethanol, AA: Ascorbic acid. 












































































































Figure 3.2.2: DPPH radical scavenging activity of leaves, stem bark and root bark extracts of A. 
boonei. Results are reported as mean ±SD of three replicas. a-cDifferent alphabets over the bars for a given concentration 
for each extract indicate significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). EtAc: Ethyl 
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Figure 3.2.3: Percentage of nitric oxide scavenging activities of extracts from leaves, stem bark and 
root bark of A. boonei. Results are reported as mean ±SD of three replicas. a-dDifferent alphabets over the bars for a 
given concentration for each extract indicate significance of difference (Tukey’s-HSD multiple range post hoc test, p < 
0.05). EtAc: Ethyl acetate, EtOH: Ethanol, GA: Gallic acid, AA: Ascorbic acid. 
The α-glucosidase and α-amylase inhibitory activities of the extracts are shown in Figures 3.2.4 and 
3.2.5 when their respective IC50 values are represented in Table 3.2.2. The ethanol extracts 





































































































































which was similar to the standard drug (acarbose) used. Pancreatic α-amylase activity was also 
inhibited in vitro by all the extracts in a dose dependent fashion (Figure 3.2.5) and again the ethanol 




Figure 3.2.4: The α-glucosidase inhibitory effects of a) leaves, b) stem bark and c) root bark extracts 
of A. boonei. The results are reported as mean ±SD of three replicas. a-cDifferent alphabets over the bars for a given 
concentration of each fraction indicate significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
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Figure 3.2.5: α-amylase inhibitory effects of leaves, stem bark and root bark extracts of A. boonei. 
The results are reported as mean ±SD of three replicas. a-dDifferent alphabets over the bars for a given concentration of each 
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Table 3.2.2: The IC50 values of the different extracts of A. boonei in different antioxidant and anti-
diabetic models 
IC50 (µg/mL) 
 DPPH NO -glucosidase -amylase 
Leaves     
Ethyl acetate 7.54±0.55e 21.16±1.76d             495.65±1.62d                 259.21±5.72e      
Ethanol 8.61±0.09e 8.49 ±1.07b              87.05±0.87c                  102.93±9.76c 
Aqueous 13.03±0.71f 59.57±5.69f              >1000 684.59±98.62f 
Stem bark     
Ethyl acetate 6.24±0.11d 9.44±1.21b               >1000 >1000 
Ethanol 3.73±0.08b 17.68±2.64c              26.95±1.72a 16.78±1.02a 
Aqueous 6.95±0.71d 2.92±1.23a                423.61±9.27d                256.91±2.94e 
Root bark     
Ethyl acetate 7.46±0.46d 23.59±3.71d >1000 154.83±23.81d 
 
Ethanol 5.29±0.08c 34.32±4.28e 594.71±9.87e 129.06±3.21d 
 
Aqueous 2.34±0.10a >1000 >1000 734.52±3.20f 
 
Standards     
Gallic acid ND 365.25±14.82h           ND ND 
Ascorbic acid 2.19±0.05a 4.13±2.92e               ND ND 
Trolox 5.79±0.54c              156.83±3.62g           ND ND 
Acarbose ND ND 36.70±5.43b             87.21±7.43b 
The results are reported as mean ±SD of three replicas. a-hDifferent alphabets presented in a column for a given parameter 
for each fraction are significantly different from one another (Tukey’s-HSD multiple range post hoc test, p < 0.05). IC50: 
Concentration for 50% inhibition. 
Based on the above-mentioned results, the ethanol and aqueous extracts of the stem bark and leaves 
were subjected to GC-MS analysis . The results revealed the presence of aliphatic acids, esters, 







Table 3.2.3: Compounds identified from the different extracts of Alstonia boonei by GC-MS  
Compounds Molecular formula RT (min) Molecular mass Relative abundance (%) 
Ethanol extract of the leaves     
Megastigmatrienone C13H18O 13.65 190 0.41 
Tetradecanoic acid C14H28O2 15.58 228 0.41 
Phytol acetate C22H42O2 16.43 338 2.96 
Phytol C20H40O 19.11 296 2.00 
Octadecanoic acid C18H36O2 19.56 284 2.56 
4-Phenylbenzophenone C19H14O 20.07 258 1.09 
Stigmasterol-3,4-dedihydro-3-acetate C31H48O2 20.63 452 0.40 
9-(4-Methoxyphenyl) xanthene C20H16O2 22.40 288 2.89 
Acridin-9-yl-(4-methoxy-phenyl)-amine C20H16N2O 24.33 300 0.38 
Squalene C30H50 24.75 410 0.47 
Oleana-11,13(18)-diene C30H48 27.22 408 1.48 
Vitamin E C29H50O2 27.38 430 1.16 
Stigmasterol C29H48O 28.97 412 2.32 
Sitosterol C29H50O 29.77 414 1.81 
Aqueous extract of the leaves 
Xanthone C13H8O2 16.87 196 1.23 
Hexadecanoic acid methyl ester C17H34O2 17.25 270 3.27 
Octadecanoic acid methyl ester C19H38O2 19.18 298 2.08 
Octadecanoic acid C18H36O2 19.54 284 7.37 
Stigmasta-3,5-diene C29H48 26.83 396 4.78 
Ethanol extract of the stem bark 
Phytol acetate C22H42O2 16.41 338 0.43 
Xanthone C13H8O2 16.98 196 0.33 
Hexadecanoic acid methyl ester C17H34O2 17.30 270 0.41 
n-Hexadecanoic acid C16H32O2 17.65 256 4.85 
Hexadecanoic acid ethyl ester C18H36O2 17.98 284 2.85 
4-Phenylbenzophenone C19H14O 20.06 258 0.51 
9-(4-Methoxyphenyl) xanthene C20H16O2 22.40 288 3.56 
Stigmast-4-en-3-one C29H48O 23.25 412 0.85 
Squalene C30H50 24.75 410 0.48 
Ergost-5-en-3β-ol C28H48O 28.65 400 2.30 
Stigmasterol C29H48O 28.96 412 3.43 
Sitosterol C29H50O 29.77 414 2.67 




Figure 3.2.6:  Aliphatic acids and esters isolated from Alstonia boonei 
 
Figure 3.2.7: Sterols, sterol precursors and aromatics from Alstonia boonei 
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In silico analysis (molecular docking) was carried out to determine the inhibition potentials of the 
extracts. Table 3.2.3 revealed that α-amylase complex with Vitamin E from ethanol extract of leaves 
showed the highest inhibition potential with binding energy of 11.66 kcal/mol compared to other 
compounds while stigmasterol had the strongest binding affinities of 9.98 kcal/mol for α- glucosidase. 
Figure 3.2.8 and 3.2.9 showed the hydrogen bonding interactions between the atoms of the 
compounds with the highest binding energies and the amino acid residues around the active sites.  
The high binding energy associated with Vitamin E and stigmasterol may be due to the presence of 
methoxy and hydroxyl groups in their structures, respectively. The binding energies analysis and the 
hydrogen bonding interactions with active site residues gives further insight about the catalytic 
mechanism. 
Table 3.2.4: Highest binding energies (∆G) of compounds from the different extracts of Alstonia 






Ethanol extract of the leaves     
Vitamin E 11.66  9.82  
Aqueous extract of the leaves     
stigmasta-3,5-diene 8.88  -  
Xanthone -  8.11  
Ethanol extract of the stem bark     
Ergost-5-en-3β-ol 9.68  -  
Stigmasterol -  9.98  






Figure 3.2.8: The 3D representation of (a) hydrogen bonding interaction and (b) complex with active 
site residues of α- Glucosidase complexed with Vitamin E (highest binding energy). 
 
Figure 3.2.9: The 3D representation of (a) hydrogen bonding interaction and (b) complex with active 





Oxidative stress still remains a deleterious process for the generation of maladies such as T2D 
(Francisqueti et al., 2017). The antioxidant properties of medicinal plants can be measured through 
their reducing capacity, free radical scavenging ability, hydrogen ion donating and singlet oxygen 
quenching powers (Kasote et al., 2015, Seifu et al., 2012). The presence of total phenols in all 
investigated plant parts of A. boonei as shown in Figure 3.2.1 were mainly concentrated in the leaves 
which showed the antioxidant potential of A. boonei. The method used to determine the total phenol 
content is based on reducing capacity of A. boonei relative to gallic acid as compared to just reporting 
the amount of phenols present (Singleton et al., 1999). Compounds of phenolic derivatives are key 
antioxidants which exhibit free radical scavenging abilities and are interestingly widely distributed in 
plants (Maqsood et al., 2014). Some studies have reported that plants with an abundance of 
polyphenols can act as good antioxidants (Hossain and Shah; 2015; Noreen et al., 2017). The 
effectiveness of plant phenolics as antioxidants is also backed up by the ability of the different extracts 
to reduce Fe3+ to Fe2+ (Figure 3.2.2) and to inhibit the free radical DPPH (Figure 3.2.3). From our 
results, the ethanol extract of the leaves especially showed higher total phenol content and better 
reducing capacities which may suggest that the antioxidant capacity of A. boonei is mainly due to its 
more polar constituents as reported previously for the root bark of A. boonei (Obiagwu et al., 2014).  
Nitric oxide (NO) (low levels) under normal physiological conditions, acts as a regulator in 
physiological functions such as immune response, blood pressure and neural communication 
(Moncada et al., 1991). However, an overabundance of NO can lead to tissue damage and it is also 
associated with the cardiovascular complications of T2D (atherosclerosis and hypertension) (Adela 
et al., 2015; Pacher et al., 2007). Therefore, there has been focus on discovering antioxidants which 
may act as potential inhibitors of NO production (Chen et al., 2017). Our results showed that only 
ethanol and aqueous extracts of the stem bark were able to inhibit NO in a dose- dependent manner 
(Figure 3.2.3) which could be linked to the ability of A. boonei to inhibit inducible nitic oxide 
synthase (iNOS) as reported in a previous anti-diabetic study (Kehinde et al., 2016).  
Inhibition of -glucosidase and -amylase still remains a potent strategy in the development of 
antidiabetic drugs (Khan et al., 2016). These two enzymes present in the digestive tract or pancreas 
are responsible for the hydrolysis of disaccharides and starch to glucose and breakdown of long chain 
carbohydrates to smaller carbohydrate moieties (Kawamura-Konishi et al., 2012). Natural products 
which arephenolic in nature have been reported to inhibit the activity of these enzymes (Ramkumar 
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et al., 2010). In this study, the different extracts from the parts of A. boonei showed potent -
glucosidase (Figure 3.2.4) and -amylase (Figure 3.2.5) inhibitory activities. The in-silico results 
obtained from this study also suggest the ability of some compounds identified in A. boonei to bind 
effectively to the active and allosteric sites of the target enzymes, -glucosidase and -amylase 
(Figure 3.2.8 and 3.2.9). These findings further suggest that the plant extracts might reduce the 
hydrolysis of disaccharides and polysaccharides   as well as aid small intestinal absorption of glucose 
and thereby reduce blood glucose levels. 
GC-MS analysis of the leaves, stem bark and root bark revealed the presence of various bioactive 
compounds (Figures 3.2.6 and 3.2.7). Studies have investigated the characteristics of phenols in 
relation to their roles as antioxidants and it has been shown that this role can be due to their high 
capacity of hydrogen atom or single electron transfer potential to a free radical (Craft et al., 2012; 
Espinosa et al., 2015). Compounds which act best as phenolics have an electron donor group attached 
to an aromatic ring (antioxidant activity increases with a high number of rings) (Cheng et al., 2003). 
A total of 14 compounds (most of the phenols) were identified from the ethanol extract of the leaves 
alone (Table 3.2.2). Phenolics have also been proposed to be responsible for -glucosidase and -
amylase inhibitory activities (Ali Asgar, 2013) and this occurs through hydrogen bond formation in 
the active site of the enzyme between the -COO groups of Asp 197 and Glu233 with the hydroxyl 
groups in the phenols.  
Phytol and phytol acetate were also identified by GC-MS in the ethanol extract of the leaves and stem 
bark respectively. Some studies have proven the antioxidant and anti-diabetic effects of phytol and 
its derivatives (Ali Asgar, 2013; Santos et al., 2013). Our study showed a relative abundance (%) of 
phytol and phytol acetate in the ethanol extract of the leaves to be 2.00 and 2.96, respectively (Table 
3.2.2). Phytosterols are bioactive natural products present in plants with similar structure to 
cholesterol but have no effect on human cholesterol (Wang et al., 2017). Our study revealed the 
presence of stigmasterol, a member of the phytosterol family in the ethanol extract of the leaves and 
stem bark. Interestingly, phytosterols have gained recent attention in their role as antioxidants by 
preventing angiogenesis through inhibition of reactive oxygen species production and oxidative 
stress. The antioxidant activities of the plant earlier explained could be due to the synergistic effects 
of the identified phytosterols. Antidiabetic effects of phytosterols have also been demonstrated in a 
recent study (Kushwaha et al., 2015), which further gives credence to the efficacy of A. boonei as an 
antidiabetic agent. However, the observed antioxidant and antidiabetic effects of the different parts, 
especially the ethanol extract of the leaves and stem bark could be due to the synergistic effects of 
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the identified bioactive compounds. This assumption was further explored by using in silico 
molecular docking simulation to investigate the binding affinity of some of the compounds to the 
active site of the -glucosidase and -amylase enzymes. The highest binding energy of the 
compounds was exhibited by a phytol precursor (vitamin E) and stigmasterol from the ethanol extract 
of the leaves and stem bark, respectively (Table 3.2.3). 
In conclusion, this study suggests that the ethanol extract of the leaves and stem bark of A. boonei 
contains potent antioxidant agents coupled with -glucosidase and -amylase inhibitors which could 
be further exploited for the development of a therapeutic strategy for the management and control of 
post meal blood glucose levels, T2D and its macrovascular complications. Future work will entail 
solvent based fractionation of the crude extracts and a detailed study of the active fraction in a T2D 
model of rats.  
Postscript: From the above studies, the ethanol extract of the leaves showed the best antioxidant and 
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Preface: This chapter reports the detailed in vitro and ex vivo anti-diabetic effects of the fractions 
obtained from the ethanol extract of the leaves. It is currently under review in Indian Journal of 
Experimental Biology.   
3.3.1 Abstract 
The in vitro and ex vivo antioxidant, inhibitory effect on α-glucosidase and α-amylase activities as 
well as glucose absorption in rat jejunum, with concomitant enhanced glucose uptake in rat psoas 
muscle by different solvent fractions derived from the crude ethanol extract of the leaves of Alstonia 
boonei were investigated. There was marked increase in catalase, SOD activities and GSH levels, as 
well as reduced MDA levels which signified an improved pancreatic endogenous antioxidant activity. 
The butanol and aqueous fractions showed a high (p < 0.05) inhibitory activity on α-glucosidase (IC50 
= 26.98 and 6.49 µg/mL respectively) even higher than that of the standard drug, acarbose. The 
aqueous fraction caused a significant (p < 0.05) reduction in glucose absorption in isolated rat jejunum 
and enhanced glucose uptake in isolated rat psoas muscle. GC-MS analysis on the fractions revealed 
the presence of alkyl esters and alcohols which may be responsible for the antidiabetic potentials of 
the plant.  Data from this study suggest that the butanol and aqueous fractions could possess potent 
antioxidant agents and inhibitors of conditions linked to sustained hyperglycaemia. This can further 
be exploited for developing alternate treatments for type 2 diabetes and its accompanying 
complications.  
Keywords: Alstonia boonei, oxidative stress, type 2 diabetes, glucose absorption, glucose uptake. 
3.3.2 Introduction 
Globally, diabetes is on the rise with over 451 million people currently living with the disease (IDF, 
2017). This number is a lot more than that of the year 1980 (IDF, 2015) and is projected to increase 
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to 693 million by the year 2045 (IDF, 2017). Shockingly, about 49.7% of people living with diabetes 
remain undiagnosed and Africa seems to hold the largest population of undiagnosed cases (Cho et 
al., 2018). 
The three common types of diabetes are type 1 diabetes (T1D), type 2 diabetes (T2D) and gestational 
diabetes (Baynest, 2015). T2D holds the largest percentage (90%) of all the diabetic cases seen in the 
world today (Baynest, 2015).  
The prevalence of T2D is rapidly increasing due to changes in diet and sedentary lifestyle noticeable 
amongst the population today. Sadly this also arises due to an increase in the number of obese 
individuals (Kahn et al., 2014). This disease presents with persistent hyperglycaemia which occurs 
when there is a malfunction in the action of the hormone insulin responsible for transport of glucose 
to peripheral tissue and this phenomenon is call insulin resistance ((Halban et al., 2014). This 
hormone is produced in the pancreatic β-cells of the islet of Langerhans (Fu et al., 2013) and insulin 
resistance encourages continuous build-up of glucose in the blood stream which leads to major 
complications of T2D (Soumya and Srilatha, 2011). These complications include nephropathy, 
cardiomyopathy, neuropathy, retinopathy, skin and limbs problems (Soumya and Srilatha, 2011). 
Complications arising from the deleterious effects of hyperglycaemia could also be pronounced by 
the actions of reactive oxygen species (ROS) (Kaneto et al., 2010; Volpe et al., 2018). The destructive 
effects of ROS are usually controlled by the action of the natural endogenous antioxidants present in 
the body (Sarangarajan et al., 2017). However, in conditions such as oxidative stress, the effect of the 
ROS overwhelms the action of the antioxidant defence systems. Oxidative stress has been implicated 
to play a part in the progression of the above-mentioned complications of T2D (Asmat et al., 2016).  
Different treatment modalities are currently in place for the management of T2D and their 
mechanisms of action ranges from inhibition of hepatic glucose output, improvement and secretion 
of insulin (Meneses  et al., 2015). Unfortunately, the affordability, availability and undesirable side 
effects of these drugs warrant the development of an alternative therapy (Pandey et al., 2011). Since 
plants are natural carriers of antioxidants, so it is wise for them to be exploited. They are widely 
available and can be used to boost socio-economic status of humans. Fortunately, Africa has a diverse 
flora of plants which offers opportunities in the discovery of medicinal plant rich in nutrients and 
bioactive compounds that can prevent and treat diseases such as T2D.  
Alstonia boonei is a large deciduous tree towering up to 45 m in height, which belongs to the dogbane 
family (Apocynaceae) and is native to tropical West Africa (Okoye et al., 2014). The shape of the 
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leaves is oblanceolate, with the prominent lateral veins almost at right angles to the midrib. 
Traditionally, the plant parts of A. boonei are used for its aphrodisiac, antimalarial, antipyretic and 
antimicrobial activities (Adotey et al., 2012). The antioxidant properties of the fractions from the 
roots of this plant has been demonstrated (Obiagwu et al., 2014). Few research groups have 
investigated the antidiabetic effects of the plant parts of A. boonei (Akinloye et al., 2013; Enechi et 
al., 2014; Kehinde et al., 2016; Nkono et al., 2014; Zajac et al., 2010), most of these researchers have 
worked on the stem bark extract, but the other parts of the plant have been neglected. The possible 
mechanisms behind the antidiabetic effects have also not been investigated. Based on the diverse 
medicinal values of A. boonei, this study was carried out not only to understand the antidiabetic effects 
of all parts of the plants but also to understand the mechanisms behind its antidiabetic effects.  
3.3.3 Materials and methods 
Please refer to Chapter 2 for the detailed materials and methods used for A. boonei. 
3.3.4 Results 
Table 3.3.1 shows the total phenolic contents of the different fractions obtained from the ethanol 
extract of A. boonei leaves by solvent-based fractionation. The aqueous and butanol fractions showed 
the highest total phenol content compared to the remaining fractions. 
All fractions obtained from the ethanol extract of the leaves were found to inhibit the DPPH radical 
in a dose-dependent manner (Figure 3.3.1) but lowest IC50 value was exhibited by the aqueous 




Figure 3.3.1: DPPH radical scavenging activities of different solvent fractions of ethanol extract of 
A. boonei leaves. The results are reported as mean ± SD of three replicas. a-dDifferent alphabets over the bars for a given 
concentration indicate significant difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). DCM: Dichloromethane, 
EtAc: Ethyl acetate, AA: Ascorbic acid. 
All fractions demonstrated impressive ferric reducing potential. However, the total reducing power 
of the aqueous fraction was significantly (p < 0.05) higher than that of the other fractions and even 
than that of the standard antioxidant (Trolox) used (Figure 3.3.2). 
 
Figure 3.3.2: Total reducing power (relative to gallic acid) of different solvent fractions of ethanol 
extract of A. boonei leaves. The results are reported as mean ± SD of three replicas. a-dDifferent alphabets presented 
over the bars for a given concentration indicate significance of difference (Tukey’s-HSD multiple range post hoc test, p < 
0.05). DCM: Dichloromethane, EtAc: Ethyl acetate. 
Upon induction of oxidative stress with Fe2+ in the liver homogenate, there was a reduction in the 



























































































groups (Figure 3.3.3 a & b) however; treatment with different concentrations of the fractions 
significantly (p < 0.05) increased the endogenous antioxidant enzyme activity and GSH level and 
deceased MDA levels almost back to normal levels. The butanol and DCM fractions showed highest 
ability to induce catalase activities (Figure 3.3.3 a) in the treated cells. The aqueous fraction showed 
the highest SOD-activity inducing ability compared to other fractions (Figure 3.3.3 b). The butanol 
and aqueous fractions showed highest GSH level (Figure 3.3.3 c) inducing activities with 




Figure 3.3.3: Effect of fractions of A. boonei leaves on a) catalase activity, b) SOD activity, c) GSH 
level and d) lipid peroxidation in oxidative hepatic injury. Data are presented as mean ± SD of three replicas. 
*Significantly different from untreated sample and #Significantly different from normal sample (p < 0.05, Tukey’s-HSD-
multiple range post-hoc test, IBM SPSS for Windows). Normal = normal tissues, Untreated = oxidative stress injured tissues 
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Figure 3.3.4 shows the effect of the different fractions of ethanol extract of A. boonei leaves on -
glucosidase and -amylase activities. All fractions showed potent α-glucosidase and -amylase 
inhibitory activity with the butanol and aqueous fractions giving significantly (p < 0.05) higher 
enzyme-inhibitory activities compared to other fractions, and even higher than that of the standard 
drug (acarbose) tested. 
 
Figure 3.3.4: α-glucosidase inhibitory effects of the fractions from ethanol extract of A. boonei 
leaves. The results are reported as mean ±SD of three replicas. a-eDifferent alphabets presented over the bars for a given 
concentration indicate the significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). DCM: 





Table 3.3.1: IC50 values of the different solvent fractions of ethanol extract of A. boonei leaves in 
different antioxidant and antidiabetic models. 












Catalase SOD GSH LPO 
DCM                     51.4±1.4a 8.6±1.8c 110.1±4.7d 230.1±23.2d 11.3±2.4c 15.4±1.3d 8.3±1.4b 17.1± 2.2d 
EtAc 93.2±0.6b 11.4±0.5d 122.9±2.1e 145.6±15.1c 8.5 ± 1.5b 26.8±2.3e 13.3±1.0c 21.3±3.3e 
Butanol 122.7±0.8c 11.3±1.3d 26.9±1.4b 65.2±9.2b 1.2±0.4a 9.4±1.1c 1.4±0.2a 4.3±0.3b 
Aqueous 126.8±1.8d 2.1±0.2a 6.5±1.0a 53.1±10.2a 6.4±1.1b 5.4±1.1b 2.2±0.1a 2.2±0.4a 
Standards 
AA ND 2.2±0.4a ND ND  1.3±0.4a 1.1±0.04a 7.4±1.1b 9.5±1.7c 
Trolox ND 5.8±1.3b ND  ND ND ND ND ND 
Acarbose ND ND 36.3 ± 4.3c 65.1±2.4b ND ND ND ND 
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, ND-not determined, EtAc, Ethyl acetate fraction, TPC, Total Phenol Content, 
AA, Ascorbic acid, SOD, Superoxide dismutase, GSH, Reduced glutathione, LPO, Lipid peroxidation. Data are presented 
as mean ± SD values of three replicas. a-eDifferent letters stand for significantly different values from one another within a 
column (Tukey’s-HSD multiple range post hoc test, p < 0.05): the same letters stand for non-significant difference. 
The effect of the fractions from the ethanol extract of A. boonei leaves on glucose absorption in 
isolated rat intestinal jejunum is depicted in Figure 3.3.5 (a). All fractions inhibited glucose 
absorption by the intestine in a dose-dependent manner but the aqueous fraction showed the best 
inhibition.  
All fractions also induced glucose uptake by the rat psoas muscle in a dose-dependent manner, but 




Figure 3.3.5: Effect of the fractions from the ethanol extract of A. boonei leaves on (a) glucose 
absorption in isolated rat jejunum and (b) glucose uptake in rat psoas muscle. Data are presented as mean 
± SD of three replicas. a-cDifferent letters over the bars for a given concentration are significantly different from one another 
(p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). DCM: Dichloromethane. 
From the GC-MS result, the aqueous and butanol fractions of A. boonei were found to contain mainly 
alkyl esters and alcohols (Figure 3.3.6).  Phytol, phytol acetate and squalene are common natural 
products; squalene is the precursor to triterpenoids and sterols.  The dichloromethane extract also 
contained these compounds; however, five sterols were also present, ergost-5-en-3β-ol, stigmasterol, 
sitosterol, olean-12-en-3-one and urs-12-en-3β –acetate (Figure 3.3.7). These are common sterols 



















































































Figure 3.3.6:  Long chain hydrocarbons, alkyl esters and alcohols from fractions of A. boonei leaves. 
 














Aqueous fraction     
2-hydroxy-1-(hydroxymethyl ) ethyl 
hexadecanoate 
C19H38O4 23.58 330.50 41.67 
2,3-dihydroxypropyl octadecanoate C21H42O4 25.14 358.56 22.47 
Squalene C30H50 25.77 410.72 1.25 
Butanol fraction     
4-((1E)-3-hydroxy-1-propenyl)-2-
methoxyphenol 
C10H12O3 16.55 180.20 0.27 
Phytol acetate C22H42O2 17.42 338.57 0.54 
2-hydroxy-1-(hydroxymethyl) ethyl 
hexadecanoate 
C19H38O4 23.60 330.50 31.36 
2,3-dihydroxypropyl octadecanoate C21H42O4 25.15 358.56 17.37 
Squalene C30H50 25.76 410.72 0.38 
Dichloromethane fraction     
Phytol acetate C22H42O2 17.42 338.57 2.04 
Ethyl eicosanoate C22H44O2 18.98 340.58 0.82 
Phytol C20H40O 20.12 296.31 2.19 
Ethyl 14-methylhexadecanoate C19H38O2 20.85 298.50 0.51 
2-hydroxy-1-(hydroxymethyl) ethyl 
hexadecanoate 
C19H38O4 23.57 330.50 13.18 
2,3-dihydroxypropyl octadecanoate C21H42O4 25.13 358.56 5.78 
Vitamin E C29H50O2 28.04 430.70 0.88 
Ergost-5-en-3β-ol C28H48O 29.06 400.68 0.70 
Stigmasterol C29H48O 28.30 412.69 0.72 
Sitosterol C29H50O 29.91 414.71 0.97 
Olean-12-en-3-one C30H48O 31.42 424.70 2.96 
Urs-12-en-3β-acetate C32H52O2 32.05 468.40 13.76 






Antioxidants of natural origin are being used successfully to combat oxidative stress which aids in 
curbing the alarming increase of complications associated with diseases such as diabetes, cancer and 
others (Vijay and Vimukta, 2014). This study demonstrated that the fractions of the ethanol extract 
of A. boonei leaves possess significant antioxidant and anti-diabetic activity. The presence of 
polyphenols in the fractions could suggest the antioxidant activity of this plant. The total phenol 
content was determined by Folin-Ciocalteu method which gives an estimation of the total phenolic 
compounds present in a sample (Kopjar et al., 2009). Polyphenols have been reported to be 
responsible for the antioxidant activity of some medicinal plants due to their free radical scavenging 
activity (Kopjar et al., 2009). The phenolics present in this plant may delay the onset of lipid oxidation 
and decomposition of hydroperoxides in tissues by neutralizing free radicals, quenching singlet 
oxygen through redox reactions. This could make the plant useful in ameliorating oxidative stress in 
T2D. 
DPPH is a free radical that becomes a stable diamagnetic molecule by attracting electrons (hydrogen) 
from stable molecules (Kedare and Singh, 2011). The odd nitrogen atom in DPPH (violet colour) is 
reduced to yellow colour by receiving a hydrogen atom from antioxidants to generate a stable 
hydrazine complex. The observed DPPH radical scavenging activity of fractions of A. boonei may be 
linked to the presence of polyphenols in the plant. Table 3.3.1 shows that the aqueous fraction gave 
the lowest IC50 value and also the highest total phenol content. It was reported that plants with DPPH 
scavenging activity portray antioxidant activity by transferring hydrogen to free radicals, specifically 
hydroperoxide radicals which are major initiators of lipid autooxidation (Bamforth et al., 1993; 
Sowndhararajan and Kang, 2013). Interestingly, our results also reported the ability of these fractions 
to inhibit lipid peroxidation Figure 3.3.3 d.   
FRAP assay is widely used in the evaluation of antioxidant potentials of medicinal plants (Gil et al., 
2002). Iron is actively involved in the propagation of free radicals through the Fenton reaction by 
gaining or loosing electrons (Sudan et al., 2014). The aqueous fraction in this study showed a 
significant (p < 0.05) ferric reducing capacity which serves as an indicator of antioxidant ability 
Figure 3.3.2. This activity was also seen to be dose-dependent which indicates that with increasing 
doses there was an elevated activity. Although iron is an important trace element needed for sustaining 
physiological homeostasis, an overload of this element can lead to toxicity and cell death through 
formation of free radicals and lipid peroxidation (Imam et al., 2017) therefore, FeSO4 was used to 
induce oxidative stress in this study.     
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Incubation of the pancreatic homogenate with FeSO4 caused a reduction in both enzymatic (catalase 
and SOD) and non-enzymatic GSH  system which signals the initiation of oxidative stress (Figure 
3.3.3 a-d).  
Catalase and SOD are cellular antioxidant enzymes that work closely to convert superoxide radicals 
to less harmful H2O2 and then finally to water and oxygen molecules. If no antioxidants are present, 
the H2O2 dismutation by SOD from the superoxide ion can react with ferric ions which then elevate 
MDA levels thereby triggering lipid peroxidation (Erukainure et al., 2017b). Interestingly, the 
improvement of catalase and SOD activities and consequently inhibition of lipid peroxidation by the 
fractions of A. boonei signifies the antioxidant potential of this plant.   
GSH is an important cellular non-enzymatic antioxidant biomolecule that prevents oxidative damage 
by alleviating free radical induced lipid peroxidation. Low GSH levels and inactive GSH metabolism 
have been reported to facilitate the progression of complications seen in T2D (Kalkan and Suher, 
2013). Our results showed the ability of the fractions (especially the butanol and aqueous fraction) to 
significantly (p < 0.05) increase the GSH levels even more than the activity of the standard tested 
(ascorbic acid) (Figure 3.3.3 c). This could further justify the proposed antioxidant potential of this 
plant.   
An effective way of managing T2D is reduction of postprandial hyperglycaemia which can be 
accomplished by inhibiting enzymes that hydrolyse carbohydrate (-glucosidase and -amylase) in 
the stomach (Erukainure et al., 2017b , Kalita et al., 2018). Acarbose, a synthetic drug which inhibits 
carbohydrate metabolism in the gastrointestinal tract presents with side effects such as nausea, 
blotting, itching, diarrhoea, and easy bruising (Telagari and Hullatti, 2015). Fortunately, medicinal 
plants have been known to exhibit -glucosidase inhibiting activities which sheds more light on their 
hypoglycaemic tendencies (Yin et al., 2014).  The ability of the fractions, especially the butanol and 
aqueous fractions, to inhibit these key carbohydrate hydrolysing enzymes in a dose-dependent manner 
substantiates the antidiabetic potential of A. boonei (Figure 3.3.4). The ability of this plant to inhibit 
-glucosidase and -amylase might be useful in minimising side effects such as nausea and flatulence 
associated with anti-diabetic synthetic drugs. 
Since the aqueous, butanol and DCM fractions showed inhibition of key carbohydrate digesting 
enzymes it was important to investigate their ability to inhibit glucose absorption in normal rat 
jejunum. Excess glucose absorption by the intestine is one key pathological dysfunction in T2D and 
this, together with ineffective glucose uptake by peripheral organs such as the muscle, leads to 
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sustained hyperglycaemia (Szablewski, 2011). The rate of absorption of glucose varies from one 
intestinal segment to the other with highest absorption seen at the joining of the duodenum to the 
jejunum (proximal to mid small intestine) (Oyebode et al., 2018; Rider et al., 1967). This justified 
the use of this part of the intestine for our ex vivo study. From our result (Figure 3.3.5 a), without the 
fractions there was a high peak value absorption of glucose at 13.5±1.02 mg/cm jejunum which was 
seen to reduce with increasing doses of the different fractions. However, this value was significantly 
(p < 0.05) reduced to 1.13±0.24 mg/cm jejunum in the presence of the highest dose of the aqueous 
fraction, which suggests the inhibitory effect of the fraction on intestinal glucose absorption. In 
normal conditions, glucose homeostasis is regulated by insulin through glucose transporters (GLUT4) 
in effectively transporting excess glucose to peripheral organs where it is needed (Alvim et al., 2015). 
Insulin resistance in the skeletal muscle occurs as a precursor to beta cell failure and persistent 
hyperglycaemia (DeFronzo and Tripathy, 2009). In our study, the fractions at increasing doses were 
able to stimulate induction of glucose uptake in the rat psoas muscle with the highest induction 
exhibited by the aqueous fraction. This results in collaboration with the -glucosidase and -amylase 
inhibitory potential further justifies the anti-diabetic activity of A. boonei.  
Possible bioactive compounds in the aqueous, butanol and DCM fractions of A. boonei were detected 
using GC-MS analysis. The aqueous fraction showed a high relative abundance of 2-hydroxy-1-
(hydroxymethyl) ethyl hexadecanoate (41.67%); this compound has been reported to possess 
antioxidant and hypocholesterolemic activities (Jegadeeswari et al., 2012; Tyagia and Argawak, 
2017). The high abundance of this compound in the aqueous and butanol fractions (Table 3.3.2) could 
be responsible for the observed antioxidant and anti-diabetic activities of the fractions. Furthermore, 
the high presence of total phenols in this plant could also account for the presence of the sterols 
identified in the fractions. Interestingly, the observed anti-diabetic activity of this plant could be due 
to the likely synergistic actions of the compounds detected through GC-MS analysis.  
In summary, this study showed that the fractions of A. boonei leaves (especially the aqueous fraction) 
contains polyphenolic compounds with free radical scavenging ability and also key anti-diabetic 
enzymes (-glucosidase and -amylase) inhibitory potential. Furthermore, the identified bioactive 
agents in this study might be responsible for its antioxidant and anti-diabetic ability which can be 
further exploited in future studies.  
Postscript: The butanol fraction was picked for in vivo experiment since it had high antioxidant and 
antidiabetic activity in the tested models.  
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3.4 Effects of the butanol fraction of Alstonia boonei leaves on pancreatic histology, 
glucose homeostasis and insulin secretion in diabetic rats 
O.A Oyebode, O.L Erukainure, O. Sanni, M.S. Islam* 
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville 
Campus), Durban 4000, South Africa  
*Corresponding author: islamd@ukzn.ac.za; Tel: +27 (0)31-260-8717; Fax: +27 (0)31-260-7942 
Preface: This article reports the detailed in vivo anti-diabetic studies of the butanol fraction and it is 
currently under revision in the Journal of Ethnopharmacology. 
3.4.1 Abstract 
The potential use of Alstonia boonei for the management of symptoms related to type 2 diabetes 
(T2D) has gained more attention in recent times. However, only a few published evidences explained 
the roles of A. boonei in protecting pancreatic β-cells. This study was conducted to assess changes in 
polyphagia, polydipsia, body weight, glucose level, insulin secretion, β-cell function (HOMA-β), 
insulin resistance (HOMA-IR), serum fructosamine, liver glycogen, serum lipids, biomarkers of 
hepatic and renal function and histological changes in the pancreas of streptozotocin (STZ)-induced 
diabetic rats following treatment with butanol fraction of A. boonei leaves (ABBF). ABBF was given 
to six-weeks old STZ-induced diabetic rats for a 5-week intervention period. The glucose tolerance 
was assessed by oral glucose (2 g/kg) tolerance test (OGTT) and subsequently, insulin resistance and 
pancreatic β-cell function was assessed by calculating homeostatic model assessment (HOMA-IR and 
HOMA-β). The histological changes in the pancreas were then observed by hematoxylin-eosin 
(H&E) staining. ABBF treatment at 150 mg/kg bw, significantly (p < 0.05) lowered blood glucose 
level, improved oral glucose tolerance ability, stimulated insulin secretion and hepatic glycogen 
synthesis and promoted islet regeneration. These results suggest that ABBF could be exploited as a 
therapeutic agent for treating T2D. 
Keywords: Type 2 diabetes, Alstonia boonei, pancreatic β-cells, histopathology, serum insulin 
3.4.2 Introduction 
The prevalence of diabetes has seen a steep rise, the IDF reported that in 2017 over 451 million (age 
18-99 years) people are living with diabetes and this figure is expected to increase to 693 million by 
the year 2045 (IDF, 2017). This staggering statistic is being further aggravated as almost half of the 
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global diabetic population (49.7%) remains undiagnosed (Ogurtsova et al., 2017). In 2017 alone, over 
5 million fatalities were attributed to diabetes in the 20-99 age range, and the global expenditure on 
diabetes rakes USD 850 million (Cho et al., 2018). Over 95% of all diabetic cases are type 2 diabetes 
which makes T2D the most common form of diabetes (IDF, 2017). T2D is a disease characterised by 
insulin resistance and partial pancreatic β-cell dysfunction which leads to persistent hyperglycemia 
(Kohei, 2010). Pancreatic β-cell dysfunction has been proposed to occur not only due to the loss of 
pancreatic β-cell mass (as a result of exhaustion) but also due to oxidative stress subsequently β-cell 
failure (Swisa et al., 2017). Replenishing insulin-producing pancreatic β-cells could be a crucial 
approach to treat T2D and its numerous complications (Aguayo-Mazzucato and Bonner-Weir, 2017). 
Despite different treatment modalities of T2D, glucose fluctuation in type 2 diabetic patients still 
remains a challenge (Li et al., 2016). Hence, there is an urgent need to find better alternatives from 
medicinal plants with glucose lowering abilities as well as fewer side effects.  
Alstonia boonei is a large deciduous tree which belongs to the Apocynaceae family. A. boonei is being 
used for different purposes due to its high antioxidant power and there is a large volume of published 
data described that the stem bark of A. boonei is rich in polyphenols, tannins and flavonoids which 
are potent in the treatment of disease such as diabetes (Nkono et al., 2014, Kehinde et al., 2016, 
Akinloye et al., 2013). In this study, the butanol fraction of the leaves of A. boonei was subjected to 
a detailed anti-diabetic study in a T2D rat model. 
3.4.3 Materials and methods 
Please refer to Chapter 2 for the detailed materials and methods used for A. boonei. 
3.4.4 Results 
The data in Figure 3.4.1 represents the mean of daily food and fluid intake during the five-week 
intervention period. The DBC group showed significantly (p < 0.05) higher food and fluid intake 
compared to the normal groups (NC and NAB). Although the food consumption in the ABBF treated 
groups was not statistically significant compared to the DBC group, the fluid intake in the ABBF 
treated groups was significantly lower than the DBC group, with no significant difference with 




Figure 3.4.1: The effects of oral treatment of butanol fraction of A. boonei leaves on food and fluid 
intake in different animal groups during the experimental period. Data are presented as mean ± SD of seven 
animals. a-cValues with different letters over the bars for a given parameter are significantly different from one another 
(Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DABL, Diabetic A. 
boonei low dose, DABH, Diabetic A. boonei high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NAB, 
Normal A. boonei high dose (toxicological control). 
The data of weekly body weight changes are presented in Figure 3.4.2. In the initial 2 weeks of the 
experiment, there was no significant difference in the body weight amongst the different animal 
groups. However, the diabetic groups showed lower body weight gain compared to the normal groups 
during the rest of the period of the study (Figure 3.4.2).   
 
Figure 3.4.2: The effects of oral treatment of butanol fraction of A. boonei leaves on mean body 
weight gain for all groups of experimental animals over the seven weeks experimental period. Data are 
presented as the mean ± SD of seven animals. a-cValues with different letters for a given week are significantly different 
from one another (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DABL, 
Diabetic A. boonei low dose, DABH, Diabetic A. boonei high dose, DBM, Diabetic metformin, DBG, Diabetic 
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After STZ injection, the diabetic groups showed significantly higher blood glucose concentrations 
when compared to the normal groups. However, as soon as treatment of the animals started the DABL 
and the DABH groups portrayed a significantly lower (p < 0.05) blood glucose levels than the 
untreated group (DBC) throughout the entire intervention period (Figure 3.4.3). The low dose 
(DABL) showed relatively lower blood glucose levels than the high dose (DABH) (Figure 3.4.3)  . 
The DABL group showed lower blood glucose level in both non-fasting (week 1-4) and fasting (week 
5) levels compared to the DABH group. 
Figure 3.4.3:  The effects of oral treatment of butanol fraction of A. boonei leaves on weekly blood 
glucose concentrations in different animal groups during the intervention period. Data are presented as 
the mean ± SD of seven animals. a-dValues with different letters for a given week are significantly different from one another 
(Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DABL, Diabetic A. 
boonei low dose, DABH, Diabetic A. boonei high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NAB, 
Normal A. boonei high dose (toxicological control), STZ, Streptozotocin, NFBG, Non-fasting blood glucose, FBG, Fasting 
blood glucose. 
The data for OGTT and the corresponding area under the curve (AUC) are shown in Figure 3.4.4. 
The glucose tolerance of DABL and DABH groups were significantly (p < 0.05) better than the DBC 
group and even comparable to the metformin group (DBM). A better glucose tolerance ability was 
observed in the DABL group at 120 min mark which was manifested all through the OGTT. The total 
area under the curve (AUC) of DABL and DBM groups were significantly lower than the other 










































   
Figure 3.4.4: The effects of oral treatment of butanol fraction of A. boonei leaves on oral glucose 
tolerance test (OGTT) and corresponding area under the curve (AUC) of different animal groups in 
the last week of the intervention period. Data are presented as the mean ± SD of seven animals. a-eValues with 
different letters for a given time are significantly different from one another (Tukey’s-HSD multiple range post hoc test, p 
< 0.05). NC, Normal control, DBC, Diabetic control, DABL, Diabetic A. boonei low dose, DABH, Diabetic A. boonei high 
dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NAB, Normal A. boonei high dose (toxicological control), 
AUC, Area under the curve. 
The liver weight, relative liver weight and liver glycogen level of different animal groups are shown 
in Table 3.4.1. There was no significant difference in the liver weight of all animal groups; however, 
the relative liver weight of the normal groups (NC and NAB) were significantly (p < 0.05) lower than 
that of the diabetic groups. The DABL group showed a significantly (p < 0.05) lower relative liver 
weight compared to the DBC group. The treatment with ABBF increased the liver glycogen level 









































NC DBC DABL DABH DBM DBG NAB
AUC: 424.28±20.15a 2290±389.47d   1602±127.35b 1901±118.49c 1765.67±215.28b 2106.38±256.39d 426±25.39a
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 Table 3.4.1: The effects of different doses of ABBF on liver weight, relative liver weight and liver 
glycogen levels in the different animal groups at the end of the intervention period 
      NC       DBC 
      
DABL 
     
DABH       DBM       DBG      NAB 
Liver 
weights (g) 10.7±0.8 8.7±0.9 9.6±0.5 10.9±1.1 9.6±0.7 9.9±0.9 9.7±0.9 
Rel. liver 
weights (%) 2.9±0.1a 3.8±0.2b 3.9±0.1b 4.0±0.5b 2.7±0.1a 2.4±0.1a 2.7±0.1a 
Liver 
glycogen 
(mg/g tissue) 36.0±0.9e 11.8±1.1a 31.3±1.1c 29.0±0.9b 31.4±1.1c 21.8±0.8b 34.9±0.6d 
Results are reported as mean ± SD (n=7). a-fDifferent superscript letters for a given parameter along a row indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
Figure 3.4.5 shows the data for the serum lipid profile of all animal groups at the end of the 
experimental period. The DBC group showed significantly (p < 0.05) higher total and LDL 
cholesterol than the normal groups (NC and NAB) however, a reduced level of these cholesterols was 
noticed in the DABL, DABH and DBM groups. On the other hand, the DBC group showed a 
significantly (p < 0.05) lower level of HDL-cholesterol which was increased in the ABBF and 
standard drug-treated groups. Induction of T2D also caused significant (p < 0.05) increase in serum 
triglycerides level which was reduced in the ABBF treated groups.  
Figure 3.4.5: The effects of oral treatment of butanol fraction of A. boonei leaves on serum lipid 
profile of different animal groups at the end of the intervention period. Data are presented as the mean ± SD 
of seven animals. a-eValues with different letters for a given parameter significantly different from one another (Tukey’s-
HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DABL, Diabetic A. boonei low 
dose, DABH, Diabetic A. boonei high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NAB, Normal A. 
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Data of other serum indices of diabetic complications investigated are shown on Table 3.4.2. Serum 
ALT level was not affected neither by the induction of T2D nor by the treatment with plant fraction 
and standard anti-diabetic drugs. Levels of ALP, AST and urea in the serum were elevated in the 
DBC group compared to the NC and NAB groups. Interestingly, ABBF treatment significantly 
ameliorated the ALP, AST, urea and creatinine levels in the respective groups. 
Table 3.4.2: Serum biochemical parameters in different animal groups at the end of the 
experimental period.        
      NC DBC DABL DABH DBM DBG NAB 
AST (U/L) 57±5.3b 119±11.4f 45.7±3.4a 86±8.2d 102.5±7.1e 85±7.3d 66.4±3.5c 
ALT (U/L) 87.8±1.3 87.3±0.7 89.5±1.1 85±2.4 85.5±1.41 86.3±1.6 86.3±1.5 
ALP (U/L) 72.3±2.5a 308.3±45.3e 294.5±12.4d 492.3±9.3f 206.8±30.1c 341.5±45.9e 89.3±2.7b 
Urea (mg/dL) 48±2.3a 77±1.7d 51±2.6b 58±3.1c 51±2.3b 52±2.1b 47±3.6a 
UA (mg/dL) 0.78±0.43a 3.5±0.9d 1.5±0.7ab 2.4±0.3c 1.3±0.5ab 1.6±0.7ab 1.5±0.3ab 
CK-MB (U/L) 118.9±15.2a 293.2±21.1d 274.1±15.1d 382.5±19.6e 113.9±11.5a 175.3±18.5c 138.1±15.3b 
Data are reported as mean ± SD (n=7). a-fDifferent superscript letters along a row for a given parameter indicate significance 
of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DABL, 
Diabetic A. boonei low dose, DABH, Diabetic A. boonei high dose, DBM, Diabetic metformin, DBG, Diabetic 
glibenclamide, NAB, Normal A. boonei high dose (toxicological control), AST, Aspartate aminotransferase; ALT, Alanine 
aminotransferase; ALP, Alanine phosphatase; UA, Uric acid, CK-MB, Creatinine kinase-myocardial band.   
The DBC group showed a significantly (p < 0.05) lower serum insulin concentration compared to the 
normal groups (NC and NAB) however, the ABBF treated groups showed significantly (p < 0.05) 
higher insulin concentration than the untreated group (DBC) (Table 3.4.4). In the DBC group, the 
HOMA-IR score was significantly (p < 0.05) higher wile HOMA-β score was lower compared to the 
normal groups. Interestingly, the DABL treatment significantly (p < 0.05) improved the HOMA-IR 
and HOMA-β scores at the end of the treatment period. 
Table 3.4.3: Serum insulin and fructosamine concentrations as well as calculated HOMA-IR and 
HOMA-β scores of different animal groups at the end of the experimental period. 
      NC DBC DABL DABH DBM DBG NAB 
Serum Insulin 
(pmol/L) 138.7±19.3e 23.6±3.3a 41.5±2.6b 25.2±1.1a 59.9±8.3c 41.5±5.8b 74.4±3.5d 
Fructosamine 
(µmol/L) 495.8±17.0a 956.3±206.7c 827±137.1b 1016±309.7d 897.5±160.8b 858.5±138.6b 505.3±104.3a 
HOMA-IR 4.1±1.4b 14.1±2.1d 4.4±0.9b 3.35±1.1b 6.51±0.8c 5.2±0.7bc 2.3±0.6a 
HOMA-β 100.3±1.7f 2.7±0.2a 25.9±0.5e 9.2±0.3c 11.9±1.3d 7.0±0.4c 130.5±5.3g 
Results are reported as mean ± SD (n=7). a-dDifferent superscript letters for a given parameter along a row indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, 
DABL, Diabetic A. boonei low dose, DABH, Diabetic A. boonei high dose, DBM, Diabetic metformin, DBG, Diabetic 
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glibenclamide, NAB, Normal A. boonei high dose (toxicological control), HOMA-IR and HOMA-β; Homeostatic model 
assessment for IR (insulin resistance) and β (β-cell function).  
Histopathological examination of the pancreas is shown in Figure 3.4.6. Microscopic examination of 
the normal (NC) pancreas sections showed the normal appearance of the pancreatic islets which 
looked lightly stained than the surrounding acinar cells (black arrow). The acinar cells are generated 
from pyramidal cells with basal nuclei and apical acidophilic cytoplasm. Induction of T2D caused a 
severe destruction to both the exocrine and endocrine components of the pancreatic islets in the DBC 
group (red arrow). The acinar cells appear swollen and vacuoles were seen in almost all acinar cells 
compared to the pancreas of NC group. The β-cells of pancreatic islets are almost entirely lost in 
STZ-injected rats (red arrow). Similar findings were seen in the DBG group (green arrow). However, 
lower dose (grey arrow) of ABBF treatment rendered protection and regeneration abilities to the T2D-
associated destruction of β-cells because atrophic alterations of the acinar cells were less severe with 
larger islets. while higher dose (yellow arrow) of ABBF could not show any such protection of 
pancreatic β-cells (Figure 3.4.6).    
 
Figure 3.4.6: Histopathological images of the pancreas of different animal groups at the end of the 
experiment. NC, Normal control, DBC, Diabetic control, DABL, Diabetic A. boonei low dose, DABH, Diabetic A. boonei 





Medicinal plants have been used for many years for the treatment of diseases such as type 2 diabetes 
(T2D). The goal of most treatment modalities of T2D is to maintain near normal levels of blood 
glucose both in the fasting and non-fasting states. Although extensive researches have been done on 
the efficacy of medicinal plants as a source of anti-diabetic agents, some plants are yet to be explored 
and Alstonia boonei is one of them.  
Frequent thirst (polydipsia) and constant hunger (polyphagia) with subsequent weight loss are major 
symptoms of T2D (Pan et al., 2017). The ability of ABBF to ameliorate these symptoms particularly 
fluid intake is noteworthy (Figure 3.4.1).  The short time frame for the intervention period (5 weeks) 
might be responsible for the insignificant alteration of food intake and body weight gain of the 
experimental animals as shown in Figure 3.4.2.  
A common pathogenesis of T2D is sustained hyperglycemia, shown by high fasting (> 7 mmol/L) or 
non-fasting (> 8.5 mmol/L) blood glucose levels. Insulin resistance together with partial pancreatic 
β-cell dysfunction has been implicated in favouring the progression of hyperglycemia (Cerf, 2013). 
Maintaining normal blood glucose levels in diabetic patients is a key factor in eliminating the various 
subsequent complications associated with this disease (Asif, 2014). Some medicinal plants have been 
reported to show their anti-diabetic activities through stimulating glucose uptake in peripheral tissues 
(Oyebode et al., 2018), insulin release (Islam and Choi, 2008; Patel et al., 2012), or β-cell protecting 
activities (Oh, 2015). In this study, the low dose of the fraction of A. boonei (150 mg/kg body weight) 
showed better anti-hyperglycemic ability than the high dose (300 mg/kg body weight). It has been 
noticed from other serum parameters and histopathological study of pancreas that the higher dose 
(300 mg/kg body weight) of ABBF was more detrimental or toxic rather than hypoglycemic and anti-
diabetic in this study. However, ABBF did not show any hypoglycemic tendencies since the normal 
toxicological group (NAB) remained normal all through the experimental period (Figure 3.4.3), 
however the effects of the higher dose of ABBF in normal and diabetic animals may not be the same.  
Additionally, treatment with ABBF led to  improved glucose intolerance (Figure 3.4.4), which might 
be due to increased secretion of insulin or reduced insulin resistance that increased the uptake of 
glucose in peripheral tissues. In addition to the glucose tolerance improving activity, the lower dose 
of the fraction reduced HOMA-IR score (insulin resistance) and improved HOMA-β scores (β-cell 
functions) (Table 3.4.3) and pancreatic β-cell regeneration (Figure 3.4.6). These results suggest the 
hypoglycemic activity of A. boonei may not only be via reducing insulin resistance (HOMA-IR) but 
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also by improving pancreatic β–cell dysfunction (HOMA-β). In addition to these two mechanisms, 
ABBF also increased glucose mobilization by stimulating the synthesis of hepatic glycogen as shown 
by the increased liver glycogen content (Table 3.4.1).  
Reduction of liver glycogen levels as a result of sporadic glycogen phosphorylation or reduced 
glycogen synthesis is another pathogenic feature of STZ-induced T2D (Islam, 2011). Medicinal 
plants have been reported to possess hepatic glycogen synthetic abilities and this has been suggested 
to be responsible for their anti-diabetic activity (Ezeani et al., 2017; Patel et al., 2012). The observed 
hepatic glycogen stimulatory activity of the fraction could suggest that the fraction might enhance 
glucose uptake by the liver and skeletal muscles.  
Lipids are the key players in the pathogenesis of many complications of T2D. Elevated serum total 
cholesterol and depletion of serum HDL-cholesterol in diabetes can lead to atherosclerosis and 
coronary heart diseases, which are some of the fatal macrovascular complications of T2D if left 
untreated (Farook et al., 2011). In this study, the significant reduction of serum total cholesterol, 
triglycerides and LDL-cholesterol with concomitant increase of serum HDL-cholesterol after 
treatment with the lower dose of A. boonei fraction render cardiac protective effect A. boonei in type 
2 diabetic condition (Figure 3.4.5). Plants elicit harmful cholesterol reduction and high HDL/LDL 
ratio by the activation of LDL receptors in liver cells to encourage effective LDL-cholesterol 
excretion (Kapur et al., 2008).  
Other markers of diabetic complications, ALT, AST for hepatocellular injury and ALP for cholestasis 
were also explored in this study. Induction of T2D caused significant increase in serum levels of AST 
and ALP suggesting impaired liver function, while increased serum urea levels denotes impaired 
kidney function (Table 3.4.2). However, treatment of diabetic rats with low dose of ABBF reduced 
the levels of these enzymes indicating the amelioration of T2D-related liver and kidney damages.  
Elevated serum uric acid levels and CK-MB (creatinine kinase-myocardial band) causes an 
accumulation of uric acid in the joints and soft tissues triggering arthritis, gout, insulin resistance, 
hypertension, cardiovascular and renal diseases (Jalal et al., 2011; Momeni, 2012). The ability of the 
fractions of A. boonei to reduce serum uric acid levels (Table 3.4.2) could suggest the potency of the 
fractions in ameliorating insulin resistance and also render cardio and renal protection in type 2 
diabetic patients, thereby limiting the risks of diabetic complications.   
It is interesting to note that an earlier research reported the toxicity of fractions/extracts of A. boonei 
at a dose of 200-400 mg/kg bw (Olanlokun and Olorunsogo, 2018). This might be responsible for the 
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observed low antidiabetic activities and eminent β-cell toxicity as observed in our study with the high 
dose of ABBF (Figure 3.4.6). From the data of our study, it is clear that the low dose (150 mg/kg 
bw) of ABBF is a better choice for controlling hyperglycemia while >200 mg/kg bw may be toxic, 
as observed in a previous study (Olanlokun and Olorunsogo, 2018). However, our data clearly 
demonstrated the toxicity of 300 mg/kg bw dose in diabetic condition. 
In conclusion, this study shows that the butanol fraction of Alstonia boonei leaves (at a dose of 150 
mg/kg BW) is hypoglycemic which might be mediated by the modulation of pancreatic β-cell 
function, stimulation of insulin sensitivity and hepatic glycogen synthesis. In addition, the fraction 
















3.5 Butanol fraction of Alstonia boonei leaves ameliorates oxidative stress in a type 2 
diabetes model of rats 
Olajumoke A. Oyebode, Ochuko L. Erukainure, and Md. Islam* 
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville 
Campus), Durban 4000, South Africa  
*Corresponding author: islamd@ukzn.ac.za; Tel: +27 (0)31-260-8717; Fax: +27 (0)31-260-7942 
Preface: This article reports the detailed in vivo antioxidant status of the serum and organs collected 
from the rats in the above experiment and it is currently awaiting revision before submission to a 
journal for publication. 
3.5.1 Abstract 
The effects of oral administration of the butanol fraction of Alstonia boonei (ABBF) on antioxidative 
status in the serum, pancreas, liver, kidney and heart of type 2 diabetic rats was examined. The 
markers of oxidative stress measured in vivo were TBARS (thiobarbituric acid reactive substances), 
catalase, super oxide dismutase (SOD), reduced glutathione, glutathione reductase and peroxidase. 
Induction of type 2 diabetes (T2D) using 40 mg/kg BW caused a noticeable reduction of endogenous 
antioxidant enzymes as well as an increment in MDA levels (a marker of lipid peroxidation) in 
diabetic rats. However, treatment with ABBF (especially the low dose) significantly (p < 0.05) 
increased reduced glutathione levels and other endogenous antioxidant enzymes in the serum and 
other organs compared to diabetic controls. Results of this study indicate that ABBF has a strong 
antioxidant effect in a type 2 diabetic rat model. 
Keywords: A. boonei, oxidative stress, antioxidants, lipid peroxidation, type 2 diabetes 
3.5.2 Introduction 
In type 2 diabetes (T2D), macro and micro vascular complications arise as a result of persistent 
hyperglycemia (Stolar, 2010). This sustained hyperglycemia tends to favor the production of free 
radicals through different pathways such as: glucose autooxidation, advanced glycation end products, 
polyol pathway, protein kinase C activation, and increased flux of the hexosamine pathway 
(Ahmadinejad et al., 2017). When an imbalance in the ratio of free radicals to antioxidant enzymes 
favors free radicals it leads to a condition known as oxidative stress (Kurutas, 2015). The duo of 
oxidative stress and hyperglycemia have combinatorial roles in the generation of multiple 
complications of T2D (Matough et al., 2012). Therefore, amelioration of in vivo oxidative stress is 
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an important therapeutic mechanism that could be beneficial to people suffering from T2D and its 
complications.  
The deleterious effects of oxidative stress in normal body function is curbed by the action of both 
enzymatic and non-enzymatic antioxidant defence mechanism (Birben et al., 2012). Enzymatic 
antioxidants comprise of superoxide dismutase, catalase and glutathione peroxidase while the non-
enzymatic antioxidants comprise of glutathione, vitamin C and E (Birben et al., 2012, Nita and 
Grzybowski, 2016). However, there are significant alterations in the levels and activities of these 
antioxidants in diabetic condition (Dal and Sigrist, 2016; Asmat et al., 2016). Oxidative stress can 
cause low grade inflammation which can lead to the alterations in cardiovascular structure and activity 
promoting cardiac complications during T2D (Valko et al., 2007). Apart from the heart, many organs 
are also affected by oxidative stress such as nerves, eyes, kidneys and these promote macro- and 
micro-vascular complications during T2D (Dal and Sigrist, 2016). Fortunately, antioxidants from 
plant sources have been found to render protection against the different complications of T2D. 
Medicinal plants have been credited for their role as antioxidants with blood glucose lowering abilities 
from time immemorial and an example of such a plant is Alstonia boonei.   
Alstonia boonei belongs to the Apocynaceae family and is currently used in the management of 
diabetes mellitus in some parts of Africa (Akinloye et al., 2013; Osadolor et al., 2015). Various 
preliminary in vitro and ex vivo studies have been done in our lab in order to verify the antidiabetic 
and antioxidative activity related claims of this plant. The butanol fraction of the leaves of A. boonei 
was found to show promising antidiabetic activity when subjected to in vivo antidiabetic study in a 
T2D rat model (see section 3.4 above). The present study was performed in a bid to examine if the 
observed antidiabetic activity can be credited to the role of the antioxidant defence mechanism.  
3.5.3 Materials and methods 
Please refer to the Chapter 2 for the detailed materials and methods used for A. boonei. 
3.5.4 Results 
The extent of lipid peroxidation in the pancreas was lower than the other organs. The DBC group 
showed a significantly (p < 0.05) higher level of MDA compared to the normal and treated groups 
(Figure 3.5.1). This was also replicated in the serum, liver, heart and kidneys of the animals. The 
MDA levels was seen to reduce upon treatment with the ABBF, which shows the lipid peroxidation 




Figure 3.5.1: The effects of oral treatment of ABBF on thiobarbituric acid reactive substances (MDA 
equivalent) in the serum, liver, pancreas, heart and kidneys of all animal groups at the end of the 
intervention period. Data are presented as mean ± SD of 7 animals. a-dValues with different letter above the bars for a 
given sample are significantly different from other group of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
NC, Normal Control, DBC, Diabetic Control, DABL, Diabetic A. boonei low dose, DABH, Diabetic A. boonei high dose, 
DBM, Diabetic Metformin, DBG, Diabetic Glibenclamide, NAB, Normal A. boonei high dose, MDA, Malondialdehyde. 
The reduced glutathione (GSH) concentrations of the serum and organs of all the groups is presented 
on Figure 3.5.2. The GSH concentration in the serum, liver, pancreas and heart was significantly (p 
< 0.05) lower in the DBC group upon induction of diabetes compared to the normal groups. However, 
the reduction in the kidney was not statistically (p > 0.05) different among the animal groups. Oral 
administration of the fraction significantly (p < 0.05) increased the GSH levels in the serum and all 
other organs of the DABL group except kidney.  
 Figure 3.5.3 shows the data for the catalase activity in serum and organs of all animal groups. The 
catalase activity in the liver, pancreas, heart and kidneys of DBC group was significantly (p < 0.05) 
decreased compared to the normal groups. However, ABBF treatment in the diabetic animals 
significantly (p < 0.05) increased the catalase activity in the organs, while it was not significant in the 
serum.  
The activity of superoxide dismutase (SOD) in the serum and organs of all the animal groups is shown 
on Figure 3.5.4. The SOD activity in the serum and organs of DBC group was significantly (p < 0.05) 
decreased. However, oral administration of ABBF for 5 weeks significantly (p < 0.05) increased SOD 






















































Figure 3.5.2: The effects of oral treatment of ABBF on reduced glutathione (GSH) levels in the 
serum, liver, pancreas, heart and kidneys of all animal groups at the end of the intervention period. 
Data are presented as mean ± SD of 7 animals. a-eValues with different letter above the bars for a given sample are 
significantly different from one another group of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DABL, Diabetic A. boonei low dose; DABH, Diabetic A. boonei high dose; DBM, Diabetic 
Metformin; DBG, Diabetic Glibenclamide; NAB, Normal A. boonei high dose. 
 
Figure 3.5.3: The effects of oral treatment of ABBF on catalase activity in the serum, liver, pancreas, 
heart and kidneys of all animal groups at the end of the intervention period. Data are presented as mean ± 
SD of 7 animals. a-dValues with different letter above the bars for a given sample are significantly different from other group 
of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DABL, 
Diabetic A. boonei low dose; DABH, Diabetic A. boonei high dose; DBM, Diabetic Metformin; DBG, Diabetic 





































































































Figure 3.5.4:  The effects of oral treatment of ABBF on SOD activity in the serum, liver, pancreas, 
heart and kidney of all animal groups at the end of the intervention period. Data are presented as mean ± 
SD of 7 animals. a-dValues with different letter above the bars for a given sample are significantly different from other group 
of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal Control; DBC, Diabetic Control; DABL, 
Diabetic A. boonei low dose; DABH, Diabetic A. boonei high dose; DBM, Diabetic Metformin; DBG, Diabetic 
Glibenclamide; NAB, Normal A. boonei high dose. 
The results of the glutathione reductase activity in the serum and organs of all the animal groups are 
shown in Figure 3.5.5. In the kidneys, the glutathione reductase activity was not altered by diabetes 
induction. However, the activity of this enzyme was significantly (p < 0.05) decreased in the serum, 
liver, pancreas and heart of the DBC group when compared to the NC and NAB groups. Oral 
administration of the ABBF improved the enzyme activity in the serum and organs. 
 
Figure 3.5.5: The effects of oral treatment of ABBF on glutathione reductase (GR) activity in the 
serum, liver, pancreas, heart and kidney of all animal groups at the end of the intervention period. 
Data are presented as mean ± SD of 7 animals. a-eValues with different letter above the bars for a given sample are 
significantly different from other group of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DABL, Diabetic A. boonei low dose; DABH, Diabetic A. boonei high dose; DBM, Diabetic 



































































































































Figure 3.5.6 shows the glutathione peroxidase (GPx) activity in the serum and organs. The GPx 
activity was significantly (p < 0.05) decreased in the serum and organs of DBC group compared to 
the NC and NAB groups. However, treatment with ABBF significantly (p < 0.05) increased the GPx 
activity in the diabetic treated groups which was comparable to the DBM and DBG groups.  
 
 
Figure 3.5.6: The effects of oral treatment of ABBF on glutathione peroxidase (GPx) activity in the 
serum, liver, pancreas, heart and kidney of all animal groups at the end of the intervention period. 
Data are presented as mean ± SD of 7 animals. a-eValues with different letter above the bars for a given sample are 
significantly different from other group of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal 
Control; DBC, Diabetic Control; DABL, Diabetic A. boonei low dose; DABH, Diabetic A. boonei high dose; DBM, Diabetic 
Metformin; DBG, Diabetic Glibenclamide; NAB, Normal A. boonei high dose. 
3.5.5 Discussion 
The role of plants in the treatment of diseases such as T2D which arises as a result of the impact of 
oxidative stress is very important. Medicinal plants contain numerous antioxidants which are able to 
lend a helping hand in scavenging free radicals that are formed due to autooxidation of glucose in the 
severe cases of hyperglycemia.  
In our previously reported data (Section 3.3), we have shown that the fractions of Alstonia boonei 
leaves contain high total phenol content, which might be responsible for their observed antioxidant 
activity. The present study went a step further by investigating the ability of the butanol fraction of 
A. boonei to upregulate the endogenous antioxidant system in the blood and various organs of a T2D 












































































diabetic rats were examined for both enzymatic (Catalase, SOD, GPx, GR) and non-enzymatic 
(MDA, GSH) after the treatment with ABBF.   
Increased oxidative stress or free radicals in T2D leads to a concomitant increase in MDA levels 
which is a key index in determining the initiation of lipid peroxidation in the cell membrane (Nita 
and Grzybowski, 2016). Lipid peroxidation as a result of unmanaged hyperglycemia and 
hyperlipidemia causes damages to the cell membrane favouring the progression of T2D and its 
complications. In this study, the DBC groups of the serum and organs showed an elevation of MDA 
levels compared to the NC group which signified the initiation of lipid peroxidation. Our previous 
findings showed that (Section 3.4) the increase in cardiac and liver function biomarkers in the diabetic 
animals could also be related for the observed increase of MDA levels in this study. However, 
administration of ABBF led to the reduction of MDA levels in the serum and organs with even more 
promising activity than glibenclamide (Figure 3.5.1). This result confirms the free radical scavenging 
and lipid peroxidation reducing ability of ABBF. The increase of levels of GSH (Figure 3.5.2) in the 
serum and organs of the treated diabetic rats was also in line with the MDA results.   
In T2D, increased free radical production reduces the activities of endogenous antioxidant enzymes, 
this was proven in our result (Figure 3.5.2) where the diabetic groups showed a reduction in GSH 
level compared to the NC group. GSH is an intracellular thiol that promotes free radical eradication 
process in oxidative stress. Reduced GSH levels in diabetes occurs as a result of the competition 
between glutathione reductase and aldose reductase for NADPH (a cofactor) (Kalkan and Suher, 
2013). Figure 3.5.2 showed the ability of the plant fraction (especially the low dose) to improve GSH 
levels in the serum and organs (except the kidneys where no GSH activity was noticed). The results 
of our study showed the higher concentration of reduced glutathione in the serum and organs of the 
DABL and DABH groups when compared to the DBC group. This result is in line with the reduced 
MDA levels as recorded earlier.  
Catalase and SOD are important endogenous antioxidant enzymes that are capable of transforming 
harmful superoxide radicals to H2O2 and then to harmless water and oxygen. Figure 3.5.3 showed a 
reduction of catalase activity in the diabetic control group which might have occurred due to the 
induction of T2D by a low dose of streptozotocin. The increase of catalase and SOD levels noticed 
in the DABL and DABH groups highlights the potency of ABBF as an antioxidant agent in managing 
the complications linked to T2D. The ability of ABBF to reduce lipid peroxidation and increase 
antioxidant enzymes correlates with an earlier reported study where the ethanol extract of the leaves 
of A. boonei were used (Enechi et al., 2014). Similar results were obtained from both studies.  
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GPx and GR are glutathione dependent enzymes and a reduction in their activities can be linked to 
the reduction of GSH level. GPx catalyses the reduction of lipid peroxides at the expense of GSH, 
which also favours H2O2 inactivation and encourages the higher consumption of GSH (Kumawat et 
al., 2013). Thus, lower level of GSH reduces the activity of these antioxidant enzymes and contributes 
to worsening oxidative stress. However, treatment with ABBF showed an increase in GPx and GR 
activities in the treated groups even up to normal levels. This shows that the butanol fraction of A. 
boonei (especially the low dose) has the potentialto improve the antioxidant status as well as reduce 
the complications of T2D.  
Studies have shown the presence of potent phytochemicals such as alkaloids, tannins, saponins, 
flavonoids and cardiac glycosides (Akinmoladun et al., 2007) and bioactive constituents such as 2-
hydroxy-1-(hydroxymethyl) ethyl, eugenol, benzenedicarboxylic acid and alpha-amyrin in A. boonei 
(Babatunde, 2017). These bioactive compounds may be responsible for the antioxidant activities of 
ABBF. 
From the results of this study, we have seen so far, the low dose of the fraction has shown better 
antioxidant activity than the high dose, this can be related to a previously reported work that showed 
the toxicity of a high dose (200-400 mg/kg body weight) of A. boonei fractions and also reported a 
longer time in recovery of subjects from the toxic effects of high dose of the plant (Olanlokun and 
Olorunsogo, 2018). We have also noticed the similar toxicological effects of the high dose (300 mg/kg 
bw) which have been evident by increment of several biochemical parameters and pancreatic 
histopathology in our study. 
In conclusion, oral administration of ABBF especially low dose (150 mg/kg bw) showed potent 
antioxidant activity through the reduction of lipid peroxidation, upregulation of glutathione levels and 
endogenous antioxidant enzymes in the serum and organs of type 2 diabetic animals. Therefore, 
ABBF could serve as a good antioxidant agent and could be used in controlling oxidative stress in 





THE ANTIOXIDANT AND ANTIDIABETIC ACTIVITIES OF 
ACALYPHA WILKESIANA IN VITRO AND IN VIVO 
4.1 Background 
Acalypha wilkesiana ‘Java white’ is a member of the family Euphorbiaceae and sub family 
Acalyphoideae (Figure 4.1), it has great decorative value due to its lovely coloured foliage. It is 
cultivated widely in tropical and subtropical countries (Bailey and Day, 2004). The Java white variant 
which is our plant of interest, has leaves with colour ranging from greenish yellow to ivory. Although 
it is native to the Pacific Islands (Tahiti, Fiji, New Zealand and Australia), it also widely seen in some 
Asian and African countries.   The leaves are oval shaped with toothed and lightly coloured edges. 
They have tiny flowers which are reddish in colour and are formed in thin hanging spikes known as 
catkins (Bailey and Day, 2004).  
 
Figure 4.1: Acalypha wilkesiana ‘Java white’ also known as Java white copperleaf (English), Mirror 
bush, Jacob’s coat (English). Photo credit: Oluwaseun Oyebode (2018) Durban, South Africa 
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4.1.1 Ethnomedical uses  
The leaves of this plant are eaten as a vegetable in treatment of hypertension in the southern part of 
Nigeria (Bailey and Day, 2004). Most Acalypha species are widely exploited for their role in 
traditional medicine in diverse parts of Africa and some parts of Asia (Duraipandiyan et al., 2006; 
Sofowora, 1982). A. wilkesiana is used in parts of Nigeria in the treatment of body aches and common 
cold; and the boiled leaves are also used in bathing babies with skin infection (Adesina et al., 2000).  
4.1.2 Biological activities 
Research carried out on the leaf extract of A. wilkesiana, showed a high activity against the 
propagation of gram-positive bacteria while extracts obtained from the seeds showed 
immunomodulating activities that were able to reduce tumours in inflammatory cells (Büssing et al., 
1999). Recently, ethyl acetate extract of A. wilkesiana in direct use with β-, γ- and δ-tocotrienols has 
been shown to possess potent anticancer activities where it was able to reduce the proliferation of 
cancer cells in the lungs (A549) and brain (U87MG) cells (Abubakar et al., 2018). The antioxidant 
activity of isolates from the butanol fraction of the leaves of A. wilkesiana was investigated recently 
and it was discovered that the isolates possess potent free radical scavenging activity (Oladipo et al., 
2016). The antioxidant capacity of this plant cannot be farfetched since phytochemical screening from 
the crude extract of the plant has indicated the presence of tannins and terpenes (Akinloye et al., 2016; 
Oladimeji et al., 2012), which have been earlier reported to exhibit antioxidant activities (Amarowicz, 
2007, Gonzalez-Burgos and Gomez-Serranillos, 2012).  
4.1.3 Phytochemistry 
To validate the antidiabetic traditional use of this plant (mentioned earlier), a comprehensive in vitro 
investigation of the antioxidant activity of this plant was tested. The different solvent crude extracts 
of this plant were subjected to a systematic and detailed investigation on its antioxidant capacities 






4.2 Acalypha Wilkesiana ‘Java white’ scavenges free radicals in vitro and abates Fe2+ 
- induced oxidative stress in rat pancreatic homogenates 
Olajumoke A. Oyebode, Ramgopal Mopuri, Ochuko. L. Erukainure, Md. Shahidul Islam* 
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville 
Campus), Durban 4000, South Africa 
*Correspondence to: islamd@ukzn.ac.za  
Preface: This article reports the detailed in vitro and ex vivo antioxidant studies on A. wilkesiana. 
The article is currently awaiting revision before submission to a suitable journal for publication.  
4.2.1 Abstract 
The in vitro antioxidant potentials of extracts from the leaves, stem and root bark of Acalypha 
wilkesiana were investigated. The plant parts were extracted sequentially with solvents of increasing 
polarity where aqueous and ethanol extracts showed higher polyphenol content compared to the ethyl 
acetate extract. However, the ethanol extract of the root bark showed significantly (p < 0.05) higher 
DPPH (1,1-diphenyl-2-picryl-hydrazyl), hydroxyl radical (OH.) and nitric oxide (NO) scavenging 
abilities, as well as ferric reducing antioxidant power (FRAP) when compared to other extracts. This 
was confirmed by lower IC50 values and comparable with the activity of positive controls (ascorbic 
or gallic acid and trolox). Their abilities to activate antioxidant enzymes in Fe2+-induced pancreatic 
oxidative injuries was also investigated in rat pancreatic homogenates. Catalase, SOD and reduced 
glutathione levels were significantly (p < 0.05) increased by the extracts as compared to low levels 
seen in untreated groups. Data from this study suggest that the different parts of A. wilkesiana, 
especially the ethanol and aqueous extracts possesses potent anti-oxidant potentials that could be 
further investigated for medicinal benefits.   
Key words: antioxidants; medicinal plants; A. wilkesiana; oxidative stress 
4.2.2 Introduction 
Medicinal plants have long been regarded as better alternatives to pharmaceutical drugs and have 
gained much interest in the area of drug discovery. This can be attributed to the fact that they contain 
necessary and substantial level of antioxidants and bioactive agents that have been reported in the 
management and treatment of diseases such as diabetes (Dewanjee et al., 2011).  
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A host of plant sources are found to be rich in polyphenols such as herbs, fruits, flowers and these 
plants are found in abundance everywhere in the world especially in Africa where there is high 
reliance on medicinal plants for the treatment of diverse ailments (Hamzah et al., 2013).  
Plants are rich in polyphenolic agents which are highly beneficial as they can react with reactive 
oxygen species/reactive nitrogen species (ROS/RNS) to bring about reduction in deleterious effects 
to cell biomolecules (Gach et al., 2015). Plant antioxidants are capable of attenuating damages to 
biomolecules (lipids, proteins and DNA), with damage ranging from lipid peroxidation to cell 
membrane damage through oxidation (Hossain and Shah, 2015).  
Oxidative stress occurs as a result of imbalance between free radical-generating enzymes (reactive 
oxygen species [ROS]) and free radical-scavenging enzymes (antioxidant enzymes) and plays a key 
role in the progression of diseases (Asmat et al., 2016). This triggers an increased level of free radicals 
which initiates cellular damage and has been recognized as the main contributing factor to late 
complications of ailments such as diabetes and cancer (Son, 2012). 
Acalypha wilkesiana ‘Java white’ belongs to the genus Acalypha of the family Euphorbiaceae (spurge 
family). It has over 570 variants which include A. amentacea and A. tricolor (Sule et al., 2012). Its 
common names include copperleaf, fire dragon and java white due to the green and white coloured 
variant. They are found all over the world most especially in the tropics of Africa and its native to 
Fiji and nearby islands in the South Pacific. It is also widely spread in the southern part of Nigeria 
and many parts of South Africa (Ikewuchi, 2013). 
In some parts of Africa, A. wilkesiana is used in the treatment of bacterial and fungal infections, and 
the leaves and root bark are used as antidiuretics (Alade and Irobi, 1993; Ikewuchi, 2013). Plants 
from the Acalypha genus are exploited traditionally for the treatment of diseases such as jaundice, 
diabetes, hypertension, skin and respiratory problems (Seebaluck et al., 2015). Although, a number 
of studies have been conducted with this plant, the detailed antioxidant and antidiabetic potential of 
the green leafed species i.e. java white (A. wilkesiana ‘godseffiana’) will be explored. 
Hence, apart from illustrating a detailed comparison of the in vitro antioxidant abilities of the extracts 
from the different parts of the plant, this study also aims to further examine the antioxidant effects of 
this plant on some endogenous antioxidant enzymes in rat pancreatic homogenate under conditions 




4.2.3 Materials and methods 
Please refer to Chapter 2 for details of the methods used for A. wilkesiana. 
4.2.4 Results 
Both the ethanol and aqueous extracts from the different parts of the plant were found to contain 
significant (p < 0.05) higher amount of total phenol reported as gallic acid equivalent as seen in 
Figure 4.2.1, with highest concentration observed in the ethanol extract of stem and root bark 
followed by the aqueous extract of leaves and root bark.  
 
Figure 4.2.1: Total phenolic contents of the A. wilkesiana extracts. Data are reported as mean ± SD. a-cValues 
with different letter above the bars for a given extract are significantly different from one another (p < 0.05, Tukey’s-HSD-
multiple range post-hoc test, IBM SPSS for Windows). 
The results of the DPPH radical scavenging activity of A. wilkesiana leaves, stem and root bark are 
depicted in Figure 4.2.2 and Table 4.2.1.  
The results obtained from the different antioxidant models (DPPH, HRS and NO) for the plants parts 
of A. wilkesiana are summarized in Table 4.2.1.  They all showed scavenging activity against DPPH 
radicals. The ethanol extracts of both the leaves and root bark showed significantly (p < 0.05) higher 
activity as well as lower IC50 values than the others even when compared to the standards ascorbic 
acid and trolox. In addition, all the extracts significantly (p < 0.05) scavenged nitric oxide (NO) 
radicals (Figure 4.2.3). The ethanol extracts of the root bark showed significantly (p < 0.05) higher 






































Total reducing power analysis showed the extracts could reduce Fe3+ to Fe2+ in a dose-dependent 
manner as depicted in Figure 4.2.4 (a-c). The highest level of reduction was exhibited by the ethanol 
extract of the root bark (Figure 4.2.4 c). 
The highest hydroxyl radical scavenging activity (Figure 4.2.4 d-f) was exhibited by the ethanol 
extract of the root bark (Figure 4.2.4 f). This was justified with a significantly (p < 0.05) lower IC50 




Figure 4.2.2: DPPH scavenging activities of A. wilkesiana extracts. Data are reported as mean ± SD. a-
dValues with different letter above the bars for a given extract are significantly different from one another (p < 0.05, Tukey’s-
HSD-multiple range post-hoc test, IBM SPSS for Windows) EtAc: Ethyl acetate, EtOH: ethanol, AA: ascorbic acid. 
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Figure 4.2.3: Nitric oxide scavenging activities of A. wilkesiana extracts. Data are reported as mean ± SD. 
a-fValues with different letter above the bars for a given extract are significantly different from one another (p < 0.05, 
Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows) EtAc: Ethyl acetate, EtOH: ethanol, GA; Gallic acid, 

























































































































































Figure 4.2.4: Total reducing power of a) leaves, b) stem bark and c) root bark extracts and hydroxyl 
oxide scavenging activities of A. wilkesiana d) leaves, e) stem bark and f) root bark extracts 
respectively. Data are reported as mean ± SD. a-fValues with different letter above the bars for a given extract significantly 
different from one another (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAc: Ethyl 





























































































































































































































































EtAc EtOH Aqueous Trolox
103 
 
Table 4.2.1: IC50 values of various extracts of A. wilkesiana parts in different antioxidative models 
                                                                   
 
Sample 
IC50 Value (µg/mL) 
DPPH NO Hydroxyl 
Leaves    
Ethyl acetate 2.88±0.33b >1000j 335.46±23.84f 
Ethanol 1.63±0.39a >1000j 82.44±27.12d 
Aqueous 2.14±0.10a 32.41±7.94d 87.34±35.91d 
Stem bark    
Ethyl acetate 7.78±0.06d 18.12±3.23a 156.21±48.26e 
Ethanol 5.96±0.29c 269.73±52.1h 19.67±2.03c 
Aqueous 9.63±0.31e 53.22±12.39e 58.78±8.62d 
Root bark    
Ethyl acetate 3.73±0.69b 50.52±3.65e 98.47±21.69de 
Ethanol 1.83±0.69a 14.23±0.68b 7.25±1.28b 
Aqueous 282±35.38f 304.23±14.83i 47.79±5.73d 
Standard    
Gallic acid ND 108.72±23.05f ND 
Ascorbic acid 2.19±0.05a 19.40±1.45c ND 
Trolox 5.79±0.43c 196.7±27.03g 3.54±0.91a 
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, HRS-hydroxyl radical scavenging, NO-nitric oxide radical, ND-not 
determined. Data are reported as mean ± SD values of three replicas. a-j Different letters stand for significantly different 
values from one another within a column (Tukey’s-HSD multiple range post hoc test, p < 0.05): the same letters stand for 
non-significant difference. 
The ability of the extracts, especially the ethanol extract to increase catalase activity in Fe2+-induced 
oxidative pancreatic injury is shown in Figure 4.2.5 with the ethanol extract of the root bark (Figure 
4.2.5 c) and aqueous extract of the leaves (Figure 4.2.5 a) showing the highest activity. This was also 
reflected in their lower IC50 values (Table 4.2.2). 
There was a significant (p < 0.05) reduction in SOD activity upon induction of oxidative injury by 
Fe2+ (Figure 4.2.5 d-f). However, treatment with different doses of the extracts led to remarkably 
increased SOD activities. The ethanol extracts of the stem and root bark, and the aqueous extract of 







Figure 4.2.5: Catalase activities of a) leaves, b) stem bark and c) root bark extracts and SOD activities 
of d) leaves, e) stem bark and f) root bark extracts of A. wilkesiana in oxidative pancreatic injury. 
Data are reported as mean ± SD of three replicas. *Significantly different from untreated sample and #Significantly different 

















































































































































































The effect of Fe2+-induction of oxidative pancreatic injury on GSH level is depicted in Figure 4.2.6 
(a-c). A noticeable increase in GSH levels was observed on treatment with the extracts as evident by 
the low IC50 values (Table 4.2.2), the ethanol extract of the leaves showed the lowest IC50 values 
compared to its counterparts and even lower than that of the standard, Ascorbic acid. 
 
Figure 4.2.6: Effect of A. wilkesiana a) leaves, b) stem bark and c) root bark extracts on reduced 
glutathione (GSH) level in oxidative pancreatic injury. Data are reported as mean ± SD of three replicas. 
*Significantly different from untreated sample and #Significantly different from normal sample (p < 0.05, Tukey’s-HSD-









Table 4.2.2: IC50 values of various extracts of A. wilkesiana parts in different enzymatic ex vivo 
models 
                                                                   
 
Sample 
IC50 Values (µg/ml) 
Catalase SOD GSH 
Leaves    
Ethyl acetate 5.25±1.09d 17.96±9.83b 7.24±1.87d 
Ethanol 2.28±0.03b 28.86±2.03d 1.72±4.93a 
Aqueous 1.09±0.07a 23.91±0.89c 2.26±0.05a 
Stem bark    
Ethyl acetate 4.99±0.85cd 28.96±7.65cd 3.15.11±0.82b 
Ethanol 1.61±0.14a 15.94±1.75b 9.36±3.86d 
Aqueous 3.66±0.27c 11.98±3.9a 4.75±1.28c 
Root bark    
Ethyl acetate 17.25±5.83e 33.83±8.60d 5.95±1.13c 
Ethanol 1.61±0.17a 14.86±1.52b 4.411±0.41a 
Aqueous 5.09±0.04d 16.51±5.82b 2.03±1.05a 
Standard    
Ascorbic acid 19.71±8.76e 23.04±5.91c 3.05±1.06b 
Data are reported as mean ± SD values of three replicas. a-e Different letters stand for significantly different values from one 
another within a column (Tukey’s-HSD multiple range post hoc test, p < 0.05): the same letters stand for non-significant 
difference. SOD: superoxide dismutase, GSH: reduced glutathione. 
4.2.5 Discussion 
The role and influence of oxidative stress in the pathogenesis and complications of diseases such as 
cancer and diabetes has long been validated as essential to understand the impact, trend and possible 
ways of alleviating their prevalence (Matough et al., 2012). The complications of these diseases arise 
because of poor handling of free radicals by the body’s natural defence mechanism (Bajaj and Khan, 
2012). Plants have been reported to have antioxidant activities, with polyphenolics playing a major 
role in this regard (Sowndhararajan and Kang, 2013).  
Figure 4.2.1 demonstrates the presence of total phenols in all extracts of the three parts of A. 
wilkesiana (leaves, stem and root bark) which may be responsible for its potency and continuous use 
in traditional medicine as an antibacterial, antidiuretic and anti-diabetic agent (Ikewuchi et al., 2010). 
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The mechanism of action of polyphenols can be  attributed mainly to their structure which comprises  
a hydroxyl group on an aromatic ring, a key factor to its radical scavenging and metal chelating 
activities (Scherer and Godoy, 2014).   
DPPH is a transient free radical which absorbs light maximally at 517 nm and can become stable by 
accepting an electron. This odd electron on nitrogen can be reduced by a donation of a hydrogen atom 
from an antioxidant to form a hydrazine complex. The DPPH assay is a quick and inexpensive method 
to determine the ability of compounds to act as free radical scavengers or hydrogen donors (Kedare 
and Singh, 2011). Using this model, the ethanol extracts of A. wilkesiana demonstrated valuable 
DPPH scavenging abilities, as expressed by their low IC50 values shown in Table 4.2.1.   
The hydroxyl radical is the second most deleterious and most biologically free radical. It is formed 
because of continuous reduction of oxygen to water. The first step in its formation is the reduction of 
Fe3+ to Fe2+ which is then closely followed by the Fenton reaction (Lipinski, 2011). This makes it 
easy to understand that an accumulation of iron in the body can lead to excessive generation of free 
radicals and ultimately progressive complications of diseases such as atherosclerosis, age related 
diseases and diabetes (Altamura and Muckenthaler, 2009; Brewer, 2007; Ramakrishna et al., 2003). 
Widely known polyphenols such as curcumin, resveratrol and ferulic acid have been shown to have 
hydroxyl radical scavenging activity and this action is executed through oxidation of aromatic 
compounds (Kulling and Rawel, 2008; Lipinski, 2011).  
The observed potent hydroxyl radical scavenging activities of A. wilkesiana (Figure 4.2.4 d-f) can 
be attributed to the high phenolic content Figure 4.2.1. This may also be responsible for the observed 
high reducing power of the extracts (Figure 4.2.4). This corresponds to reports on the positive 
correlation of high total phenolic content and high reducing power activities by plant extracts (Anahita 
et al., 2015; Hossain and Shah, 2015). The highest reducing power of Fe3+ was demonstrated by the 
ethanol extracts and this shows the capability of ethanol in extracting potent free radical scavengers. 
NO is a relatively small and lipophilic molecule which acts continuously with superoxide anion 
radical (O2.-) to produce peroxynitrite (ONOO-) a very strong oxidant capable of attacking a wide 
range of biological molecules (Nimse and Pal, 2015). When the amount of NO exceeds that of the 
superoxide anion, it can act as an effector molecule in the defence against cancer cells and bacteria 
and inhibit lipid peroxidation by the formation of nitrated lipid radical inhibitors thereby protecting 
the lipid bilayer from peroxides (Rapozzi et al., 2015). However, oxidant metabolites of NO. such as 
ONOO- are capable of deleterious actions by depleting enzymatic antioxidants such as glutathione 
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and ascorbic acid (Bloodsworth et al., 2000). Interestingly, extracts of A. wilkesiana showed 
significant inhibition of nitric oxide (Table 4.2.1). The ethanol extract of the root bark had the lowest 
IC50 values and showed the highest inhibition. This indicates potent antioxidant and free radical 
scavenging activity. 
The pancreas, liver and other organs play major roles in the activities of some endogenous antioxidant 
enzymes such as catalase, superoxide dismutase (SOD) and glutathione peroxidase (GPx), which 
converts the tripeptide glutathione (GSH) into oxidized glutathione (GSSG) and in the process, 
reduces H2O2 to H2O and lipid hydroperoxides (Bhattacharyya et al., 2014). Catalase converts 
hydrogen peroxide (H2O2); a major precursor in the formation of free radicals into water and oxygen. 
SOD is a first line action against free radicals and catalyses the breakdown of superoxide into oxygen 
and peroxide (Asmat et al., 2016). GSH catalyses the conversion of peroxides to water thereby 
converting glutathione disulphide back into glutathione (Githens, 1991). Oxidative stress occurs due 
to the insensitivity or reduced quantity of these enzymes in the organs particularly in the pancreas 
since it is a major site for metabolism and insulin production. High intracellular levels of these 
enzymes cushion the effect of oxidative stress (Githens, 1991; Yeh and Yen, 2006). From the results, 
there was reduction in catalase and SOD activities indicating an occurrence of oxidative stress in the 
untreated groups (refer to Figure 4.2.5). Treatment with the extracts, especially the ethanol and 
aqueous extracts of both the leaves and the root bark led to remarkable increase in catalase activity 
(Figure 4.2.5 a-c), thus indicating the antioxidant potential of this plant. SOD activities were also 
found to increase upon treatment with different doses of the extracts with the ethanol extracts of both 
the stem and root barks showing high potentials (Figure 5 d-f). The ethanol extract of the root bark 
increased the GSH levels as compared with the depleted levels of the untreated groups (Figure 4.2.6). 
This can be attributed to the high phenolic content and high ferric reducing ability of the ethanol root 
bark of this plant as seen in Figure 4.2.1 and 4.2.4 (a-c). 
4.2.6 Conclusion 
The existence of free radical scavenging and oxidative stress ameliorating compounds in A. 
wilkesiana has been established in this study. These results indicate that no part of A. wilkesiana is a 
waste as all its parts have been demonstrated to possess rich antioxidant activities which gives 
antecedence to its use in folk medicine. These findings specifically portray the ethanol extract of the 
root bark as the most capable of modulating oxidative stress. Further research will entail bioassay 
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4.3.1 Abstract 
In this study, we identified bioactive compounds from the ethanol extracts of the leaves, stem and 
root bark of Acalypha wilkesiana through GC-MS analysis and investigated the effects of these 
extracts on some of the enzymes linked to type 2 diabetes. Plant parts were extracted sequentially 
with ethyl acetate, ethanol and water. GC-MS analysis revealed the presence of long chain alkyl acids, 
esters, ketones and alcohols including phytol and phytol acetate along with some secondary 
metabolites such as xanthone, vitamin E and various types of sterols including stigmasterol, 
campesterol and sitosterol. Ethanolic extracts of all the parts showed a dose-dependent inhibition of 
-glucosidase and -amylase activity. The extracts also demonstrated anti-lipase activity. The 
ethanolic extract of the root bark showed the highest inhibition of enzymes compared to other extracts. 
The EC50 values (concentration for 50% inhibition) of α-glucosidase, α-amylase and lipase inhibition 
were 35.75±1.95, 6.25±1.05 and 101.33±5.21 µg/mL, respectively. This study suggests that A. 
wilkesiana ethanolic extracts have the ability to inhibit the activity of enzymes linked to type 2 
diabetes. Further studies are needed to confirm the responsible bioactive compounds in this regard. 
Keywords: Acalypha wilkesiana, α-glucosidase, α-amylase, lipase, type 2 diabetes, ethanolic extract 
4.3.2 Introduction 
Diabetes has gradually become a major health concern in both developed and developing countries, 
while controlling hyperglycaemia is one of the major challenges in the management of this disease 
(IDF, 2017). Apart from hyperglycaemia, almost 50% of diabetic patients suffer from at least one or 
two diabetic complications such as diabetic retinopathy, cardiomyopathy, nephropathy, neuropathy 
and lower limb amputations, which are more noticeable in elderly patients (Roglic, 2016). 
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Approximately 108 million people were diagnosed with diabetes in 1980, which has increased to 422 
million in 2014, with a projected increase to 642 million by the year of 2030 (Roglic, 2016).  
Diabetes is a metabolic disorder caused by deficiency of insulin secretion by the pancreatic beta-cells 
(type 1), insulin insensitivity, and partial pancreatic beta-cell malfunction (type 2) (Lakshmi et al., 
2012). Type 2 diabetes (T2D) is the most prevalent form of diabetes and occurs due to the insensitivity 
of insulin to postprandial glucose overload which causes persistent hyperglycaemia (Al-Goblan et al., 
2014). The spread of this disease has been linked to societal and cultural changes in diet and lifestyle 
which could lead to obesity, a major risk factor for the rapidly rising prevalence of T2D (Tobias et 
al., 2014). Obesity as a result of abdominal fat deposit may lead to sustained insulin resistance in 
obesity related T2D (Levelt et al., 2016). Controlling hyperglycaemia is a major challenge in the 
management of T2D. 
A number of conventional drugs such as sulfonylureas, biguanides and α-glucosidase inhibitors are 
currently being used for the management of hyperglycaemia as well as T2D. α-glucosidase is linked 
to the breakdown of disaccharides and starch into glucose and α-amylase breakdowns long-chain 
carbohydrates into glucose (Kumar et al., 2011). Inhibition of α-glucosidase and α-amylase is one of 
the key targets in the discovery of potential drugs for the treatment of T2D via reducing small 
intestinal glucose absorption (Yilmazer-Musa et al., 2012). However, high cost and numerous side-
effects of these synthetic drugs has led to the exploration of some alternative therapies in alleviating 
T2D (Safavi et al., 2013). Additionally, the side-effects including nausea, diarrhoea (commonly seen 
in patients on metformin), hypoglycaemia, weight gain (sulfonylureas), increased risk of heart failures 
and bone fractures (thiazolidinediones) (Wu et al., 2016) led to the search for alternative therapies, 
particularly from medicinal plants. Medicinal plants are found in abundance in all over the world 
including Africa and have been reported to be rich in bioactive phenolics which can be used to treat 
diverse diseases (Bahadoran et al., 2013) including T2D.  
Acalypha wilkesiana ‘Java white’ is a member of the spurge family (Euphorbiaceae). It is a tropical 
and subtropical evergreen shrub with greenish yellow to white dotted green leaves mottled with 
irregular green spots. It grows in various parts of Africa but native to South Pacific islands. In western 
Nigeria, a boiled decoction of the leaves of A. wilkesiana Müll. Arg. is used in the treatment of fungal 
infections seen in new-borns, and also against hypertension and diabetes mellitus in adults (Olukunle 
et al., 2016). The leaves of this plant also possess anti-inflammatory, anti-microbial and anti-pyretic 
activities (Ikewuchi et al., 2011). Although some hypoglycaemic, anti-diabetic and hypolipidemic 
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effects of A. wilkesiana Müll. Arg. of leaves and roots have been reported in some recent studies 
(Olukunle et al., 2016, Odoh et al., 2014, Mohammed et al., 2014), underlying mechanisms behind 
these effects and phytochemical constituents of different parts of this plant are not fully understood.  
Odoh et al. (2014) and Olukunle et al. (2016) reported the antidiabetic and hypoglycaemic as well as 
hypolipidemic activities of root and leaf extracts respectively in alloxan-induced diabetic rats, 
however, stembark was not used in their studies and Odoh et al. (2014) only qualitatively determined 
the phytochemical constituents in root extracts. Furthermore, Igwe et al. (2016) only analysed leaf 
ethanol extract to identify its bioactive compounds by using GC-MS, when other parts of the plant 
have not been analysed. On the other hand, although aqueous and ethanol extracts of the leaves and 
root bark of this plant have been shown to reduce blood glucose levels in alloxan-induced diabetic 
animals (Odoh et al., 2014; Olukunle et al., 2016), the mechanisms behind these effects are still 
unknown.   
Hence, this study was designed not only to analyse the phytochemical constitutes of the ethanolic 
extracts of leaf, root bark and stem bark of A. wilkesiana “Java white” via GC-MS analysis but also 
to examine the effects of various extracts from the different parts of the plant on the activity of 
enzymes linked to T2D such as α-glucosidase, α-amylase and lipase to understand the mechanisms 
behind their reported hypoglycaemic and antidiabetic effects (Odoh et al., 2014; Olukunle et al., 
2016). 
4.3.3 Materials and methods 
Please refer to Chapter 2 for details of the methods used for A. wilkesiana. 
4.3.4 Results and Discussion 
GC-MS analysis 
Ethanolic extracts of the leaves, stem bark and root bark of A. wilkesiana ‘Java white’ were subjected 
to GC-MS analysis to identify some major bioactive compounds.  
According to the data reported (Figures 4.3.1, 4.3.2, 4.3.3 and Tables 4.3.1, 4.3.2 and 4.3.3), 25 
phytochemicals were identified from this plant which included four major classes of compounds: 
fatty acids and fatty acid esters, phytols, xanthones and sterols, many of which have been reported to 
have various medicinal effects including α-amylase and α-glucosidase inhibitory activities (Fotie and 
Bohle, 2006; Ghosh et al., 2015; Olofsson et al., 2014; Takato et al., 2017; Mahendran et al., 2014; 
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Mahammed et al., 2015; Luo et al., 2014). Additionally, EC50 or the maximum concentration required 
for 50% inhibition of enzyme activity was also calculated for different extracts from each part of the 
plant for different enzymes and reported in Table 4.3.4.   
 
Figure 4.3.1:  Long chain alkyl acids, esters, ketones and alcohols identified from the ethanolic 





Figure 4.3.2: Aromatics, sterols and triterpenes identified in the ethanolic extract of leaves, stem and 






Figure 4.3.3: GC-MS chromatogram of ethanol extract of A. wilkesiana leaves a), stem bark b) and 













Phytol acetate C22H42O2 16.42 338.57 5.76 
6-Octadecenoic acid methyl ester C19H36O2 19.00 296.49 0.57 
Phytol C20H40O 19.10 296.53 2.00 
Octadecanoic acid C18H36O2 19.55 284.48 2.56 
9-(4-Methoxyphenyl) xanthene C20H16O2 22.39 288.39 2.89 
2-Hydroxy-1-(hydroxymethyl)ethyl 
hexadecanoate 
C19H38O4 22.52 330.50 1.76 
Acridin-9-yl-(4-methoxy-phenyl)-
amine 
C20H16N2O 24.33 300.35 0.38 
Oleana-11,13(18)-diene C30H48 27.22 408.70 1.48 
Vitamin E (α-tocopherol) C29H50O2 27.37 430.71 1.16 
Campesterol C28H48O 28.64 400.68 1.77 
Stigmasterol C29H48O 28.96 412.69 2.32 
Sitosterol C29H50O 29.77 414.71 1.81 
The compounds reported in the table are those which matched the same compounds in the NIST library software. 
Table 4.3.2: Compounds identified in the ethanol extract of the stem bark of A. wilkesiana by GC-
MS 
Compound Molecular formula tR (min) Mr Relative 
abundance (%) 
Tetradecanoic acid C14H28O2 15.56 228.37 0.39 
1-Methylethyl tetradecanoate C17H34O2 16.25 270.45 0.31 
Phytol acetate C22H42O2 16.41 338.57 2.00 
Ethyl hexadecanoate C18H36O2 17.97 284.48 2.60 
Methyl cis-13-octadecenoate C19H36O2 18.99 296.43 0.43 
Phytol C20H40O 19.10 296.53 1.05 
9-(4-Methoxyphenyl) xanthene C20H16O2 22.39 288.34 5.01 
Stigmast-4-ene-3-one C29H48O 23.24 412.69 1.82 
Campesterol C28H48O 28.64 400.68 3.08 
Stigmasterol C29H48O 28.96 412.69 1.56 
Sitosterol C29H50O 29.75 414.71 7.57 
The compounds reported in the table are those which matched the same compounds in the NIST library software.  
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Table 4.3.3: Identified compounds in the ethanol extract of the root bark of A. wilkesiana by GC-
MS 
The compounds reported in the table are those which matched the same compounds in the NIST library.  
Although Odoh et al. (2014) qualitatively determined the presence of alkaloids, terpenoids, 
flavonoids, saponins, steroids and tannins in root methanol extract and Igwe et al. (2016) identified 
12 compounds in leaf ethanol extract, in our study, 25 major bioactive compounds were identified in 
the ethanol extracts of various parts of the plant (Figures 4.3.1-3 and Tables 4.3.1-3). Igwe et al. 
(2016) identified predominantly terpenes followed by long chain fatty acids, long chain fatty acyl 
alcohols, esters and their derivatives when we additionally identified phytol, phytol acetate, vitamin 
E, and various types of sterols such as campesterol, stigmasterol and sitosterol in our study (Table 
4.3.1, Figures 4.3.1-3). Apart from leaf, the ethanol extracts of root bark and stem bark were also 
analysed by GC-MS in our study although no additional type of compounds were identified (Figures 
4.3.1-3 and Tables 4.3.2, 4.3.3) except xanthone and an aromatic amine in root ethanol extract 
(Figure 4.3.2 and Table 4.3.3). From the results of the GC-MS analysis, although a number of 










C11H14O3 14.37 194.23 0.63 
Phytol acetate  C23H46O 16.41 338.57 0.46 
6,10,14-Trimethyl-2-pentadecanone C18H36O 16.46 268.48 0.89 
Xanthone C13H8O2 16.95 196.20 1.68 
Hexadecanoic acid methyl ester C17H34O2 17.30 270.45 0.43 
Hexadecanoic acid ethyl ester C18H36O2 17.97 284.48 1.54 
8-Octadecenoic acid methyl ester C19H36O2 18.99 296.49 1.91 
(Z,Z)-9,12-octadecadienoic acid C18H32O2 19.28 280.45 0.70 
9-(4-Methoxyphenyl) xanthene C20H16O2 22.38 288.34 21.02 
Acridin-9-yl-(4-methoxy-phenyl)-amine C20H16N2O 24.55 300.35 0.36 
Campesterol C28H48O 28.64 400.68 3.71 
Stigmasterol C29H48O 28.96 412.69 2.08 
Sitosterol C29H50O 29.75 414.71 9.60 
117 
 
as- LC-MS or HPLC-PDA could expand the list of bioactive compounds so further studies are 
warranted in this regard.  
α-glucosidase and α-amylase inhibitory activity 
The effects of various extracts on two key enzymes, -glucosidase and -amylase, implicated in T2D 
are shown in Figure 4.3.4 (a-f). All the extracts showed significant α-glucosidase (p < 0.05) 
inhibitory activity, in a dose dependent manner. The ethanolic extracts from the stem bark and root 
barks, however, showed significantly (p < 0.05) higher activities than the others. This is also evident 
by their lower EC50 values compared to other extracts (Table 4.3.4). The ethanol extract of the root 
bark showed the presence of xanthone (Figure 4.3.2, Table 4.3.3). Xanthones are biologically active 
plant phenols which have received profound interest lately (Fotie and Bohle, 2006). Xanthones have 
been found to possess anti-inflammatory, anti-cancer, anti-hyperglycemic and anti-hypertensive 
effects amongst others (Mahendran et al., 2014, Mahammed et al., 2015). A study conducted in 2014 
has shown that xanthones extracted from the plant Swertia mussotii exert -glucosidase inhibitory 
activity (Luo et al., 2014). In a previous study, it has been also reported that long chain unsaturated 
fatty acids have significant α-glucosidase inhibitory activity (Artanti et al., 2012). This implies that 
the -glucosidase inhibitory activity of A. wilkesiana, especially the low EC50 values of the ethanolic 
root bark (Table 4.3.4) could be attributed to the xanthones and long-chain unsaturated fatty acids 
and their derivatives. 
In vitro pancreatic -amylase activity was also inhibited by all extracts of the plant parts, with the 
most significant (p < 0.05) activity exhibited by the ethanol extract of the root bark. with the lowest 
EC50 value of 6.25±1.05 µg/mL. 
Ethanolic extracts of the various parts of A. wilkesiana have been reported to have various long chain 
fatty acid and fatty acid esters e.g. tetradecanoic acid, octadecanoic acid, octadecanoic acid methyl 
ester, phytol, phytol acetate, xanthone and various sterols including stigmasterol (Figures 4.3.1-3). 
In a number of recent studies, plants extract containing these compounds have been shown to have 
-amylase, -glucosidase and lipase inhibitory activity (Mopuri et al., 2018, Chen et al., 2017, 
Payghami et al., 2015). Hence, the enzyme inhibitory activity of this plant might be linked to some 
of these bioactive compounds. We are inclined to believe that the inhibition of these enzymes by A. 
wilkesiana might indicate potential anti-hyperglycemic efficacy, which could corroborate its folkloric 




Figure 4.3.4: α-glucosidase and α-amylase inhibitory activities of leaves (a & b), stem bark (c & d) 
and root bark (e & f) extracts of A. wilkesiana. Data are reported as mean ± SD of three replicas. a-cDifferent 





Figure 4.3.5: Anti-lipase activities of: a) leaves, b) stem bark and c) root bark extracts of A. 
wilkesiana. Data are reported as mean ± SD of three replicas. a-dDifferent letters over the bars for a given concentration 
are significantly different from one another (p < 0.05). EtAc; ethyl acetate, EtOH; ethanol.  
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Table 4.3.4: EC50 values of various extracts of A. wilkesiana parts in inhibiting α-
glucosidase, α-amylase and lipase activities 




α-glucosidase α-amylase Lipase 
Leaves    
Ethyl acetate 74.63±2.87b 296.18±37.18f 384.55±23.84e 
Ethanol 67.18±7.65b 75.35±8.25c 149.70±8.34c 
Aqueous 88.35±15.37c 118.9±19.3de 203.71±1.82d 
Stem bark    
Ethyl acetate 242.99±41.83e 274.55±31.09f 146.88±19.84c 
Ethanol 37.10±2.71a >1000g 113.38±18.23b 
Aqueous 267.94±24.90e >1000g 894.61±36.28f 
Root bark    
Ethyl acetate 124.04±16.72d 98.65±15.11d >1000f 
Ethanol 35.75±1.95a 6.25±1.05a 101.33±5.21b 
Aqueous 127.25±23.60d 151.04±12.59e >1000e 
Standard    
Acarbose 36.27±1.84 53.77±3.95 ND 
Orlistat ND ND 0.03 
Data are reported as mean ± SD values of three replicas. a-gDifferent superscripts in a column for a given parameter denote 
significant difference from one another; p < 0.05. EC50 - the minimum extract concentration required for 50 % inhibition, 
ND - not determined. Due to the difference between the extracts (mixture of many compounds) and standard (pure 
compound) their values cannot be compared with one another. 
Pancreatic lipase inhibitory activity 
Results given in Figure 4.3.5 (a-c) show the inhibitory potential of the extracts of all parts for 
pancreatic lipase activity, thus demonstrating potential anti-obesogenic activity, with the best activity 
exhibited by the ethanol extract of the root bark (EC50: 101.33±5.21 µg mL-1).  
Overweight and obesity are responsible for causing insulin resistance, one of the two major 
pathogenesis ways of T2D (Wing et al., 2011). On the other hand, the most popular screening method 
in the discovery of anti-obesogenic drugs is to identify potent lipase inhibitors (Ado et al., 2013).  
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Hence, one of our objectives was to examine the ability of the plant extracts to inhibit lipase. Ethanolic 
and aqueous extracts of the leaves have been reported to have serum triglycerides lowering abilities 
(Omage et al., 2018). This might be due to their reducing small intestinal absorption of dietary lipids 
via inhibiting lipase activity. The pancreatic lipase inhibitory activity displayed by the ethanolic 
extract of the root bark (Figure 4.3.5 c) with considerably low EC50 values (Table IV) could further 
support the potential of A. wilkesiana for the management of T2D and its associated risk factors such 
as overweight and obesity.  
4.3.5 Conclusions 
The presence of potentially bioactive compounds in A. wilkesiana exerting carbohydrates and lipids 
digesting enzymes inhibitory effects is suggested in this study. These results indicate that no part of 
A. wilkesiana is a waste since it could contain potent inhibitory activities against some key enzymes 
linked to diabetes and obesity, which also gives antecedence to its use in folk medicine. These 
findings specifically point out the ethanolic extract of the stem bark and root bark as the more active 
extracts compared to the leaf extracts. Although a number of bioactive compounds have been 
identified in A. wilkesiana extracts by GC-MS analysis, some additional techniques such as LC-MS 






THE ANTIOXIDANT AND ANTIDIABETIC ACTIVITIES OF 
CRASSOCEPHALUM RUBENS IN VITRO AND IN VIVO 
5.1 Background 
Crassocephalum rubens Juss. ex Jacq. is an erect annual aromatic shrub (traditional leafy vegetable) 
growing up to 1 m in height, it belongs to the family Asteraceae. The plant is cultivated in western 
tropical Africa as a vegetable it is commonly eaten in parts of Africa like Nigeria and Benin republic 
and falls under the under-utilized and neglected plants (Dansi et al., 2012). It is usually found in areas 
with an annual rainfall of 1000-1600 mm and openly distributed in lowlands. The leaves are 
mucilaginous in nature and they are eaten raw or cooked in some parts of Africa (Cameroon and 
Nigeria) (Dansi et al., 2008, Yehouenou et al., 2010).    
 
Figure 5.1: Crassocephalum rubens  English name: Ragweed, Nigerian names: Ebire, Ebolo, Gbolo 
Photo credit: Adjatin et al. (2013b). 
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5.1.1 Ethnobotanical uses 
The leaves can be used to treat liver problems as a laxative and provided to women before or during 
childbirth to ease labour pains  (Burkill and Dalziel, 1985). Skin burns can be treated using a poultice 
made from the leaves. The sap from the leaves has anti-parasitic and analgesic properties. A trace 
presence of alkaloids has been discovered in the leaves. The powdered root has been used for the 
treatment of breast cancer externally. It is also used as a nutraceutical as it is believed to have 
antibiotic, anti-inflammatory, anthelminthic, anti-diabetic, antimalaria and blood purifying 
properties. The leaves are eaten to manage indigestion, colds and intestinal worms   (Dansi et al., 
2012).  
5.1.2 Biological activities  
The fresh leaves of C. rubens has been reported to contain essential oils which have antimicrobial 
properties and inhibitory effects on food borne pathogenic microorganisms (Yehouenou et al., 2010). 
The phytochemical analysis of the leaves of C. rubens showed the presence of coumarins, tannins, 
mucilage, flavonoids and other reducing compounds (Adjatin et al., 2012). The aqueous extract of 
the leaves of this plant has also been shown to possess hepatoprotective abilities in a study where co-
administration of rifampicin with 300 mg/kg body weight of the extract alleviated oxidative stress in 
the liver considerably (Omoregie et al., 2015). Another study also reported the hepatoprotective effect 
of C. rubens in carbon tetrachloride-induced hepatic damage (Olusola et al., 2015).  The β-cell 
protective and antidiabetic activity of C. crepidioides (also a member of the Asteraceae family) has 









5.2 Crassocephalum rubens, a leafy vegetable suppresses oxidative pancreatic and 
hepatic injury, and inhibits key enzymes linked to type 2 diabetes in vitro, ex vivo 
and in silico  
1Olajumoke A. Oyebode, 1Ochuko L. Erukainure, 2Neil A. Koorbanally, 1Md. Shahidul Islam* 
1 Department of Biochemistry, 2 School of Chemistry and Physics University of KwaZulu-Natal, 
(Westville Campus), Durban 4000, South Africa. 
*Corresponding author: islamd@ukzn.ac.za; Tel: +27 (0)31-260-8717; Fax: +27 (0)31-260-7942 
Preface: This article reports the detailed in vitro antioxidant and anti-diabetic effects of the crude 
extracts from C. rubens, which is currently under review in the Journal of Food Biochemistry. 
5.2.1 Abstract 
Crassocephalum rubens is a shrub that falls under the wild, underutilized and under cultivated 
traditional leafy vegetables (TLV) in Africa. It is eaten by few (old aged people) in the management 
of symptoms of diabetes mellitus. This study was undertaken to examine the in vitro, ex vivo 
antioxidant and antidiabetic potential of different extracts of C. rubens. The ferric reducing 
antioxidant power (FRAP), DPPH and NO (nitric oxide) scavenging activity as well as α-glucosidase 
and pancreatic lipase inhibitory potentials of the extracts were examined in vitro. Also, the 
ameliorative effects of the extracts on Fe2+-induced oxidative injury was investigated ex vivo together 
with the effects of the aqueous extract on intestinal glucose absorption and muscle glucose uptake in 
freshly harvested tissues from normal rats. The aqueous extract was further subjected to Liquid 
Chromatography-Mass Spectrometry (LC-MS) analysis to identify the possible bioactive compounds. 
The extracts showed potent free radical scavenging and antioxidant activities, while ethanol and 
aqueous extracts showed better effects compared to others. The aqueous extract also significantly (p 
< 0.05) inhibited α-glucosidase and lipase enzymes activity, intestinal glucose absorption and 
enhanced muscle glucose uptake when compared to controls. The extract significantly (p < 0.05) 
improved the activity of catalase, superoxide dismutase (SOD) and GSH levels in Fe2+-induced 
oxidative injury as evident in concomitant reduction of lipid peroxidation ex vivo. The results of this 
study suggest that the aqueous extract of C. rubens possess better antioxidant and anti-diabetic 




Keywords: Crassocephalum rubens, antioxidant, glucose absorption, glucose uptake, enzyme 
inhibition 
5.2.2 Introduction 
Globally, the spread of diabetes mellitus cannot be underestimated; it currently affects over 425 
million people and this number will experience an increase to over 600 million by the year 2045 (IDF, 
2017). More than 16 million from this number are located in the African region (Roglic, 2016). This 
increase has largely occurred due to a rapid increase in sedentary lifestyle and increased consumption 
of junk foods which are responsible for the increase of central or visceral obesity, one of the major 
risk factors of type 2 diabetes (Forouhi and Wareham, 2010). 
Diabetes mellitus is a disease which occurs due to prolonged impaired insulin secretion (type 1) or 
action (type 2) which then leads to hyperglycaemic (Kerner and Brückel, 2014). Type 2 diabetes 
(T2D) is the most prevalent form (95%) of all diabetes types and is characterized mainly by loss of 
insulin sensitivity (WHO, 2016), while partial pancreatic beta-cells dysfunction as well as lower 
insulin secretion is the another major pathogenesis of T2D. These all lead to sustained   
hyperglycaemic. Sustained   hyperglycaemic leads to the generation of reactive oxygen species which 
overburdens the antioxidant defence mechanism present in the body,  resulting in oxidative stress 
(Yan, 2014). Oxidative stress leads to deleterious consequences which affects the cell 
macromolecules such as DNA, proteins and lipids. It has long been implicated in the development of 
multiple complications such as diabetic nephropathy, retinopathy, neuropathy, and cardiomyopathy 
(Asmat et al., 2016; Vikram et al., 2014).  
Different treatment modalities are currently available for the management of T2D, but the 
shortcomings and limitations of this approach has led to the search for alternative therapies with the 
aim of reducing hyperglycemia (Kokil et al., 2015, Pandey et al., 2011). Traditional leafy vegetables 
(TLV) are strongly consumed due to their high nutritional value and are mostly grown in the rural 
areas. TLVs have recently started gaining recognition for the management and control of various 
noncommunicable diseases including diabetes. These plants are rich in fibres, micronutrients such as 
minerals and vitamins which can act as antioxidants (Adjatin et al., 2012; Wais et al., 2012; Yuan et 
al., 2016). An example of such plant is Crassocephalum rubens. 
C. rubens is an erect herb 30-70 cm in height. It belongs to the family Asteraceae and its common 
English names include thickhead, fireweed, or regleaf while its local names are ebolo (Yoruba, 
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Nigeria), shafta (Hausa, Nigeria). Unlike most TLVs that occur seasonally, C. rubens is available all 
year round since it can be harvested when it is blooming, sundried, stored and consumed in dry 
seasons when it becomes unavailable (Adjatin et al., 2012). This plant is highly recommended 
because it has a high nutritional value and gives diversity to food by adding flavour (Ahohuendo et 
al., 2012, Oseni and Olawoye, 2015). The leaves are eaten like a salad or in soups and sauces and it 
is believed to be fibre-rich, which is good for lowering blood glucose levels in diabetic patients 
(Adjatin et al., 2012). The plant is also consumed for its antioxidant, anti-helminthic, anti-
inflammatory and anti-malarial properties (Iwalewa et al., 2005). 
The toxicity of the aqueous extract of the leaves of C. rubens has been investigated on experimental 
animals and up to 1000 mg/kg body weight dosages were found to be non-toxic and even offer 
protection to some body organs (Adewale et al., 2016, Iwalewa et al., 2005). The phytochemical 
screening of the leaves of this plant showed the presence of pharmacologically active substances such 
as tannins, coumarins, flavonoids and all which works to emphasize its role as a nutraceutical (Adjatin 
et al., 2013b). The details of the hypoglycemic properties of this plant remains unresolved and this 
has led to the aim of this study. 
5.2.3 Materials and methods  
Please refer to Chapter 2 for the detailed materials and methods used for C. rubens. 
5.2.4 Results 
The ethanol extract showed the highest total phenol contents recorded as gallic acid equivalent 
































Figure 5.2.1: Total phenolic contents of C. rubens extracts. Data are reported as mean ± SD of three replicas. 
a-c Values with different letters above the bars for a given extract are significantly different from each other (p < 0.05, 
Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows).    
Figure 5.2.2 shows the DPPH free radical scavenging activities of the different extracts of C. rubens. 
All extracts showed a dose-dependent inhibition of DPPH with the aqueous extract showing the best 
activity with resultant low EC50 values (Table 5.2.1). 
 
Figure 5.2.2: DPPH scavenging activity of C. rubens extracts. Data are reported as mean ± SD three replicas. 
a-c Values with different letters above the bars for a given concentration are significantly different from each other (p < 0.05, 
Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAC, Ethyl acetate; EtOH, Ethanol; AA, Ascorbic 
acid. 
The total reducing power of all the extracts is shown in Figure 5.2.3; all extracts showed high Fe3+ 
to Fe2+ reducing potential. However, the ethyl acetate extract showed the highest total reducing power 
amongst the extracts.  
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Figure 5.2.3: Ferric reducing antioxidant power (FRAP) activity of C. rubens extracts. Data are reported 
as mean ± SD of three replicas. a-d Values with different letter above the bars for a given concentration are significantly 
different from each other (p < 0.05, Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAC, Ethyl 
acetate; EtOH, Ethanol; AA, Ascorbic acid. 
Figure 5.2.4 depicts the nitric oxide scavenging activities of the plant. All extracts were able to inhibit 
nitric oxide effectively in a dose-dependent manner with the ethanol and aqueous extract showing 
better activities even from their calculated EC50 values (Table 5.2.1). 
 
Figure 5.2.4: Nitric oxide scavenging activities of C. rubens extracts. Data are reported as mean ± SD of 
three replicas. a-d Values with different letter above the bars for a given concentration are significantly different from each 
other (p < 0.05, Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAC, Ethyl acetate; EtOH, Ethanol, 
GA; Gallic acid, AA; Ascorbic acid. 
The effect of different doses of the extracts from C. rubens on endogenous antioxidant enzymes is 
shown in Figure 5.2.5 (a-d). Induction of oxidative injury in the pancreatic tissue homogenate is 
confirmed by the low levels of antioxidant enzymes compared to the respective controls. The extracts 
were able to increase the activities of catalase (Figure 5.2.5 a) and SOD (Figure 5.2.5 b) with the 
aqueous extract showing the best activity for both enzymes. Figure 5.2.5 c shows the ability of the 
extracts to improve GSH levels in oxidative pancreatic injury. The ethanol extract showed the best 
activity in this experiment. The MDA levels is also depicted in Figure 5.2.5 d as a representation of 
lipid peroxidation in the pancreatic tissue homogenate. Interestingly, the aqueous extract showed the 
best lipid peroxidation inhibiting activity which proves the presence of potent endogenous antioxidant 



















































Figure 5.2.5: Effect of extracts of C. rubens on (A) catalase activity, (B) Superoxide dismutase 
(SOD) activity, (C) Reduced glutathione (GSH) level and (D) lipid peroxidation in oxidative 
pancreatic injury. Data are reported as mean ± SD of three replicas. *Significantly different from untreated sample and 
#Significantly different from normal sample (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). 
Normal = normal tissues, Untreated = tissues oxidatively injured but not treated. EtAc; Ethyl acetate, EtOH; Ethanol, AA; 
Ascorbic acid, MDA; Malondialdehyde.  
Figure 5.2.6. a) and b) shows the -glucosidase inhibiting and anti-lipase activity of the plant 























































































































Figure 5.2.6: (A) α-glucosidase, (B) Lipase inhibitory activity of extracts of C. rubens. Data are reported 
as mean ± SD of three replicas. a-c Different letters over the bars for a given concentration for each extract are significantly 
different from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAC, Ethyl 
acetate; EtOH, Ethanol. 
The effect of the aqueous extract (since it showed best results in the tested models) of C. rubens on 
glucose absorption and glucose uptake in tissues is shown in Figure 5.2.7 a & b. The aqueous extract 
was able to significantly (p < 0.05) inhibit glucose absorption and induce glucose uptake in the tested 
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Figure 5.2.7: Effect of the ethanol extract of C. rubens on (A) glucose absorption in isolated rat 
jejunum and (B) glucose uptake in rat psoas muscle. Data are reported as mean ± SD of three replicas. a-c 
Different letters over the bars for a given concentration are significantly different from each other (p < 0.05, Tukey’s-HSD-









































































Table 5.2.1: EC50 summary table for inhibitory effects of different extracts of C. rubens  
                                                                   
 
Sample 




   
DPPH 
 















Ethyl acetate 2.08±0.71a >1000d 35.03±2.53c 25.82±3.61a 12.51±2.04d 52.68±9.34b 2.26±1.08a 1.69±1.03b ND 
Ethanol 2.97±0.23a 14.46±3.24a 15.72±1.04a 42.85±5.64c 1.95±0.83a 64.28±7.51b 19.66±3.84b 13.12±6.23c 4.35±0.74 
Aqueous 6.73±0.16b 20.86±2.81b 13.51±1.26a 33.32±4.62b 5.21±1.17c 31.27±3.62a 2.16±1.12a 2.84±1.01b ND 





19.71±3.91b 32.01±5.27b 3.05±0.58b 35.15±7.24a ND ND ND 
Gallic acid ND 191.12±23.0
5c 
ND ND ND ND ND ND ND 
Trolox 5.79±0.4b 19.4±1.06b ND ND ND ND ND ND ND 
Acarbose ND ND ND ND ND ND 36.27±1.84c ND ND 
Orlistat ND ND ND ND ND ND ND 0.03±0.12a ND 
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, NO-nitric oxide radical, ND-not determined. Data are reported as mean ± SD values of three replicas. a-d Different letters stand 
for significantly different values from each other within a column (Tukey’s-HSD multiple range post hoc test, p < 0.05): the same letters stand for non-significant difference.
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Figure 5.2.8. shows the structures of the compounds identified by Liquid Chromatography-Mass 
Spectrometry.  
 
Figure 5.2.8: Structures of the compounds isolated from the aqueous extract of C. rubens by LC-MS 
analysis. 
Table 5.2.2 shows the binding affinities (kcal/mol) of compounds isolated from the extract with 
Sanguisorbic acid dilactone showing the highest binding affinity for catalase (-10.5 kcal/mol) and 
lipase (-10.4 kcal/mol) enzymes.    
Table 5.2.2: Binding affinities (kcal/mol) of compounds isolated from the aqueous extract with 
antioxidant and anti-diabetic enzymes. 






 α-glucosidase lipase 
6-hydroxy-2-cyclohexen-
one-carboxylate 




-5.0 -7.3 -6.5  -5.5 -6.4 
8-Methoxy-6,7-
methylenedioxycoumarin 
-5.1 -8.3 -7.0  -5.5 7.5 
Sanguisorbic acid dilactone -7.9 -10.5 -8.7  -7.9 -10.4 
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Figure 5.2.9 shows images of 3-D (a) and 2-D (b) interactions of Sanguisorbic acid dilactone isolated 
from the aqueous extract (the highest binding affinity -10.5 kcal/mol) with amino acid residues of 
docked complex of catalase enzyme. 
 
Figure 5.2.9:  Illustration of 3-D (a) and 2-D (b) interactions with amino acid residues of docked 
complex (Sanguisorbic acid dilactone-catalase) isolated from the aqueous extract with the highest 
binding affinity -10.5 kcal/mol (Highest binding affinity compared to all antioxidant enzyme 
considered). 
Figure 5.2.10 shows images of 3-D (a) and 2-D (b) interactions of Sanguisorbic acid dilactone with 
amino acid residues of docked complex of lipase. When compared to the binding energy of this 
compound with the α-glucosidase enzyme, lipase had the highest binding energy. 
 
Figure 5.2.10: Illustration of 3-D (a) and 2-D (b) interactions with amino acid residues of docked 
complex (Sanguisorbic acid dilactone-lipase) isolated from the aqueous extract with the highest 




The antioxidant activities of traditional leafy vegetables have recently been exploited. These plants 
contain a wide array of phytochemicals (Kinyi et al., 2016), so it is not surprising tha   they are 
enjoyed as a delicacy and used by the locals in the treatment of diseases like T2D (Chauhan et al., 
2014). Out of the complex multiple pathogenesis of T2D, oxidative stress remains the precursor of 
the diverse complications associated with this disease (Folli et al., 2011). Fortunately, alternate 
therapies can be produced from plants rich in antioxidants, which can serve as free radical scavengers 
(Heravi et al., 2015).  
The presence of total phenols in the different extracts of C. rubens in this study shows its strong 
antioxidant potentials (Figure 5.2.1). Polyphenols in food and vegetables are antioxidant 
phytochemicals that contribute to free radical scavenging activities (Zhang et al., 2015).  
DPPH assay is a fast and reliable method to estimate free radical scavenging activity (Pavithra and 
Vadivukkarasi, 2015). DPPH, a stable free radical, which accepts an electron of hydrogen radical 
from an antioxidant to form a diamagnetic molecule (Jadid et al., 2017). An antioxidant can donate 
an electron to DPPH, thereby reducing the violet color of DPPH to orange. The DPPH scavenging 
activity demonstrated by the different extracts of C. rubens especially the aqueous extract (Figure 
5.2.2 & Table 5.2.1) suggests that this plant has constituents with hydrogen-donating ability.  
Iron has been reported to play a major role in the generation of free radicals through its enzymatic or 
non-enzymatic reaction with superoxide ion (Haber Weiss reaction) or hydrogen peroxide (Fenton 
reaction). The reducing power of plants has been linked to their antioxidant capacity (Apak et al., 
2016). The reduction of Fe3+ is often used as a marker for electron donating ability which signals 
potent antioxidants (Nabavi et al., 2009). Antioxidants perform their roles by donating a hydrogen 
atom with the sole intention of breaking a free radical chain (Meir et al., 1995). The extracts showed 
good reducing power in a dose dependent manner (Figure 5.2.3). The polyphenols present in the 
extracts of C. rubens caused the reduction of Fe3+ to the ferrous form (Fe2+) thereby proving its 
antioxidant potential.  
Nitric oxide is a free radical normally produced in mammalian cells and is involved in the regulation 
of various physiological processes. Unfortunately, high generation of nitric oxide radicals has been 
linked to the progression of several diseases (Ohkawa et al., 1979). Substances which prevent the 
production of NO radicals have become an interesting material of research for targeting chronic 
inflammatory diseases (Phaniendra et al., 2015). This study investigated the inhibitory effects of the 
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plant extracts on nitric oxide production. The generation of nitric oxide from sodium nitroprusside at 
physiological pH was inhibited by C. rubens (Figure 5.2.4 & Table 5.2.1).  
In the mitochondria, the electron transport chain (ETC) causes the formation of reactive oxygen 
species (ROS), molecular oxygen is reduced to form superoxide anions which can yield more ROS. 
H2O2 is either scavenged by catalase or it helps in the formation of more ROS. Studies have shown 
that depletion of endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase, 
reduced glutathione (GSH) leads to the progression of lipid peroxidation which can ultimately lead 
to oxidative stress (Tiwari et al., 2013). In Figure 5.2.5, incubation of the pancreatic homogenate 
with FeSO4 led to a reduced concentration of SOD, catalase and GSH levels which is indicative of 
successful induction of pancreatic oxidative injury (Oyebode et al., 2018; Ramakrishnan et al., 2011). 
There was also a concomitant increase in malondialdehyde (MDA) levels which signalled the 
induction of lipid peroxidation (Figure 5.2.5 D). The dismutation of superoxide by SOD forms 
molecular oxygen or hydrogen peroxides (H2O2), which is more stable than the superoxide anion. The 
H2O2 was efficiently broken down to water and molecular oxygen. Extracts from C. rubens were able 
to effectively improve the activities of these enzymes with simultaneous reduction of lipid 
peroxidation (Figure 5.2.5). These activities could be due to the presence of polyphenols which could 
also be responsible for the observed in vitro antioxidant ability (Table 5.2.1). 
The treatment of diabetes and its related complications can be achieved by inhibiting the action of 
key enzymes linked to carbohydrate (-glucosidase) and lipid (lipase) digestion (McCulloch, 2007). 
Bioactive compounds from plant sources have been reported to be useful in inhibiting -glucosidase 
and lipase activities (Mai et al., 2007; Oyebode et al., 2018; Tan et al., 2017). The aqueous and 
ethanol extract of C. rubens demonstrated potent -glucosidase and lipase inhibitory activities which 
could be due to the presence of polyphenols in these extracts (Figure 5.2.6).  
The high antidiabetic activity exhibited by the aqueous extract prompted the need for more 
investigation of the effect of this extract on glucose absorption and uptake in jejunal tissues and psoas 
muscle of normal rats respectively. In T2D, there is sustained and prolonged hyperglycemia as a result 
of build-up of glucose in the blood stream. Peripheral tissues such as the jejunum engage actively in 
the uptake of the excess glucose from the blood which then causes complications such as T2D and 
obesity (Thazhath et al., 2014). This also occurs with concomitant inhibition of glucose uptake by the 
muscle as a result of defective insulin signalling (Bonadonna et al., 1996; Kelley et al., 1993). C. 
rubens was able to inhibit intestinal glucose absorption in harvested rat jejunum (Figure 5.2.7 A) and 
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also induce the uptake of glucose in isolated rat psoas muscle (Figure 5.2.7 B). This effect was 
consistent and dose-dependent in both assays which shows that a higher dose of the aqueous extract 
of the plant will bring the required anti-diabetic activity.   
Liquid chromatography-mass spectrometry analysis on the aqueous extract was carried out to identify 
bioactive components present in the aqueous extract. This study revealed the presence of four 
compounds, including a polyphenolic dilactone (Figure 5.2.8). 3,4-Methylenedioxybenzoic acid 
found in the plant is a phenol and it is also known as piperonylic acid. 3,4-Methylenedioxybenzoic 
acid has been reported to possess antioxidant properties (Polya, 2003; Tan et al., 2017). The anti-
diabetic properties of 8-Methoxy-6,7-methylenedioxycoumarin also found in this study has been 
reported (Tk, 2012, Venugopala et al., 2013). Sanguisorbic acid dilactone an ellagitannin found 
present in the extract (Figure 5.2.8) has been reported to alleviate oxidative stress (García-Villalba et 
al., 2015). The presence of these compounds in the aqueous extract of C. rubens might render 
synergistic activities to its anti-diabetic and antioxidant activity of the plant. 
Molecular docking results revealed Sanguisorbic acid dilactone have the highest binding potential for 
catalase when compared to other antioxidant enzymes considered in this study. The docking study 
for Sanguisorbic acid dilactone showed the formation of hydrogen bonding, Pi interactions and Van 
der Waals interactions as shown in Figure 5.2.9. The O-H and oxygen group of Sanguisorbic acid 
dilactone forms hydrogen bonding with the following amino acid residues of catalase (ARG72, 
ARG112, GLY147). The Van der Waals interactions were with MET350, HIS218, LEU299, SER217, 
ASN148, PHE 132 TYR358, PHE132, GLY131 ALA133, PHE3334, HIS362, THR361, VAL74 
VAL73, PHE161. It was also observed that Sanguisorbic acid dilactone gave the highest docking 
binding energy for lipase compared to α-glucosidase (Table 5.2.2, Figure 5.2.10). These high binding 
energies of Sanguisorbic acid dilactone revealed more stable interactions with catalase and lipase 
compared to other compound identified in this study. This could provide valuable information 
towards proposing the catalytic mechanism of these compounds.  
5.2.6 Conclusions 
This study sheds light on the antioxidant and anti-diabetic capacity of C. rubens extracts and also 
identified the role of the bioactive constituents present in the aqueous extract. The free radical 
scavenging, inhibiting key enzymes linked to diabetes and intestinal glucose absorption together with 
the induction of muscle glucose ability of C. rubens was well justified in this study. However further 
in vivo work should be done to confirm the results obtained in this study.  
138 
 
5.3 Crassocephalum rubens improves pancreatic histology, insulin secretion, liver 
and kidney function parameters in a type 2 diabetic rat model 
Olajumoke A. Oyebode, Ochuko L. Erukainure, Olakunle Sanni, Md. Shahidul Islam* 
Department of Biochemistry, School of Life Sciences, University of KwaZulu-Natal, (Westville 
Campus), Durban 4000, South Africa  
*Corresponding author: islamd@ukzn.ac.za; Tel: +27 (0)31-260-8717; Fax: +27 (0)31-260-7942 
Preface: This article reports the detailed in vivo anti-diabetic effects of the crude extracts from C. 
rubens, it is currently awaiting revision before submission to a journal for publication. 
5.3.1 Abstract 
Crassocephalum rubens is a traditional leafy vegetable (TLV) eaten in parts of Africa for the 
management of diabetes mellitus. This study was conducted to investigate the in vivo anti-diabetic 
activity of aqueous extract of C. rubens aerial parts (CRAQ) in a type 2 diabetes model of rats. In this 
study, type 2 diabetes (T2D) was induced in male Sprague dawley (SD) rats by feeding 10% fructose 
solution for two weeks followed by a single intraperitoneal injection of streptozotocin (40 mg/kg bw). 
After confirmation of T2D, animals were treated with a low (150 mg/kg bw) and a high dose (300 
mg/kg bw) of the extract for five weeks. During this period, food and fluid intake was measured daily 
and body weight and blood glucose were measured weekly when oral glucose tolerance test was 
conducted in the last week of the intervention period. Treatment with the high dose of extract 
significantly (p < 0.05) reduced blood glucose level, improved oral glucose tolerance level and 
pancreatic β-cell function and histology compared to diabetic control group. The high dose also 
increased the serum insulin, liver glycogen, and improved cardiac, liver and renal damages 
significantly compared to the untreated diabetic group.  Data from this study suggest that C. rubens 
possesses anti-diabetic activity and could be useful in ameliorating some macrovascular 
complications associated with T2D, therefore this plant can be exploited in finding new alternate 
therapies for the treatment of T2D.  
Key words: Crassocephalum rubens, type 2 diabetes, histopathology, liver glycogen, rats. 
5.3.2 Introduction 
Diabetes mellitus is a global world health problem, the prevalence is on the rise and in 2017 over 427 
million people were considered diabetic (IDF, 2017). This number represents only the people who 
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were tested as a large number of people are presently living with diabetes undiagnosed (WHO, 2016). 
Diabetes is a complex metabolic disease characterised by hyperglycaemia, pancreatic β-cell 
dysfunction and insulin resistance (Arredondo et al., 2018). Type 2 diabetes (T2D) accounts for over 
90% of all recorded diabetic cases and unhealthy eating habits, lack of exercise, urbanisation favours 
the prevalence of T2D. Hyperglycaemic-induced oxidative stress is responsible for the multiple 
complications associated with T2D. These complications grouped into microvascular (affecting the 
small blood vessels) and macrovascular (affecting the large blood vessels) complications range from 
retinopathy, nephropathy, neuropathy, and cardiovascular problems (Forbes and Cooper, 2013). The 
effective control of high blood glucose levels is very important for curbing the complications 
associated with T2D.  
Presently, different drugs are available for the treatment and management of T2D. These drugs 
include but are not limited to sulfonylureas, biguanides, thiazolidinediones, glucagon-like peptide 
(GLP-1 analogues), incretin memetics and so on. These drugs although quite effective when used 
alone or in combination with other drugs, possess some unwanted short and long-term side effects 
such as nausea (biguanides such as metformin), increased risk of heart problems (thiazolidinediones), 
weight gain (metformin, insulin secretagogues), weight loss (glibenclamide) (Chaudhury et al., 
2017). 
Despite different treatment modalities currently used for T2D, getting a diabetic patient to normal 
glucose levels still remains a challenge. Fortunately, nature has provided mankind with medicinal 
plants which holds the key to wellness and longevity. These plants have since time immemorial been 
exploited for treating diverse diseases since they are loaded with antioxidants and blood lowering 
nutrients in abundant supply (Rani and Maheshwari, 2014). 
An example of such potent medicinal plant is Crassocephalum rubens which is a traditional leafy 
vegetable (Figure 5.1) and is used in various parts of Africa for the treatment of diseases such as 
T2D. In previous sections of this chapter, the in vitro, ex vivo antioxidant and antidiabetic activities 
of this plant has been reported in detail. This section serves to outline the effect of aqueous extract of 
aerial parts of Crassocephalum rubens (CRAQ) in a type 2 diabetes rat model.  
5.3.3 Materials and methods 





The data for mean daily food and fluid intake during the five-week intervention period are shown in 
Figure 5.3.1. The normal groups (NC and NCR) showed significantly (p < 0.05) lower food and fluid 
intake compared to the diabetic untreated group (DBC). Although, the food intake of the CRAQ 
groups showed no statistically significant difference compared to the standard drugs (DBM and 
DBG), it was relatively lower compared to the DBC group. However, there was significantly (p < 
0.05) lower fluid consumption seen in the DCRH group compared to the DBC and DCRL group 
although not as low as the standard drug metformin but statistically the same as glibenclamide. 
 
Figure 5.3.1: Mean feed and fluid intake in different animal groups during the experimental period. 
Data are reported as mean ± SD of seven animals. a-cValues with different letters over the bars for a given parameter are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, 
Diabetic control, DCRL, Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, 
DBG, Diabetic glibenclamide, NCR, Normal C. rubensi high dose (toxicological control). 
Figure 5.3.2 shows the mean weekly body weight change over the seven-weeks experimental period. 
No significant difference was observed in the body weight of all animal groups (both normal and 
diabetic) before the induction of T2D. However, there was a reduction in the body weight of the 
animals in the diabetic groups which is very common after streptozotocin injection. Interestingly, in 
the last 2 weeks of the experiment (weeks 6 and 7), there was a steady increase in the body weight of 











































Figure 5.3.2: Mean body weight change in all groups over the seven weeks experimental period. Data 
are reported as the mean ± SD of seven animals. a-cValues with different letters for a given week are significantly different 
from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DCRL, 
Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic 
glibenclamide, NCR, Normal C. rubens high dose (toxicological control), STZ, Streptozotocin, T2D, Type 2 diabetes. 
All the diabetic groups showed significantly higher blood glucose concentrations compared to the 
normal groups after injection of STZ. However, treatment of the diabetic animals with CRAQ and 
the standard drugs showed a reduced blood glucose levels than the untreated groups all through the 
intervention period (Figure 5.3.3). The high dose (DCRH) showed significantly lower blood glucose 
level than the low dose which demonstrated a dose-dependent reduction of blood glucose levels by 
the extract.  The DCRH group showed lower blood glucose level in both non-fasting (week 1-4) and 
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Figure 5.3.3: Weekly blood glucose concentrations in different animal groups during the intervention 
period. Data are reported as the mean ± SD of seven animals. a-dValues with different letters for a given week are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, 
Diabetic control, DCRL, Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, 
DBG, Diabetic glibenclamide, NCR, Normal C. rubens high dose (toxicological control), STZ, Streptozotocin, NFBG, Non-
fasting blood glucose, FBG, Fasting blood glucose. 
The data for OGTT and the corresponding area under the curve (AUC) are shown in Figure 5.3.4 
The glucose tolerance of the CRAQ-treated groups was significantly (p < 0.05) better than the DBC 
group. A better glucose tolerance ability was observed in the DCRH group at the 60 min mark which 
was manifested all through the OGTT period. The total area under the curve (AUC) of DCRH group 
was significantly lower than the other diabetic groups (DBC, DCRL, DBM and DBG), which again 












































Figure 5.3.4: Oral glucose tolerance test (OGTT) and corresponding area under the curve (AUC) of 
different animal groups in the last week of the intervention period. Data are reported as the mean ± SD of 
seven animals. a-fValues with different letters for a given time (line graph) or AUC in different groups are significantly 
different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control; DBC, Diabetic control; 
DCRL, Diabetic C. rubens low dose; DCRH, Diabetic C. rubens high dose; DBM, Diabetic metformin; DBG, Diabetic 
glibenclamide; NCR, Normal C. rubens high dose (toxicological control). 
Table 5.3.1 shows the liver weight, relative liver weight and liver glycogen level of different animal 
groups at the end of the experimental period. No significant difference in the liver weight was 
observed in all the animal groups, however, the relative liver weight of the normal groups (NC and 
NCR) and DCRH group were significantly (p < 0.05) lower than that of the diabetic untreated group 
(DBC). The treatment with CRAQ increased the liver glycogen level in the DCRH group when 
compared to the DBC group (Table 5.3.1).   
Table 5.3.1: The effects of different doses of CRAQ on liver weight, relative liver weight and liver 
glycogen levels in the different animal groups at the end of the intervention period. 
Parameter NC DBC DCRL DCRH DBM DBG NCR 
Liver weights (g) 10.7±0.8 8.7±0.9 9.5±0.5 8.2±0.7 9.6±0.7 9.9±0.9 10.7±1.1 
Rel. liver weights (%) 2.9±0.3a 3.8±0.2b 4.1±0.7b 2.5±0.2a 2.7±0.1a 2.4±0.1a 2.9±0.5a 
Liver glycogen (mg/g 
tissue) 36.0±0.9c 11.8±1.1a 22.3±1.5b 28.3±0.6c 31.4±1.1c 21.8±0.8b 24±1.6b 
Results are expressed as mean ± SD (n=7). a-cDifferent superscript letters for a given parameter along a row indicate the 
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At the end of the experimental period, the serum lipid profile of all the animals were measured and 
reported in Figure 5.3.5. The DBC group showed a significantly (p < 0.05) higher total- and LDL-
cholesterol compared to the normal groups. However, treatment with CRAQ and standard drug 
(metformin) reduced the levels of these cholesterols as seen in the DCRL, DCRH and DBM groups, 
respectively, while the DBG and DCRL groups showed similar results compared to the DBC group 
for total cholesterol and triglycerides. T2D-induction caused a significant (p < 0.05) elevation of 
serum triglycerides level which was reduced by the CRAQ and metformin treatment in the DCRH 
and DBM groups, respectively.  
 
Figure 5.3.5: Serum lipid profile of different animal groups at the end of the intervention period. Data 
are reported as the mean ± SD of seven animals. a-cValues with different letters for a given parameter significantly different 
from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DCRL, 
Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic 
glibenclamide, NCR, Normal C. rubens high dose (toxicological control). HDL, High density lipoprotein, LDL, Low density 
lipoprotein.  
Table 5.3.2 shows the data for other serum parameters of diabetic complications. Serum levels of 
AST, ALP and urea were elevated in the DBC group compared to the NC and NCR groups. 
Interestingly, CRAQ significantly ameliorated the ALP, AST and urea with uric acid levels in the 
respective groups. Serum CK-MB was increased in the DBC group compared to the normal (NC and 




 Table 5.3.2: Serum biochemical parameters in different animal groups at the end of the experimental 
period.        
Parameter      NC DBC DCRL DCRH DBM DBG NCR 
AST (U/L) 49.5±5.6a 147±16.3f 120±4.2e 74±3.9bc 102.5±12.5de 85±8.8cd 57.7±6.9ab 
ALT (U/L) 87.8±1.1 87.3±2.0 86.3±2.7 87.5±0.5 85.5±2.1 86.3±1.3 85.8±1.1 
ALP (U/L) 72.3±6.2a 308.3±44.8bc 353.3±43.9c 233.7±81.1b 206.8±59.5b 395.9±86.2c 76.8±4.7a 
Urea(mg/dL) 52.6±4.8ab 73.8±3.4d 62.3±1.9c 43.1±7.3a 51±5.8ab 71.5±3.9d 52.5±2.2ab 
UA (mg/dL)   0.78±0.43a 3.5±0.9c 3.2±0.5c 2.3±0.3b 1.3±0.5ab 1.6±0.7ab 1.1±0.1ab 
CK-MB(u/L) 118.9±14.7a 305.5±27.8d 249.4±14.1c 146.5±24.6a 113.9±17.7a 185.9±7.6b 120.2±3.2a 
Results are expressed as mean ± SD (n=7). a-eDifferent superscript letters for a given parameter along a row indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, 
DCRL, Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic 
glibenclamide, NCR, Normal C. rubens high dose (toxicological control).  AST, Aspartate aminotransferase, ALT, Alanine 
aminotransferase, ALP, Alanine phosphatase, UA, Uric acid, CK-MB, Creatinine Kinase-myocardial band. 
The NC, NCR and DCRH groups showed significantly (p < 0.05) higher serum insulin levels 
compared to the DBC group (Table 5.3.3). The HOMA-IR score in the NC group was significantly 
lower than that of the DBC group and the treatment with CRAQ was able to reduce to HOMA-IR 
scores. In the other case, the HOMA-β scores of the DBC group was seen to be significantly lower 
than the NC group and all treated groups showed a significant increase in HOMA-β scores compared 
to the DBC group. Serum fructosamine level significantly increased in the DBC group compared to 
normal groups which was significantly improved in the diabetic treated groups compared to the DBC 
group. 
Table 5.3.3: Serum insulin and fructosamine concentrations as well as calculated HOMA-IR and 
HOMA-β scores in different animal groups at the end of the experimental period. 
      NC DBC DCRL DCRH DBM DBG NCR 
Serum Insulin 
(pmol/L) 
65.2±1.1c 23.5±1.8a 58.5±1.8c 99.3±7.0d 59.8±6.7c 41.8±2.3b 96.8±2.5d 
Fructosamine 495.8±17.9a 990±10.4d 792.4±72.9c 607.3±5.3b 572.5±9.2b 743.6±37.4c 438.8±38.8a 
HOMA-IR 2.1±0.3a 14.0±0.3f 8.4±0.3e 6.9±0.5d 6.5±0.7d 5.2±0.3c 3.1±0.1b 
HOMA-β 100.3±1.7e 2.7±0.2a 8.3±0.3bc 35.6±2.5d 11.9±1.3c 7.0±0.4b 169.7±4.3f 
Results are expressed as mean ± SD (n=7). a-fDifferent superscript letters for a given parameter along a row indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, 
DCRL, Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic 
glibenclamide, NCR, Normal C. rubens high dose (toxicological control). HOMA-IR and HOMA-β; Homeostatic model 
assessment for IR (insulin resistance) and β (β-cell function).  
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Histopathological analysis of pancreatic tissues excised from normal as well as extract and drug-
treated rats are shown in Figure 5.3.4. The parenchyma of normal rats (green and black arrow) 
showed compact acinar cells with an abundance of granular eosinophilic cytoplasm and normal 
interlobular connective tissues with intact islets of Langerhans. Examination of the DBC pancreas on 
the other hand, showed a degeneration of endocrine cells within the islets (red arrow) indicating 
necrosis of the pancreatic β-cells. Pancreatic sections from the metformin and extract-treated groups 
(blue, grey and yellow arrows respectively) showed although not quite as intact as the normal cells 
but a promising regeneration of the pancreatic islets were achieved. The DBG pancreas (purple arrow) 
looked almost same as the untreated islets (DBC).   
 
Figure 5.3.6: Histopathological images of the pancreas of different animal groups at the end of the 
experiment. NC, Normal control, DBC, Diabetic control, DCRL, Diabetic C. rubens low dose, DCRH, Diabetic C. rubens 





The T2D animal model used in this study successfully mimicked the two main pathological features 
of T2D which are insulin resistance and partial pancreatic β-cell dysfunction. Normal rats were first 
given a 10% fructose solution for two weeks to induce insulin resistance and then an intraperitoneal 
injection of streptozotocin (40 mg/kg bw) to induce partial pancreatic β-cell dysfunction (Wilson and 
Islam, 2012).   
Severe complications of T2D include hyperosmolar and hyperglycaemic non-ketotic syndrome 
(Knentz et al., 1991) while more common symptoms of T2D include polydipsia, polyphagia, lethargy, 
visual blurriness and weight loss (Afolayan and Sunmonu, 2010). In this study, the increased fluid 
intake seen in the diabetic groups reflected successful T2D-induction (Figure 5.3.1). Although 
CRAQ-treatment reduced the fluid intake of the animals, it was not as low as the fluid intake of the 
normal group which could be as a result of a short intervention time (5 weeks).  Body weight loss is 
another physical symptom of T2D which occurs due to increased protein glycation which is a 
consequence of persistent   hyperglycaemic and leads to the loss of muscle and tissue protein (Mbaka 
et al., 2014). There was a decrease in body weight of all diabetic animals after STZ injection which 
again confirmed the induction of T2D. Interestingly, the high dose of CRAQ was able to increase and 
sustain the body weight of the diabetic animals all through the intervention period.  This may be 
related to the high nutrient level of C. rubens  (Adjatin et al., 2013b).  
The non-fasting and fasting (at the last week) blood glucose levels were measured during the 5-week 
intervention period, this is because NFBG is a key parameter in understanding the severity of T2D 
(Group, 1998). From our result (Figure 5.3.3), CRAQ showed potent blood glucose lowering activity. 
Right from the second week and all through the intervention period, the DCRH group displayed low 
blood glucose levels.  Some processes might be responsible for the observed blood glucose lowering 
activity of CRAQ, such as improvement of insulin action (Islam and Choi, 2008), pancreatic β-cell 
stimulation (Remedi and Emfinger, 2016) or improved uptake of glucose by the peripheral tissues 
(Oyebode et al., 2018). There are reports that plants have β-cell protecting and regenerating abilities 
(Oh, 2015). Since the DCRH group showed reduced blood glucose level from as early as the second 
week of intervention, it might be due to CRAQ stimulated the survival of pancreatic β-cells as well 
as induced insulin production after the oxidative damage caused by STZ. This could also be explained 
by Figure 5.3.6 where   marked regeneration of the damaged pancreatic islets in the DCRH group 
was observed compared to the DBC group.   
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Maintaining glucose homeostasis is very important in T2D so as to reduce any risk of micro or macro-
vascular complications (Chawla et al., 2016). Treatment with CRAQ showed promising improvement 
in glucose tolerance abilities of the plant (Figure 5.3.4) especially at the high dose of 300 mg/kg bw. 
This activity might be due to lower insulin resistance and increased insulin secretion that would 
induce glucose uptake by the peripheral tissues. In addition, the high dose of the extract reduced 
HOMA-IR index (for insulin resistance), and also improved the HOMA-β (for β-cell function) score 
(Table 5.3.3 and Figure 5.3.6). Homeostatic model assessment (HOMA) is a technique used for 
estimating insulin resistance and β-cell function from fasting blood glucose levels and insulin 
concentration (Wallace et al., 2004). Plants that reduce HOMA-IR scores have been reported to 
contain potent antidiabetic activities (Vianna et al., 2011). In addition to altering insulin resistance 
and β-cell function, CRAQ also showed fructosamine reducing ability (Table 5.3.3). Fructosamine 
is a marker of glucose control showing average serum glycaemic level, in some cases it is regarded 
as more efficient in detecting early response to treatment (Nansseu et al., 2015).  
The CRAQ-treated groups also showed improved levels of hepatic glycogen (Table 5.3.1). Increased 
phosphorylation of glycogen or reduced activity of glycogen synthase are pathological features 
observed in STZ-induced T2D, which could be responsible for reduced glycogen level seen in the 
DBC group (Islam, 2011). The liver glycogen storing activity might also be responsible for the lower 
blood glucose level in the CRAQ treated group compared to the DBC group. Interestingly, plants 
have been reported to exhibit hepatic glycogen synthesizing activities,  which may contribute to their 
observed anti-diabetic activity (Bhat et al., 2011, Ezeani et al., 2017). 
Hyperglycaemia and insulin resistance lead to various metabolic disorders such as hyperlipidaemia. 
Hyperlipidaemia occurs due to reduced action of insulin which then increases lipase activity thereby 
releasing free fatty acids from the adipose tissue (Mbaka et al., 2014). This study showed the efficacy 
of CRAQ in the modulation of hyperlipidaemia (Figure 5.3.5). Treatment with CRAQ led to 
significant reduction in triglycerides, total- and LDL-cholesterol, while a promising increase was 
shown in HDL-cholesterol. From these results, it is possible to say that the extract inhibited lipase 
enzyme activity as well as mobilized free fatty acids from peripheral fat deposit to the blood vessels. 
Studies have demonstrated the potency of plant extracts in alleviating hyperlipidaemia (Eze et al., 
2012). The reduced CK-MB levels of the CRAQ-treated animals compared to the DBC group in 
Table 5.3.2 also supports the cardiac-protective ability of this plant. Creatinine kinase is used as a 
marker for coronary heart disease and increased levels of this enzyme signals increased risk of heart 
diseases (Patel et al., 2014). The ability of CRAQ to reduce CK-MB levels supports the 
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hyperlipidaemia-alleviating properties of this plant (Table 5.3.3) which together renders cardio-
protective ability in T2D patients.  
Core markers of liver injury are alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) while alkaline phosphatase (ALP) is a marker for cholestasis (liver disease which causes 
itching) (Malakouti et al., 2017). Although T2D-induction did not show any impact on serum ALT 
levels (Table 5.3.2), increased ALP and AST levels were observed in the DBC group compared to 
the NC group; however treatment with CRAQ showed reduced levels of these enzymes which shows 
the hepatoprotective ability of the extract.  
Serum urea and uric acid are markers of kidney failure. Studies have shown that in T2D, serum urea 
and uric acid is usually elevated (Kushiyama et al., 2014). In Table 5.3.2 the DBC groups showed 
elevated urea and uric acid levels compared to the normal groups. Treatment with CRAQ alleviated 
the effect of these enzymes, which shows the ability of this extract to limit the risk of kidney problems. 
5.3.6 Conclusions 
In conclusion, the results of this study suggest that the aqueous extract of Crassocephalum rubens 
aerial parts dose-dependently portrays  anti-diabetic activity,  mechanisms may include improving 
pancreatic β-cell function, stimulating insulin secretion, improving glucose tolerance, reducing 
hyperlipidemia and increasing hepatic glycogen. The extract also ameliorated some T2D-induced 
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Preface: This article reports the detailed in vivo antioxidant status of the serum and organs collected 
from the rats in the above experiment and it is currently awaiting revision before submission to a 
journal for publication. 
5.4.1 Abstract 
The effects of oral administration of the Crassocephalum rubens aqueous extract (CRAQ) on 
antioxidant status in the serum, pancreas, liver, kidney and heart of type 2 diabetic rats was examined. 
Alterations in important functional groups in the liver and pancreas were also monitored using Fourier 
Transform Infrared (FT-IR) spectroscopy. The male SD rats were induced with type 2 diabetes (T2D) 
and treated with 150 or 300 mg/kg bw of CRAQ. Levels of TBARS (thiobarbituric acid reactive 
substances), catalase, super oxide dismutase (SOD), reduced glutathione, glutathione reductase and 
glutathione peroxidase were measured in selected organs and serum were investigated at the end of 
the intervention period. Induction of type 2 diabetes (T2D) caused a significant (p < 0.05) decrease 
of endogenous antioxidant enzymes, as well as an increment in MDA levels (a marker of lipid 
peroxidation) in the diabetic rats. However, treatment with CRAQ caused a dose-dependent and 
significant (p < 0.05) increase in reduced glutathione levels and other endogenous antioxidant 
enzymes in the serum and other organs compared to diabetic control group. The FT-IR analysis 
showed a reduction of fasting blood glucose levels after the treatment with the high dose of CRAQ 
which is consistent with reduced FT-IR peaks at 1200-900 cm-1. Results of this study indicate that 
high dose (300 mg/kg bw) of CRAQ possess strong antioxidant effect in a type 2 diabetic model of 
rats. 






Under normal physiological conditions, a complex system of endogenous enzymatic and non-
enzymatic antioxidant defences work to combat the deleterious effects of free radicals generated from 
normal metabolic processes (Kurutas, 2015). These free radicals are implicated in the generation of 
complications linked to diseases such as diabetes (Asmat et al., 2016). Diabetes mellitus is a complex 
disease that has quickly become a problem to global public health (Roglic, 2016). Out of the three 
main types of diabetes, type 2 diabetes (T2D) remains the most prevalent form with 95% of all 
diabetic cases being type 2 diabetic (IDF, 2017). Persistent hyperglycemia, insulin resistance and 
partial pancreatic β-cell dysfunction are the main pathogenesis of T2D. Autooxidation of excess 
glucose in the blood stream as a result of insulin resistance has been linked to the generation of free 
radicals in T2D (Lyons et al., 1992). These free radicals overwhelm the concentration of antioxidant 
enzymes in the body thereby leading to the progression of oxidative stress. Oxidative stress causes a 
host of complications affecting various organs such as heart, liver, kidney, eyes, arteries of patients 
suffering from T2D. Fortunately, plants have been used successfully as a source of potent antioxidants 
in curbing the effects of free radicals in oxidative stress conditions. Medicinal plants contain potent 
hydrogen donating, oxygen quenching, free radical scavenging activities that are beneficial in 
managing complications of T2D (Garhwal, 2010). The effect of this plants can be due to the presence 
of potent bioactive components such as tannins, polyphenols, saponins, and others. An example of a 
medicinal plant with antidiabetic activity is Crasssocephalum rubens.  
Crassocephalum rubens belongs to the family Asteraceae; and is a perennial shrub that is mostly 
eaten and enjoyed as a vegetable in salads and sauces in various parts of Africa. It is successfully 
used in the treatment and management of diseases such as diabetes. Preliminary in vitro α-glucosidase 
and lipase inhibitory potential of different solvent extracts of aerial parts of C. rubens has been 
reported in Section 5.2. In a previous study, the crude ethanol, ethyl acetate and aqueous extracts of 
the plant was subjected to different in vitro, ex vivo and in silico antioxidant and anti-diabetic assays 
from which the aqueous extract was chosen as the most active compared to all other solvent extracts 
(see section 5.2 above). This also led to investigate the anti-diabetic effect of CRAQ in a type 2 
diabetes rat model (Section 5.3). Our results showed that CRAQ has glucose lowering, insulin 
resistance alleviating and β-cell protective abilities as well as cardiac, hepatic and renal protective 
abilities in diabetic conditions.  
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However, another interest of this study was to investigate comprehensively the antioxidant effect of 
CRAQ since oxidative stress plays a major role in the pathogenesis of T2D and its associated multiple 
complications, and also to determine whether functional groups in the tissues (liver and pancreas) 
were altered after the treatment with CRAQ extract.   
5.4.3 Materials and methods 
Please refer to Chapter 2 for the detailed materials and methods used for C. rubens. 
5.4.4 Results 
The DBC group showed a significantly (p < 0.05) higher level of MDA compared to the normal and 
treated groups (Figure 5.4.1). This was also replicated in the serum, liver, heart and kidneys of the 
animals. The MDA levels was seen to reduce upon treatment with the CRAQ which shows the lipid 
peroxidation alleviating property of the extract.  
 
Figure 5.4.1: Thiobarbituric acid reactive substances (MDA equivalent) in the serum, liver, pancreas, 
heart and kidneys of all animal groups at the end of the intervention period. Data are reported as mean ± 
SD of 7 animals. a-eValues with different letter above the bars for a given sample are significantly different from other group 
of animals (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DCRL, 
Diabetic C. rubens low dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic 
glibenclamide, NCR, Normal C. rubens high dose (toxicological control), MDA, Malondialdehyde. 
The reduced glutathione (GSH) concentrations of the serum and organs of all animal groups are 
reported in Figure 5.4.2. The GSH concentration in the serum, liver, pancreas and heart was 
significantly (p < 0.05) lower in the DBC group upon induction of diabetes compared to the normal 
groups. However, the reduction in the kidney was not statistically (p > 0.05) different among the 
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the liver of the DCRH group. There was no significant difference between the induction of GSH 
levels by the DCRL and DCRH groups in the serum and pancreas, while in the heart, the DCRL group 
showed significantly higher GSH level than the high dose of the extract.  
 
Figure 5.4.2: Reduced glutathione (GSH) levels in the serum, liver, pancreas, heart and kidneys of 
all animal groups at the end of the intervention period. Data are reported as mean ± SD of 7 animals. a-cValues 
with different letter above the bars for a given sample are significantly different from each other group of animals (Tukey’s-
HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DCRL, Diabetic C. rubens low 
dose, DCRH, Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NCR, Normal C. 
rubens high dose (toxicological control).  
Figure 5.4.3 shows the data for the catalase activity in serum and organs of all animal groups. The 
catalase activity in the liver, pancreas, heart and kidneys of DBC group was significantly (p < 0.05) 
lower compared to the normal groups. The liver showed the highest catalase activity amongst the 
serum and organs. However, CRAQ treatment significantly (p < 0.05) increased the catalase activity 
in the organs of diabetic animals with DCRH group showing the better activity than the low dose in 
the serum and organs. 
 
Figure 5.4.3: Catalase activity in the serum, liver, pancreas, heart and kidneys of all animal groups 
at the end of the intervention period. Data are reported as mean ± SD of 7 animals. a-eValues with different letter 
above the bars for a given sample are significantly different from other group of animals (Tukey’s-HSD multiple range post 
hoc test, p < 0.05). NC, Normal control; DBC, Diabetic control; DCRL, Diabetic C. rubens low dose; DCRH, Diabetic C. 
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The activities of superoxide dismutase (SOD) in the serum and organs of all animal groups are shown 
in Figure 5.4.4. The SOD activity in the serum and organs of DBC group was significantly (p < 0.05) 
lower compared to the NC group. However, oral administration of CRAQ for 5 weeks significantly 
(p < 0.05) increased SOD activity in the DCRH group compared to the DBC group of the serum, heart 
and kidneys while in the liver, the low dose group (DCRL) showed the better activity than the high 
dose. In the pancreas, only metformin group (DBM) showed a lower SOD activity when higher SOD 
activity was observed in the remaining groups although they were not statistically significant. 
 
Figure 5.4.4:  SOD activity in the serum, liver, pancreas, heart and kidney of all animal groups at the 
end of the intervention period. Data are reported as mean ± SD of 7 animals. a-eValues with different letter above the 
bars for a given sample are significantly different from other group of animals (Tukey’s-HSD multiple range post hoc test, 
p < 0.05). NC, Normal control; DBC, Diabetic control; DCRL, Diabetic C. rubens low dose; DCRH, Diabetic C. rubens 
high dose; DBM, Diabetic metformin; DBG, Diabetic glibenclamide; NCR, Normal C. rubens high dose (toxicological 
control); SOD, Superoxide dismutase. 
The results of the glutathione reductase (GR) activity in the serum and organs of all animal groups 
are shown in Figure 5.4.5. In the kidneys, the glutathione reductase activity was not altered by 
diabetes induction. However, the activity of this enzyme was significantly (p < 0.05) decreased in the 
serum and organs of the DBC group as compared to the NC and NCR groups. Oral administration of 
the CRAQ improved the enzyme activity in the serum and organs. There was no significant difference 
between the low dose and high dose of the extract in increasing GR activity in the serum, liver and 
pancreas. While in the heart and kidneys, the high dose (DCRH) group showed a statistically (p < 































































Figure 5.4.5: Glutathione reductase (GR) activity in the serum, liver, pancreas, heart and kidney of 
all animal groups at the end of the intervention period. Data are reported as mean ± SD of 7 animals. a-cValues 
with different letter above the bars for a given sample are significantly different from other group of animals (Tukey’s-HSD 
multiple range post hoc test, p < 0.05). NC, Normal control; DBC, Diabetic control; DCRL, Diabetic C. rubens low dose; 
DCRH, Diabetic C. rubens high dose; DBM, Diabetic metformin; DBG, Diabetic glibenclamide; NCR, Normal C. rubens 
high dose (toxicological control). 
Figure 5.4.6 shows the glutathione peroxidase (GPx) activity in the serum and organs. The GPx 
activity was significantly (p < 0.05) decreased in the serum and organs of DBC group compared to 
the NC and NCR groups. However, treatment with CRAQ significantly (p < 0.05) increased the GPx 
activity in the diabetic treated groups which was comparable to the DBM and DBG groups.  
 
Figure 5.4.6: Glutathione peroxidase (GPx) activity in the serum, liver, pancreas, heart and kidney 
of all animal groups at the end of the intervention period. Data are reported as mean ± SD of 7 animals. a-
eValues with different letter above the bars for a given sample are significantly different from other group of animals 
(Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control; DBC, Diabetic control; DCRL, Diabetic C. 
rubens low dose; DCRH, Diabetic C. rubens high dose; DBM, Diabetic metformin; DBG, Diabetic glibenclamide; NCR, 
Normal C. rubens high dose (toxicological control). 
The liver and pancreas were chosen for FT-IR analysis since the liver is the major site for metabolism 
in the body and the pancreas is the major site for production of insulin, when both organs are highly 
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in the FT-IR spectra (Figure 5.4.7). In the liver, all animal groups showed strong bands at 1200-900 
cm-1, 1500-1200 cm-1, 1800-1500 cm-1, and 300-2800 cm-1 regions which gave the indication of the 
presence of sugars, proteins, peptides and lipids, respectively (Table 5.4.1). In T2D, the most 
observable difference amongst the experimental groups was seen in the range of 1200-900 cm-1 which 
indicates the presence of sugar (glucose). Table 5.4.1 shows that the glucose peak at 1080 cm-1 was 
increased in the DBC group, which showed animals with high blood glucose; however, the intensity 
of the glucose peaks was decreased among the treated groups (DCRL and DCRH) which is consistent 
with the reduction of blood glucose concentrations by the extract.  




























Figure 5.4.7: FT-IR absorption spectra of the liver in the regions of 4000-400 cm-1 from different 
experimental groups. NC, Normal control, DBC, Diabetic control, DCRL, Diabetic C. rubens low dose, DCRH, 
Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NCR, Normal C. rubens high dose 
(toxicological control). 
Table 5.4.1: Qualitative analysis of the FT-IR spectra of the liver. 
Regions (cm-1) NC DBC DCRL DCRH DBM DBG NCR Assignment 
1200-900 1080.68 1081.82 1080.29 1080.02 1081.32 1081.79 1081.03 Glucose 
1500-1200 1452.18 1453.12 1452.39 1453.98 1400.23 1452.40 1453.69 Proteins 
1800-1500 1635.39 1638.84 1636.07 1635.39 1634.44 1635.16 1636.13 C=O stretch  
3000-2800 3275.44 3276.02 3275.62 3274.87 3276.9 3274.47 3268.23 OH stretch, 
Lipids 
NC, Normal control; DBC, Diabetic control; DCRL, Diabetic C. rubens low dose; DCRH, Diabetic C. rubens high dose; 
DBM, Diabetic metformin; DBG, Diabetic glibenclamide; NCR, Normal C. rubens high dose (toxicological control). 
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The FT-IR spectra of the pancreatic tissues from different groups are shown in Figure 5.4.8.  The IR 
spectra was divided into 3 regions: 3000-2800 cm−1, 180-1400 cm−1, and 1200-900 cm−1. Same 
changes in lipid, protein and glucose was seen in the pancreas (Table 5.4.2). 



























Figure 5.4.8: FT-IR absorption spectra of the pancreas in the regions of 4000-400 cm-1 from different 
experimental groups. NC, Normal control, DBC, Diabetic control, DCRL, Diabetic C. rubens low dose, DCRH, 
Diabetic C. rubens high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NCR, Normal C. rubens high dose 
(toxicological control). 
Table 5.4.2: Qualitative analysis of the FT-IR spectra of the pancreas. 
Regions (cm-1) NC DBC DCRL DCRH DBM DBG NCR Assignment 
1200-900 1080.62 1082.88 1084.04 1081.09 1080.02 1079.74 1081.40 Glucose 
1450-1380 1452.72 1458.41 1463.28 1465.22 1477.09 1453.2 1453.59 Proteins 
1800-1500 1634.77 1634.40 1628.93 1629.31 1639.39 1627.39 1630.18 C=O stretch 
3000-2800 3285.6 3277.02 3291.91 3293.49 3285.13 3283.49 3279.47 OH stretch, 
Lipids 
NC, Normal control; DBC, Diabetic control; DCRL, Diabetic C. rubens low dose; DCRH, Diabetic C. rubens high dose; 






Reducing the prevalence of obesity, which is closely linked to increased risk of T2D and 
cardiovascular diseases,  needs a dietary focus (Asif, 2014). Higher consumption of whole grains, 
fruits and vegetables reduces the risk of T2D and its related complications. Plant based 
phytochemicals provide much of the nutrients, taste and colour in fresh vegetables,  therefore it is is 
highly favoured by locals in parts of western Nigeria for its rich taste in making various delicacies. 
C. rubens contains potent free radical and lipid peroxidation inhibiting phytochemicals (Adjatin et 
al., 2012). 
The lipid bilayer of the cell membrane is mostly affected by peroxidation of free radicals, and lipid 
peroxidation plays a huge role in the initiation of damages to the cell in T2D (Farzaei et al., 2017). 
Induction of T2D with elevated MDA levels in the diabetic untreated group (DBC) compared to the 
normal groups. Previous research has demonstrated that pancreatic β-cell damage, increased renal, 
cardiac and liver function parameters might consequently lead to increase in MDA levels in diabetic 
rats (Ali et al., 2017). Interestingly, data from this study (Figure 5.4.1) showed lipid peroxidation-
ameliorating potential of CRAQ. Inhibition of lipid peroxidation (through reduction of MDA levels) 
in the serum and organs of the diabetic rats further highlights the oxygen quenching effect of CRAQ.  
Reduced glutathione is an effective extracellular compound which scavenges hydrogen peroxide and 
hydroperoxide and donates protons to membrane lipids and protects them from oxidant damages 
(Nurdiana et al., 2017). The ability of CRAQ to increase the levels of GSH (Figure 5.4.2) and activity 
of glutathione reductase (Figure 5.4.5) supports the antioxidant benefit of the plant.  
Three first line defence systems were investigated in this study including superoxide dismutase 
(SOD), catalase and glutathione peroxidase (Ighodaro and Akinloye, 2017). These enzymes, in the 
same order, dismutates superoxide free radical, transform hydrogen peroxides and hydroperoxides to 
relatively harmless molecules such as H2O/alcohol and oxygen. The superoxide dismutase (SOD) 
catalyses the conversion of superoxide radical generated in tissue to hydrogen peroxide (H2O2) and 
oxygen (Fukai and Ushio-Fukai, 2011). Accumulation of H2O2 causes toxicity to the cells and tissues. 
In the presence of iron (Fe2+), H2O2 is converted to hydroxyl radical through the Fenton reaction 
(Birben et al., 2012). Catalase breaks down H2O2 into water and molecular oxygen consequently 
reducing free radical damage. However, the absence of catalase in the mitochondria makes 
glutathione peroxidase responsible for breaking-down the H2O2 to water (Ighodaro and Akinloye, 
2017). Our study showed the ability of CRAQ to increase the activity of these first line defence 
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enzymes (Figure 5.4.4, 5.4.3 and 5.4.6) in the serum and organs of type 2 diabetic animals which 
again confirm its antioxidative potential.  
An important finding of the present work is the changes in liver and pancreas which are supported by 
the FT-IR peaks. Previous studies have shown that the alterations in the IR spectra is related to the 
subsequent changes in structure and function of the liver (Baker et al., 2014, Nurdiana et al., 2017). 
Most importantly, reduction of FBG is suspected by reduced FT-IR peaks at 1200-900 cm-1, while 
induction of T2D with STZ increased the intensity of glucose peak in the pancreas (Figure 5.4.8 and 
Table 5.4.2) of diabetic animals is indicative of insulin deprivation in the cells. 
5.4.6 Conclusions 
In conclusion, the high dose of CRAQ was found to provide better antioxidant effect than the low 
dose; this result is comparable to a recent study where the protective effect of 300 mg/kg bw of 
aqueous extract of C. rubens was tested in rats with rifampicin-induced oxidative damage (Omoregie 
et al., 2015). From overall findings of that study, it was suggested that the presence of flavonoids and 
proanthocyanins might be responsible for the observed free radical scavenging activity of the plant 





THE ANTIOXIDANT AND ANTIDIABETIC ACTIVITIES OF BRIDELIA 
FERRUGINEA IN VITRO AND IN VIVO 
6.1 Background 
Bridelia ferruginea Benth (Euphorbiaceae) (Figure 6.1) is a woody shrub up to 8 meters tall, though 
it can grow up to a tree of 15 meters in height in suitable environments. It thrives in the Savannah and 
rain forests of Africa, especially in moist regions extending from Guinea to Zaire. The bark is scaly, 
dark grey and rough with crooked bole branches hanging low.   
 
Figure 6.1: Bridelia ferruginea Benth (Euphorbiaceae); Common names: Iralodan (Yoruba, Nigeria), 







6.1.1 Ethnobotanical uses 
Ethnobotanically, the aqueous extract of the stem bark is effective in the treatment of ulcer, diarrhoea, 
boils (Akuodor et al., 2012), reduction of high blood sugar levels (Bakoma et al., 2013, Onunkwo et 
al., 1996), antimicrobial activity and treatment of chest infections (Magistretti et al., 1988), anti-
inflammatory (Olajide et al., 1999) and water treatment to drinkable conditions (Kolawole and 
Olayemi, 2003). The roots of B. ferruginea are used in Togo as chewing sticks and in treatment of 
bladder, intestinal and skin problems (Olaide et al., 2014). 
6.1.2 Biological activities 
The aqueous extract of the stem bark of B. ferruginea has been reported to possess quinones, 
alkaloids, flavonoids, tannins, saponins and reducing compounds (Akuodor et al., 2011). In two 
separate studies, Bakoma et al.   investigated the effect of the crude extracts and fractions from the 
root bark on insulin resistance in fructose-fed mice (Bakoma et al., 2011, Bakoma et al., 2014). The 
results from the study showed marked improvement of insulin sensitivity and glucose tolerance. 
Another study was also done to evaluate the effect of B. ferruginea aqueous extract on gestational 
diabetes; improved glucose tolerance was observed in the adult pregnant rats used in this study (Taiwo 
et al., 2012).  
B. ferruginea stem bark ethanolic extract has been reported to act as an antioxidant by protecting 
brain and liver homogenates from iron (II) sulphate-induced oxidative stress in normal rat tissue 
homogenates (Oloyede and Babalola, 2012). Although, a very high dose (4000 mg/kg bw) of the 
aqueous extract of stem bark has also been reported to cause lipid peroxidation and sperm damage, 
therefore low doses (less than 1000 mg/kg bw) should be used with caution (Awodele et al., 2015). 
The aqueous stem bark extract of this plant has also been reported to possess anti-inflammatory 
activities through p38 MAPK and NF-kB signalling. Akuodor et al. (2011) reported that the aqueous 
extract from the stem bark of B. ferruginea exhibited promising pain relieving and antipyretic 
activities in experimental mice and rats.  
Different parts of B. ferruginea have also been successfully used in the management of blood glucose 
level in experimental diabetes-induced animal models. A 100 mg/kg bw of the aqueous extract of the 
bark of this plant has been reportedly used in improving blood glucose levels in alloxan-induced 
diabetic rats and also render hypoglycaemic activity in normal rats (Adewale and Oloyede, 2012).  
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According to the literature, limited work has been done on the anti-diabetic activity of the different 
parts of B. ferruginea, which prompted the need to investigate the detailed anti-diabetic potentials 
together with antioxidant properties of the leaves, stem and root bark extracts of this plant and then 




6.2 Extracts of Bridelia ferruginea scavenges free radicals and modulates key anti-
diabetic enzymes 
Olajumoke Oyebode1, Ochuko Erukainure1, Collins Ibeji2, Neil Koorbanally3, Md. Shahidul Islam1* 
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4000, South Africa  
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Preface: This article reports the detailed in vitro antioxidant and anti-diabetic effects of the crude 
extracts from B. ferruginea. It is currently awaiting revision before submission to a journal for 
publication. 
6.2.1 Abstract 
This study investigates the in vitro antioxidant activities of extracts from three parts of Bridelia 
ferruginea. Sequential extraction was performed on the leaves, stem and root bark samples with 
solvents of increasing polarity and these extracts were assayed for total phenolic content, in vitro 
antioxidant and anti-diabetic activities using different experimental models. The electron donating, 
1,1-diphenyl-2-picryl-hydrazyl (DPPH), nitric oxide and hydroxyl radical scavenging activities of all 
the extracts were investigated in this study. The ability of these extracts to inhibit -glucosidase, -
amylase and lipase enzymes were also examined in vitro. The ethanol extract of the leaves showed 
the highest total phenolic content compared to other extracts. All extracts showed free radical 
scavenging abilities in the different models. The ethanol and aqueous extracts significantly (p < 0.05) 
inhibited the key enzymes linked to diabetes. GC-MS analysis of the different plant parts revealed 
the presence of sterols, aromatics, aliphatic acids and esters. In particular, β-amyrin, 4-
Phenylbenzophenone and lupenone showed strong binding affinities for -glucosidase, -amylase 
and lipase enzymes respectively when docked with the molecular structures of these enzymes. Data 
from this study suggest that the different parts of B. ferruginea, especially the ethanol and aqueous 
extracts of the leaves, possesses potent anti-oxidant activities that could be further explored in the 
area of anti-diabetic drug research. 





Medicinal plants have long been regarded as better alternatives to pharmaceutical drugs and have 
gained much interest in the field of drug discovery. This can be attributed to the fact that they contain 
necessary and substantial concentration of antioxidants and bioactive agents that have been reported 
in the management and treatment of diseases such as diabetes (Dewanjee et al., 2011).  
A host of plant sources are found to be rich in polyphenols such as herbs, fruits, flowers and these 
plants are found in abundance everywhere in the world especially in Africa where there is a high 
reliance on medicinal plants for the treatment of diverse ailments (Hamzah et al., 2013).  
Plants are rich in polyphenolic agents which are highly beneficial to nature as they can react with 
reactive oxygen species/reactive nitrogen species (ROS/RNS) to bring about reduction in deleterious 
effects to cell biomolecules (Gach et al., 2015). Plants antioxidants are capable of attenuating 
damages to biomolecules (lipids, proteins and DNA); these damages range from lipid peroxidation to 
cell membrane damage through oxidation (Hossain and Shah, 2015).  
Oxidative stress occurs as a result of imbalance between free radical-generating enzymes (reactive 
oxygen species [ROS]) and free radical-scavenging enzymes (antioxidant enzymes) and plays a key 
role in the progression of diseases (Asmat et al., 2016). This triggers an increased level of free radicals 
which initiates cellular damage and has been recognized as the main contributing factor to late 
complications of ailments such as diabetes and cancer (Son, 2012).  
Diabetes has become a global health problem with over 425 million people currently suffering from 
this disease (IDF, 2017). Type 1 diabetes (T1D), type 2 diabetes (T2D) and gestational diabetes 
remains the 3 main types of diabetes of which the most prevalent is T2D (ADA, 2016). Insulin 
resistance, hyperglycaemia and pancreatic β-cell dysfunction are involved in the pathogenesis of 
T2D. Oxidative stress has been implicated as a major cause of the progression of diabetic 
complications (Asmat et al., 2016). These complications range from macro and microvascular 
disorders such as heart, kidney, eyes and nerve problems. There are many synthetic anti-diabetic 
medications available, these drugs although effective sometime come with various side effects such 
as nausea, constipation, lactic acidosis, weight gain and others. Fortunately, medicinal plants with 
oxidative stress and hyperglycaemia inhibiting properties are available in nature. These plants are 
widely available, inexpensive and can be used to boost socio-economic importance. An example of 
such medicinal plant is Bridelia ferruginea. B. ferruginea Benth, (Euphorbiaceae) is a shrub or short 
tree which grows to about 15 m in height, it is found majorly in the Savannah and rainforest area of 
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Africa. However, very little is known about the detail antioxidative and antidiabetic effects of the 
different parts of this plant either under in vitro, ex vivo or in vivo conditions. 
Hence, this study was aimed to investigate the antidiabetic and antioxidant effects of the various 
extracts of leaves, stem bark and root bark extracts of B. ferruginea, as well as the identification and 
molecular docking of potent bioactive compounds present in the plant. 
6.2.3 Materials and methods  
Please refer to Chapter 2 for the detailed materials and methods used for B. ferruginea. 
6.2.4 Results 
The ethyl acetate extract of the leaves showed significantly (p < 0.05) higher total phenol content 
compared to other extracts followed by the aqueous extract of the stem bark (Figure 6.2.1).  
 
Figure 6.2.1: Total phenolic contents of B. ferruginea extracts. Data are reported as mean ± SD of three 
replicas. a-c Values with different letters above the bars for a given extract are significantly different from each other (p < 
0.05, Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows).   
The ethanol extracts of all the plant parts showed a significantly higher (p < 0.05) total reducing 
power than extracts obtained from other solvents (ethyl acetate and water), which was even higher 
than the standards (Trolox and ascorbic acid) used in this experiment. The ethanol extract of the root 
bark showed the highest total reducing power compared to the other extracts from the different parts 
of the plant (Figure 6.2.2 a-c).   
The DPPH radical scavenging activities of the different solvent extracts of B. ferruginea parts are 
shown in Figure 6.2.2 (d-f). All the extracts from all parts of the plant showed a dose-dependent 
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free radical scavenging activity than other solvent extracts. Interestingly, the ethyl acetate extract of 
the leaves and the ethanol extract of the root bark gave the lowest IC50 values compared to other 
extracts from the different parts of the plant (Table 6.2.1). 
 
Figure 6.2.2: (a-c) Ferric reducing antioxidant power (FRAP) and (d-f) DPPH scavenging activity 
of extracts from leaves, stem bark and root barks of B. ferruginea. Data are reported as mean ± SD of 
three replicas. a-e Different letters above the bars for a given extract are significantly different from each other 
(p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows) EtAc; Ethyl acetate, EtOH; 




Figure 6.2.3 (a-c) shows the nitric oxide (NO) inhibitory activities of B. ferruginea parts solvents 
extracts. The ethyl acetate extract of the plant parts showed a dose-independent inhibition of NO 
while the ethanol extracts showed a dose-dependent inhibition of NO which was significantly (p < 
0.05) higher than other solvents. Furthermore, the ethanol extract of the leaves and the ethyl acetate 
extract of the root bark showed lowest IC50 values than the other extracts (Table 6.2.1). 
 
Figure 6.2.3: (a-c) Nitric oxide and (d-f) Hydroxyl radical scavenging activity of extracts from 
leaves, stem bark and root barks of B. ferruginea. Data are reported as mean ± SD of three replicas. a-d 
Different letters above the bars for a given extract are significantly different from each other (p < 0.05, Tukey’s-
HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAc; Ethyl acetate, EtOH; Ethanol, GA; Gallic 
acid, AA; Ascorbic acid. 
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The hydroxyl (OH) radical scavenging activity of the extracts is shown in Figure 6.2.3 (d-f). The 
ethanol extract of the leaves and root bark showed OH radical (obtained through the Fenton reaction) 
scavenging activity. The ethyl acetate extracts from all the parts showed a dose-independent OH 
radical scavenging activity. However, the aqueous extract of the stem bark showed a dose dependent 
inhibition of OH radical. The ethyl acetate extract of the root bark and leaves showed the lowest IC50 
values compared to other extracts (Table 6.2.1).  
Figure 6.2.4 shows the -glucosidase and -amylase inhibitory activities of the extracts. The ethanol 
and aqueous extracts of all the plant parts showed a dose-dependent inhibition of -glucosidase 
enzyme activity (Figure 6.2.4 a-c). The ethanol extract of the root bark and leaves showed the lowest 
IC50 values which was significantly (p < 0.05) lower than even the tested standard drug (acarbose) 
(Table 6.2.1). -amylase was also inhibited by some solvents of B. ferruginea plant parts (Figure 
6.2.4 d-f). On the table showing the IC50 values, the aqueous extract showed the lowest IC50 value 
compared to the other extracts.  
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Figure 6.2.4: (a-c) -glucosidase and (d-f) -amylase inhibiting activity of extracts from leaves, 
stem bark and root barks of B. ferruginea. Data are reported as mean ± SD of three replicas. a-d Different 
letters above the bars for a given extract are significantly different from each other (p < 0.05, Tukey’s-HSD-
multiple range post-hoc test, IBM SPSS for Windows). EtAc; Ethyl acetate, EtOH; Ethanol. 
The pancreatic lipase inhibitory activities of the extracts are reported on Figure 6.2.5. All extracts 
from the different parts of B. ferruginea showed a dose-dependent inhibition of lipase enzyme. The 
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Figure 6.2.5 (a-c) Lipase inhibiting activity of extracts from leaves, stem bark and root barks of B. 
ferruginea. Data are reported as mean ± SD of three replicas. a-d Different letters above the bars for a given 
extract are significantly different from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM 
SPSS for Windows). EtAc; Ethyl acetate, EtOH; Ethanol.  
Based on the antioxidant and antidiabetic activities, the ethanol extracts from the leaves, stem bark 
and root barks were selected for GC-MS analysis. The main compounds identified from these extracts 
are steroids, terpenoids, aliphatic and aromatic compounds. Figure 6.2.5 and 6.2.6 shows the 
structures of the identified compounds. Table 6.2.2 shows the molecular formula, retention time, 
molecular mass and relative abundance of the different compounds identified from the plant. 
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Table 6.2.1: IC50 values of various extracts of B. ferruginea parts in different anti-oxidative, anti-
diabetic and anti-obesogenic models 
 IC50 (µg/mL) 




EtAc 2.54± 0.55a          76.24±16.54c 52.34±13.27b 8.17±1.61c 326.34±7.31g >1000 
EtOH 14.61±0.09d        16.95±1.73a 46.94±12.99b 3.63±1.03a 224.75±9.32f 1.34±1.02b 




EtAc 6.24±0.11c 27.53±4.82b 49.29±11.82b 4.89±2.51b 75.96±2.7d >10000 
EtOH >1000 148.57±25.71e 301.5±28.4c 8.39±1.26c 100.69±16.73d >10000 




EtAc 7.46±0.46c 15.76±9.53a 44.48±3.51b >1000 188.59±24.92e >1000 
EtOH 5.29±0.08b 35.77±7.62b 47.31±13.8b 2.42±.0.92a >1000 >1000 
Aqueous 2.34±0.10a 108.66±11.48d 30.95±17.35b >1000 519.1±15.92h >10000 
Standard  
GA ND 191.12 ±23.05f ND ND ND ND 
AA 2.19±0.05a 196.71±27.45f ND ND ND ND 
Trolox 5.79±0.43b 19.40±1.03a 3.54±091a ND ND ND 
Acarbose ND ND ND 36.27±1.84d 53.77±3.95c ND 
Orlistat ND ND ND ND ND 0.03±0.12a 
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, NO-nitric oxide radical, OH, hydroxyl radical; EtAc, Ethyl acetate, 
EtOH, Ethanol, GA, Gallic acid, AA, Ascorbic acid, ND-not determined. Data are reported as mean ± SD values of 
three replicas. a-iValues with different letters within a column are for a given test are significantly different from 


















Cymene C10H14 6.91 134.22 0.47 
Phytol acetate C22H42O2 16.43 338.32 2.64 
Phytol C20H40O 16.87 296.31 0.99 
Stigmasta-3,5-dien-7-one C29H46O 18.64 410.67 3.32 
Z-6-octadecenoic acid C18H34O2 19.35 282.46 1.29 
4-phenylbenzophenone C19H14O 20.07 258.31 0.74 
3β-acetyloxybufa-14,16,20,22-
tetraenolide 
C26H32O4 20.20 408.53 0.35 
Lupeol C30H50O 21.97 426.72 1.39 
9-(4-methoxyphenyl) xanthene C20H16O2 22.40 288.34 3.26 
β-amyrin C30H50O 23.25 426.72 2.68 
α-amyrin acetate C32H52O2 24.47 468.40 26.13 
Tocopherol acetate C31H52O3 27.39 472.74 0.57 
Stigmasterol C29H48O 28.97 412.69 0.43 
Sitosterol C29H50O 29.76 414.71 0.54 
The compounds reported in the table are those which matched similar compounds in the NIST library.  










2,3,6-trimethylhept-3-en-1-ol C10H20O 7.20 156.23 5.04 
Citronellyl butyrate C14H26O2 7.54 226.36 4.25 
3,7-dimethyl-2-octen-1-ol C10H20O 7.73 156.15 4.27 
p-menth-4-en-3-one C10H16O 9.64 152.23 0.34 
3β-hydroxydamascone C13H20O2 14.00 208.30 0.88 
4-hydroxy-3-methoxyphenyl-2-
propenal 
C10H10O3 15.44 178.18 1.35 
3,5-dimethoxy-4-
hydroxycinnamaldehyde 
C11H12O4 17.97 208.21 0.90 
4-phenylbenzophenone C19H14O 20.08 258.31 0.58 
9-(4-methoxyphenyl) xanthene C20H16O2 22.40 288.34 2.12 
The compounds reported in the table are those which matched similar compounds in the NIST library. 
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β-amyrin C30H50O 19.10 426.72 0.55 
α-amyrin C30H50O 19.31 426.72 2.85 
Olean-12-en-3-one C30H48O 19.43 424.70 1.51 
α-amyrin acetate C32H52O2 19.51 468.40 1.37 
Lupenone C30H48O 20.64 424.70 0.54 
Lupeol C30H50O 21.94 426.72 2.41 
9-(4-methoxyphenyl) 
xanthene 
C20H16O2 22.40 288.34 0.90 
24-methylenecycloartenol C31H52O 23.48 440.74 0.68 
Lupeol acetate C32H52O2 24.56 468.75 36.99 
The compounds reported in the table are those which matched similar compounds in the NIST library software. 
The binding affinities of some (compounds with high relative abundance) constituents with -
glucosidase, -amylase and lipase is shown in Table 6.2.5. β-amyrin, Lupenone and 4-
Phenylbenzophenone showed the highest binding affinities for the enzymes: -glucosidase (-8.5 
kcal/mol), -amylase (-6.8 kcal/mol) and lipase (-10.2 kcal/mol).  
Table 6.2.5: Binding affinities (kcal/mol) of compounds enzymes 
Compounds -glucosidase -amylase Lipase 
Cymene -4.7 -4.4 -6.5 
β-amyrin -8.5 -6.2 -9.5 
α-amyrin acetate -7.2 -6.4 -9.1 
4-Phenylbenzophenone -6.5 6.3 -10.2 
Lupenone -7.7 -6.8 -9.9 
Lupeol acetate  -6.2 -8.7 






The 3D illustrations of the interactions of β-amyrin, Lupenone and 4-Phenylbenzophenone with -
glucosidase, -amylase and lipase respectively is shown in Figure 6.2.8, 6 .2.9 and 6.2.10. 
  
Figure 6.2.8: Illustration of 3-D (a) and 2-D (b) interactions with amino acid residues of docked β-
amyrin-α-glucosidase complex with the highest binding affinity.  
  
Figure 6.2.9: Illustration of 3-D (a) and 2-D (b) interactions with amino acid residues of docked 4-





Figure 6.2.10: Illustration of 3-D (a) and 2-D (b) interactions with amino acid residues of docked 
4-Phenylbenzophenone – amylase complex with the highest binding affinity.  
6.2.5 Discussion 
Plants with antioxidant abilities have been exploited in recent times for management of disease such 
as diabetes whose complications arise as a consequence of oxidative stress. The thriving of oxidative 
stress in the body leads to the progression of diverse complications in diabetes. B. ferruginea has been 
reported to contain a high antioxidant potential in combating the damages of oxidative stress (Oloyede 
and Babalola, 2012). This study investigated the antioxidant and anti-diabetic activities of the leaves, 
stem bark and root bark extracts (different solvents) in order to further explain the importance of B. 
ferruginea in treatment of diseases associated with oxidative stress.  
Plants rich in polyphenols have been reported to perform antioxidant abilities through their reactive 
oxygen species (ROS) neutralising capacities (Aiyegoro and Okoh, 2010). The solvents used in this 
study extracted a good quantity of phenols. The ethyl acetate extract of the leaves showed the highest 
total phenolic content which is a similar finding to an earlier reported study (Bhandari et al., 2008). 
The ability of bioactive compounds to donate electrons as a show of their reducing power is an 
indication of their antioxidant potentials (Benzie and Strain, 1996). Antioxidants function as redox 
reactants where they are able to donate electrons to oxidants. Thus, the reduction of Fe2+ to Fe3+ could 
be due to the presence of reductants in the plant which was investigated in the FRAP assay. The 
strong reducing capacity of the leaves, stem and root bark ethanol extracts (Figure 6.2.2 a-c) showed 
the phytochemical components of B. ferruginea exhibiting high redox potential are extractable by 
ethanol.   
178 
 
The DPPH radical is a stable free radical that is commonly used to investigate the free radical 
scavenging activity of plant extracts, fractions or pure compounds in vitro (Kedare and Singh, 2011). 
Antioxidants inhibit DPPH by donating a hydrogen atom. The potent DPPH radical scavenging 
activities of the different solvent extracts especially from the leaves and root even comparable to 
standard antioxidants could suggests that bioactive compounds with hydrogen donating ability could 
serve as inhibitors of free radicals. However, the aqueous extract of the root bark showed the lowest 
IC50 (Table 6.2.1) value similar to ascorbic acid and even lower than Trolox (a standard antioxidant). 
Interestingly, a recent research examined the DPPH scavenging potential of free and bound phenolics 
extracted from the leaves of B. ferruginea (Afolabi et al., 2018). The IC50 values obtained from the 
assay was not as low as the IC50 obtained from our study which shows that root bark just like the 
leaves might contain phenolics with better DPPH scavenging capacity.  
Under aerobic conditions, nitric oxide is unstable and generates stable nitrates and nitrites by reacting 
with O2. Griess reagent is used to estimate nitric oxide, where the amount of nitrous acid is reduced 
in the presence of an antioxidant (Boora et al., 2014). The ethanol and ethyl acetate extracts of the 
leaves and root bark respectively, showed the lowest IC50 values compared to other extracts (Table 
6.2.1). This further suggests that the extracts from B. ferruginea contain potent antioxidant activity 
capable of inhibiting free radical generation and oxidative stress. 
Hydroxyl radicals are short-acting highly reactive species that are capable of initiating damages to 
important macromolecules such as proteins and lipids (Nita and Grzybowski, 2016). These radicals 
carry out destructive activities through polymerization, auto-oxidation and breakage of biomolecules. 
Therefore, medicinal plants with hydrogen radical-scavenging activities are potential targets in the 
treatment of diseases where oxidative stress causes diverse complications. From the present study 
(Figure 6.2.3 d-f), the ethanol extracts of the leaves and root barks showed a dose-dependent 
inhibition of OH radical with low IC50 values. 
An effective therapeutic method for managing T2D is through the reduction of post-prandial high 
blood glucose levels. This is achieved by reducing the rise in glucose levels by inhibiting 
carbohydrate-hydrolysing enzymes: -glucosidase and -amylase both active in the digestive tract 
(Tundis et al., 2010). Inhibiting these enzymes causes a stretch in the digestion of carbohydrates in 
food thereby giving more time to insulin to effectively offset the glucose load in the blood stream. A 
number of medicinal plants have been reported to exhibit reduction of glucose production from 
carbohydrates in the intestine (Choudhury et al., 2017). The ethanol extracts of the leaves and root 
bark showed dose-dependent inhibition (Figure 6.2.4), low IC50 values (Table 6.2.1) for -
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glucosidase and -amylase (aqueous extract of the leaves) than other counterparts, which suggests 
the presence of better groups that could inhibit the breakdown of complex carbohydrates to glucose 
thereby reducing postprandial hyperglycaemia. Obesity, one of the major risk factors of T2D is caused 
by high calorie intake, which can be reduced by inhibiting pancreatic lipase activity thereby delaying 
the absorption of lipids (Padwal and Majumdar, 2007). The ethanol extract of the leaves showed dose-
dependent lipase inhibition (Figure 6.2.5) and low IC50 values for the anti-lipase activity, which in 
combination with the -glucosidase result shows the anti-diabetic and anti-obesogenic potency of B. 
ferruginea. 
A recent study by Afolayan et al. (2018) reported that 14 compounds were identified through bioassay 
guided fractionation and purification from the methanol leaves of B. ferruginea. Our study went 
further to identify the potent bioactive constituents present in the ethanol extracts of the leaves, stem 
and root bark. Fourteen compounds were identified in the ethanol extracts of the leaves, while nine 
compounds were identified each from the stem bark and root bark extracts. The compounds identified 
were mainly phenols like sterols, triterpenes and other aliphatic compounds (Figure 6.2.6). Some 
aromatic compounds were also identified in the GC-MS analysis (Figure 6.2.7). β-Amyrin and -
amyrin acetate found in this plant are known pentacyclic triterpenes found distributed in plants and 
have been reported to have diverse biological properties like anti-inflammatory, anti-microbial, 
cytotoxic, and trypanocidal activity amongst others (Vázquez et al., 2012). The anti-diabetic 
properties of these triterpenes have also been established (Nair et al., 2014, Santos et al., 2012). 4-
phenylbenzophenone and Lupenone identified in our study have been reported to exhibit promising 
anti-diabetic activity (Lin et al., 2009, Xu et al., 2014). Conversely, the observed anti-diabetic and 
anti-obesogenic activities of B. ferruginea might be due to the synergistic effect rendered by the 
identified bioactive constituents. To further verify this claim, some of the identified compounds were 
docked with key anti-diabetic (-glucosidase and -amylase) and anti-obesogenic (lipase) enzymes 
using in silico molecular docking analysis (Table 6.2.5). Interestingly, β-amyrin, 4-
phenylbenzophenone and Lupenone had the highest binding energies for -glucosidase, -amylase 
and lipase enzymes respectively, which justified the biological properties of the compounds. The 3D 
interactions of these compounds with the enzymes is shown in Figure 6.2.8-10. Previous studies have 
also reported high binding energies of plant constituents with anti-diabetic enzymes (Bharatham et 
al., 2008, Oyebode et al., 2018).  
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In the light of the results obtained for all the antioxidant and anti-diabetic models used in this study, 
it is possible to conclude that the ethanol extract of the leaves in particular shows better activities in 
all models and should be exploited in future studies to identify and extract the exact bioactive 
constituent. Further studies will entail bioassay guided fractionation of the ethanol extract of the 
leaves.  
Postscript: From the above experiment, the ethanol crude extract from the leaves was found to have 
relatively higher antioxidant and anti-diabetic activity observed across various types of assays. It was 
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Preface: This chapter reports the detailed in vitro and ex vivo anti-diabetic effects of the fractions 
obtained from the ethanol extract of the leaves. It is currently awaiting revision before submission to 
a journal for publication. 
6.3.1 Abstract 
The antioxidant, anti-hyperglycaemic and anti-lipidaemic potentials of leaves of Bridelia ferruginea 
have been documented, but the modes of action remain elusive. The present study investigated not 
only the antioxidant potentials, but also the anti-hyperglycaemic mode of action of fractions obtained 
from the crude ethanol extract of leaves of B. ferruginea using several in vitro and ex vivo models. 
The crude ethanol extract of the leaves of B. ferruginea was subjected to solvent fractionation to yield 
four fractions: butanol, dichloromethane (DCM), ethyl acetate and aqueous fractions. The total 
phenolic content of these fractions was first determined. The abilities of these fractions to activate 
antioxidant enzymes in Fe2+-induced pancreatic oxidative injuries were also investigated ex vivo. 
Then, α-glucosidase inhibitory activity was estimated in vitro. The ex vivo effects of the fractions on 
glucose absorption in isolated rat jejunum as well as glucose uptake in isolated rat psoas muscle was 
also investigated. All fractions exhibited a moderate total phenolic content and DPPH inhibitory 
activities. Catalase, SOD and reduced glutathione levels were significantly (p < 0.05) increased by 
the fractions as compared to the untreated group. The butanol fraction showed a more potent anti-
oxidant activity which might be due to the presence of high phenolic content. The butanol fraction 
also showed a dose-dependent inhibition of α-glucosidase enzyme and a high glucose uptake activity 
in isolated rat jejunum. The fractions of B. ferruginea were also able to enhance glucose uptake in 
isolated rat psoas muscle. GC-MS analysis revealed the presence of some potent bioactive 
constituents which could render synergistic effects to the observed antioxidant and anti-diabetic 
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activities of B. ferruginea. Data from this study suggest that B. ferruginea may not only ameliorate 
oxidative stress but may also exert glycaemic control via enhancing muscle glucose uptake and 
impairing carbohydrate and glucose absorption. Thus, it may be further investigated as a useful 
dietary supplement for managing hyperglycaemia and oxidative stress. 
Key words: Bridelia ferruginea, oxidative stress, anti-oxidant, glucose absorption, glucose uptake, 
enzyme inhibition 
6.3.2 Introduction 
The increased oxidative stress in diseases related to metabolic syndrome has been long established 
(Asmat et al., 2016). Prolonged oxidative stress leads to β-cell dysfunction, insulin resistance which 
in the long run leads to diseases such as type 2 diabetes (Tiwari et al., 2013). Oxidative stress occurs 
when there is an imbalance between reactive oxygen species (ROS) and antioxidants in favour of 
ROS. This imbalance causes ROS to become harmful to macro molecules like lipids, proteins and 
nucleic acids due to the inactivity of the natural defence system of the cell (antioxidants) (Styskal et 
al., 2012). This imbalance leads to reduction in endogenous antioxidants enzymes such as catalase 
and superoxide dismutase (SOD) as well as in vivo antioxidants and reduced glutathione. The 
destruction caused by oxidative stress leads to macro- and micro-vascular complications of type 2 
diabetes which encompasses eyes, kidney and heart problems and ultimately, death (Folli et al., 
2011). The ability of natural antioxidants to reduce ROS formation by increasing the activities of 
endogenous antioxidants can be exploited for treatment of diseases caused by oxidative stress such 
as diabetes. 
Persistent hyperglycaemia has also been implicated in leading to multiple diabetic complications 
(Marcovecchio et al., 2011). The level of post prandial hyperglycaemia keeps rising due to continuous 
breakdown and digestion of dietary carbohydrates. The inhibition of carbohydrate hydrolysing 
enzymes such as α-glucosidase and α-amylase can delay the digestion, as well as the absorption of 
sugar from carbohydrates, which is a key focus in anti-diabetic drug research (Asif, 2014). The ability 
of natural products from plant sources to inhibit the activity of these carbohydrate-hydrolysing 
enzymes have been paid more attention in recent times (Kalita et al., 2018).  
Bridelia ferruginea Benth. (Euphorbiaceae) is a ligneous shrub or tree (as climate and soil favours) 
that grows in various parts of Africa and is used by traditional healers for the treatment of ailments 
like boils, arthritis, diabetes, bruises and burns (Awodele et al., 2015; Olajide et al., 2012). From the 
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work done on this plant so far, there is no report on the effects of the fractions obtained from the 
leaves of the plant on intestinal glucose absorption and muscle glucose uptake. 
Hence, the present study was conducted to examine the effects Bridelia ferruginea fraction on 
antioxidative status, inhibition of carbohydrate digesting enzymes, intestinal glucose absorption and 
muscle glucose uptake using a number of experimental models. 
6.3.3 Materials and methods 
Please refer to Chapter 2 for the detailed materials and methods used for B. ferruginea. 
6.3.4 Results 
The total phenol contents of the fractions (dichloromethane, ethyl acetate, butanol and aqueous) are 
shown on Table 6.3.1. The DCM fraction showed the significantly (p < 0.05) higher concentration 
of total phenol than other fractions.   
The ability of the fractions to scavenge free radicals was investigated using the DPPH method and is 
shown in Figure 6.3.1. Only butanol fraction showed a consistent dose-dependent inhibition of 
DPPH. The butanol fraction also showed a significantly (p < 0.05) higher inhibition of DPPH 
compared to other fractions which was also similar to the activity of the standards (Trolox and 
ascorbic acid) used in this experiment. The lowest DPPH scavenging activity was displayed by the 
DCM fraction. The butanol and aqueous fractions both showed low IC50 values for DPPH inhibition 
as reported in Table 6.3.1.  
 
Figure 6.3.1: DPPH inhibiting activity of B. ferruginea fractions. Data are reported as mean ± SD. a-d Values 
with different letter above the bars for a given concentration are significantly different from each other (p < 0.05, Tukey’s 
HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAc, DCM and AA represent Ethyl acetate, Dichloromethane 
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Figure 6.3.2 shows the free radical antioxidant power of the fractions, which was measured by the 
ability of the fractions to convert the ferricyanide complex (Fe3+) to ferrous form (Fe2+).  The butanol 
fraction gave the significantly (p < 0.05) higher activity compared to other fractions. The butanol 
fraction was closely followed by the DCM and ethyl acetate fractions and the lowest activity was 
exhibited by the most polar or aqueous fraction.  
 
Figure 6.3.2: Ferric reducing antioxidant power (FRAP) activity of fractions of B. ferruginea leaves. 
Data are reported as mean ± SD of three replicas. a-e Different letters above the bars for a given concentration are significantly 
different from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAc and DCM 
represents Ethyl acetate and Dichloromethane fractions. 
Oxidative stress was induced in the pancreatic homogenates by incubating with FeSO4. A reduction 
in reduced glutathione level, catalase and SOD enzymes activity in the untreated group showed a 
successful induction of pancreatic oxidative injury (Figure 6.3.3 a-c). The reduced levels of these 
antioxidant enzymes were further justified by an increase in malondialdehyde (MDA) levels as an 
indicator of lipid peroxidation. Interestingly, treatment with different concentrations of the fractions 
significantly (p < 0.05) increased the endogenous antioxidant enzymes activity and GSH level and 
concomitantly reduced MDA levels to almost normal levels. The butanol fraction showed the highest 
ability to induce GSH levels (Figure 6.3.3a) in the treated sample which was also replicated by the 
low IC50 value in Table 6.3.1 and was comparable to the standard ascorbic acid. For catalase activity, 
only the DCM and butanol fractions showed a dose-dependent induction of catalase (Figure 6.3.3b).  
In Figure 6.3.3c, all fractions showed a dose-dependent induction of SOD activity, interestingly, the 
high dose (250 µg/mL) of all the fractions showed statistically significant and comparable results to 
the standard (ascorbic acid). The fractions also showed a dose-dependent reduction of lipid 
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compared to other fractions which demonstrate the lipid peroxidation reducing properties of these 




Figure 6.3.3: Effect of fractions of B. ferruginea leaves on a) Reduced glutathione, b) catalase, c) 
Superoxide dismutase (SOD) and d) Lipid peroxidation in oxidative pancreatic injury. Data are reported 
as mean ± SD of three replicas Data are reported as mean ± SD of three replicas. *Significantly different from untreated 
sample and #Significantly different from normal sample (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS 
for Windows). EtAc, DCM and AA represent Ethyl acetate, Dichloromethane fractions and ascorbic acid respectively. 
The -glucosidase enzyme-inhibiting activity of the fractions is shown on Figure 6.3.4. All the 
fractions inhibited the enzyme in a dose-dependent manner, the butanol fraction showed significantly 
(p < 0.05) higher inhibition of -glucosidase compared to other fractions. The enzyme inhibitory 



































































































DCM EtAc Butanol Aqueous AA
* * * * **
#
* * * * *




















DCM EtAc Butanol Aqueous AA
186 
 
(p < 0.05) higher than the standard drug (acarbose) used. The butanol fraction gave the lowest IC50, 
as low as the standard drug, acarbose (Table 6.3.1). 
 
Figure 6.3.4: -glucosidase inhibitory activity of B. ferruginea leaves fractions. Data are reported as 
mean ± SD of three replicas. a-d Different letters over the bars for a given concentration for each extract indicate a 
significant difference from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAc 
and DCM represents Ethyl acetate and Dichloromethane fractions respectively. 
The effect of the butanol and aqueous fractions (fractions with the best results in all the models 
tested) on glucose absorption and glucose uptake in harvested organs was investigated (Figure 
6.3.5 and 6.3.6).  
 
Figure 6.3.5: Effect of the butanol and aqueous fractions of the leaves of B. ferruginea on glucose 
absorption in isolated rat jejunum. Data are reported as mean ± SD of three replicas. a-c Different letters over the 
bars for a given concentration are significantly different from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc 
























































































Table 6.3.1: IC50 values of the different solvent fractions of ethanol extract of B. ferruginea leaves 
in different antioxidant and antidiabetic models. 
 TPC  
 (mg/g 
GAE) 
IC50 value (µg/mL) 
 
DPPH  α-glucosidase  Catalase SOD GSH LPO 
DCM                     65±1.2d 108.7±1.3d 110.1±24.3c 15.6±2.3b 3.5±1.7b 28.1±2.3c 21.1±3.4c 
EtAc 39.9±0.8c 184.1±1.1e 122.9±16.8c 31.2±0.6d 2.4±1.6b 18.6±2.7b 25.6±4.2c 
Butanol 23.0±0.2b 4.7±0.8b 36.01±3.7a 25.4±0.3c 1.7±0.5b 6.3±1.1a 10.1±1.2b 
Aqueous 17.4±0.1a 6.7±1.5c 52.6±5.0b 12.6±1.3b 1.4±0.2b 15.4±1.4b 12.4±2.6b 
Standards         
AA ND 2.2±0.4a ND 1.3±0.4a 1.1±0.04a 7.4±1.1a 9.5±1.7a 
Trolox ND 5.8±1.3c ND  ND ND ND ND 
Acarbose ND ND 36.3 ± 4.3a ND ND ND ND 
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, ND-not determined, EtAc, Ethyl acetate fraction, AA, Ascorbic acid, TPC, 
Total phenol content, SOD, Superoxide dismutase, GSH, Reduced glutathione, LPO, Lipid peroxidation. Data are reported 
as mean ± SD values of three replicas. a-eValues with different superscript letters within a column are significantly different 
from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05): the same letters stand for non-significant difference. 
 
Figure 6.3.6: Effect of the a) butanol and b) aqueous fraction of the leaves of B. ferruginea on glucose 
uptake in isolated rat psoas muscle. Data are reported as mean ± SD of three replicas. a-c,w-z Different letters over the 
bars for a given concentration are significantly different from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc 
test, IBM SPSS for Windows). Metformin: 2mg/dL. 
The phytochemical compounds present in the DCM, ethyl acetate, butanol and aqueous fractions of B. 
ferruginea was identified using GC-MS analysis. The main compounds identified from these extracts 
are phenols, steroids, terpenoids, aliphatic and aromatic compounds. Figure 6.3.7 shows the structures 
of the identified compounds. Table 6.3.2 shows the molecular formula, retention time, molecular mass 




Figure 6.3.7: Identified bioactive components in the DCM, butanol, aqueous and ethyl acetate 
fractions of the B. ferruginea.  
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Aqueous      
2-methoxy-3-(2-propenyl) phenol C10H12O2 11.58 164.20 0.33 
     
Butanol      
Pyrogallol C6H6O3 11.81 126.11 0.37 
Sitosterol C29H50O 29.68 414.71 0.54 
     
Ethyl acetate      
Pyrogallol C6H6O3 11.81 126.11 0.28 
1-hydroxy-3-(4-hydroxy-3-methoxyphenyl)-2-
propanone 
C10H12O4 16.10 196.20 0.16 




C22H22O7 28.89 398.41 0.25 
Stigmasterol C29H48O 29.10 412.69 0.22 
Sitosterol C29H50O 29.68 414.71 0.66 
 
Dichloromethane      
2-coumaranone C8H6O2 9.94 134.13 0.19 
Pyrogallol C6H6O3 11.84 126.11 0.27 
5-hydroxy-5-(1-hydroxy-1-isopropyl)-2-methyl-
2-cyclohexen-1-one 
C10H16O3 14.85 184.23 2.22 
5,5,8a-trimethyl-3,5,6,7,8,8a-hexahydro-2H-
chromene 
C12H20O 16.86 180 1.00 
phytol acetate C22H42O2 17.30 338.56 0.76 
Stigmasterol C29H48O 29.10 412.69 0.32 
Sitosterol C29H50O 29.68 414.71 0.92 





The damage caused by free radicals when left unmanaged leads to the progression of diverse 
complications in T2D. Although research has shown that plants contain high amounts of polyphenols,   
hence detailed screening   is necessary in order to validate this claim. The moderately high total 
phenol content was found in the fractions of B. ferruginea in our study (Table 6.3.1), showed the 
potential as an antioxidative agent. The stem bark aqueous fraction of B. ferruginea has been reported 
to contain antioxidant activity which supports results from our data (Olaide et al., 2014).  
The ability of the fractions to scavenge free radicals was investigated using the DPPH method. This 
method due to its ease of execution is usually the first line of action in detecting the antioxidant 
activities of plants (Kedare and Singh, 2011). The DPPH radical has an odd nitrogen electron which 
can be reduced by accepting a hydrogen atom from a potential antioxidant to form a hydrazine 
complex. In vitro DPPH analysis of the fraction (Figure 6.3.1) showed a dose dependent inhibition 
of DPPH exhibited only by the butanol fraction. This could be due to the presence of compounds that 
can donate a hydrogen atom to form a stable complex in the polar butanol fraction. Plants like B. 
ferruginea have been shown to possess promising antioxidant activity using the DPPH method 
(Olaide et al., 2014).  
The FRAP assay is a sensitive, precise and simple method for understanding the interaction between 
antioxidant status and disease risk (Benzie and Strain, 1999). The principle of the FRAP assay is 
based on the ability of an antioxidant in a sample to form a coloured complex with ferric chloride, 
potassium ferricyanide and trichloroacetic acid measured at 700 nm using a UV-spectrophotometer 
(Vijayalakshmi and Ruckmani, 2016). The highest reduction of the reactive Fe3+ to an inactive Fe2+-
polyphenol complex was exhibited by the butanol fraction (Figure 6.3.2).  
Transition metals like iron have major roles to play in the generation of free radicals thereby leading 
to oxidative stress (Yoshino and Murakami, 1998). This justifies the use of FeSO4 to induce 
experimental oxidative pancreatic injury in normal pancreatic homogenate. Iron over load causes an 
increase in free radicals because the reactive superoxide anion is produced through oxygen reduction 
by ferrous ion, then dismutated to hydrogen peroxide through enzymatic and non-enzymatic systems 
(Halliwell and Gutteridge, 1990). When left untransformed, hydrogen peroxide is converted to 
extremely reactive hydroxyl radical (.OH) through the Haber-Weiss reactions using iron or copper 
(Aust et al., 1985). Iron also binds to molecular oxygen to form perferryl ion which is highly reactive 
in combination with hydroxyl radical and act as an initiator of lipid peroxidation (Yoshino and 
Murakami, 1998). Induction of oxidative injury by iron was done in the pancreas because the β-cells 
(due to high insulin action) are parts of the most metabolically active tissues and benefit highly from 
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oxidative phosphorylation for ATP generation (Wang and Wang, 2017). The secretion of insulin 
relies on oxygen utilisation due to increased blood glucose levels, thereby making the β-cells prone 
to the deleterious effects of ROS. Again, reduction of endogenous antioxidant enzymes also makes 
the β-cells vulnerable to oxidative stress (Lenzen et al., 1996, Li et al., 2008, Robertson et al., 2003).  
From our result (Figure 6.3.3 a-c), incubation of the pancreatic homogenate with FeSO4 (as earlier 
explained) caused a marked reduction of GSH levels, and catalase and SOD enzyme activities in the 
untreated cells of the antioxidant-deficient pancreatic β-cells. Reduced glutathione (GSH) has been 
reported as being low during the progression of complications of T2D (Tiwari et al., 2013). The 
ability of treatment with the different fractions of B. ferruginea in our study (Figure 6.3.3 a) shows 
the antioxidant potential of the fractions. SOD catalyses the superoxides to hydrogen to generate 
hydrogen peroxide, which is in turn dismutated by catalase to molecular oxygen and water (Robertson 
et al., 2003). If not cleared by catalase, hydrogen peroxide will react hitherto with Fe3+ (as earlier 
explained) to produce reactive hydroxyl radicals which causes lipid peroxidation by attacking the 
lipid membrane (Aslan et al., 2000). There was marked increase in the activity of catalase and SOD 
enzymes and concomitant reduction of lipid peroxidation after the treatment with varying doses of 
the fractions (Figure 6.3.3 b & c). Indeed, the antioxidant activity noticed from the fractions of B. 
ferruginea may have been brought about by different mechanisms such as inhibition of chain 
initiation, binding of transition metal enzymes, elimination of peroxides, reducing effect, radical 
scavenging and others (Diplock, 1997).  
Effective anti-diabetic agents must have good postprandial glucose lowering activities by reduction 
of the digestion of carbohydrates in food to glucose. This is done by inhibiting the action of -
glucosidase enzyme (Ghadyale et al., 2012). From our results (Figure 6.3.4), the butanol fraction 
showed the highest -glucosidase inhibitory activity. Research have shown that -glucosidase 
inhibitors have been successfully isolated from medicinal plants (Yin et al., 2014). This leads us to 
suggest that B. ferruginea can be exploited as potent candidate for isolation of -glucosidase 
inhibitors which will be effective in therapeutic use for T2D. 
The anti-diabetic potential of fractions of B. ferruginea was also shown by the inhibition of glucose 
absorption in intestinal tissues (Figure 6.3.5) and concomitant induction of glucose uptake in the 
muscle (Figure 6.3.6). The butanol and aqueous fractions alone were used for these assays since they 
showed better potential as antioxidant and anti-diabetic agents.  Motility and ease of exit of luminal 
content in the small intestine are markers of glucose absorption and in turn potential pharmacological 
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targets for the treatment of T2D (Thazhath et al., 2016). Postprandial glucose rise occurs when 
glucose is absorbed quickly in the small intestine (i.e. within the jejunal and duodenal areas) 
(Oyebode et al., 2018) and leaving this unmanaged may have adverse consequences in T2D (Hassan 
et al., 2010). Our result showed the ability of the fractions especially the aqueous fraction to reduce 
the absorption of glucose in the intestine (Figure 6.3.5); this together with the inhibition of -
glucosidase activity by the fractions  show its potential to delay the digestion and absorption of 
carbohydrates might be due to the presence of phenolic compounds (Table 6.3.1). Such activity has 
been reported in plants containing phenolic compounds in some previous studies (Inthongkaew et al., 
2017; Toma et al., 2014).   
The skeletal muscle is important in glucose homeostasis as it is the main region for exercise-
stimulated glucose disposal and it also interacts with the pancreas to induce secretion of insulin for 
effective utilization of glucose (Mizgier et al., 2014). The muscle can secrete myokines and GLUT4 
which aid in endocrine functions such as glucose uptake (Mizgier et al., 2014). Induction of muscle 
glucose uptake notwithstanding insulin levels has been reported as a key therapy for control of 
hyperglycaemia (Pereira et al., 2017). Interestingly, the butanol and aqueous fractions showed 
induction of glucose abilities both in the presence of insulin and without, which was even as 
comparable as the activity of the standard drug (metformin) used. This shows that the fractions on its 
own (Figure 6.3.6) can induce glucose uptake in peripheral tissues. Taken together with the results 
from all the anti-diabetic models shows the potential of fractions of B. ferruginea in modulating 
hyperglycaemia. 
GC-MS analysis of the fractions was conducted in order to identify the presence of bioactive 
components that might be responsible for the observed antioxidant and anti-diabetic activities. 2-
methoxy-3-(2-propenyl) phenol found solely present in the aqueous fraction which has been reported 
to act as a cytotoxic agent (Espineli et al., 2014), while, pyrogallol has been reported to act as an anti-
inflammatory agent (Nicolis et al., 2008). Phytol acetate has been reported to have insulin resistance 
alleviating properties (Nicolis et al., 2008). Of utmost importance however is the sitosterol found 
present in the fractions. Sitosterol is a dietary phytosterol mainly found in plant and studies have 
elucidated its anti-diabetic activity (Balamurugan et al., 2011; Gupta et al., 2011; Karan et al., 2012; 
Zeb et al., 2017). Conversely, the observed antioxidant and anti-diabetic activity of the fractions could 
be due to the synergistic effects of the identified bioactive compounds. 
Summarily, this study suggests that the fractions (especially the butanol and aqueous) of B. ferruginea 
leaves contains potent antioxidant agents coupled with -glucosidase and intestinal glucose 
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absorption inhibitors as well as peripheral tissue glucose uptake inducers, which could be further 
exploited for the development of a therapeutic strategy for the management and control of 
postprandial hyperglycemia in type 2 diabetes and its macrovascular complications. Future work will 
entail a detailed study of the active fraction in a type 2 diabetes model of rats.  
Postscript: The butanol fraction was picked for the in vivo experiment or animals study since it had 
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Preface: This article reports the detailed in vivo anti-diabetic studies of the butanol fraction and it is 
currently awaiting revision before submission to a journal for publication. 
6.4.1 Abstract 
This study reports the anti-diabetic effects of the butanol fraction of B. ferruginea (BFBF) leaves on 
streptozotocin induced diabetic rats. Seven weeks old male Sprague dawley (SD) rats were given a 
single intraperitoneal injection of STZ (40 mg/kg bw), after initially being fed 10% fructose solution 
for two weeks to induce type 2 diabetes. The diabetic animals were thereafter given an oral dose (150 
or 300 mg/kg bw) of BFBF. Treatments with the plant extract significantly (p < 0.05) reduced the 
concentration of blood glucose and improved glucose tolerance compared to the untreated groups. 
There was also a marked improvement in β-cell function, serum insulin levels and insulin sensitivity, 
liver glycogen, serum lipids alterations and increased activity of liver function enzymes. 
Histopathological analysis of the pancreas by H and E staining also revealed the ability of BFBF to 
protect and regenerate the pancreatic β-cells after partial damage induced by STZ injection. The 
findings of this study suggest that BFBF possesses promising anti-T2D activity, which is probably 
mediated through the modulation of β-cell function and stimulation of insulin secretion. 
Key words: Type 2 diabetes, histopathology, serum analysis, Bridelia ferruginea, SD rats 
6.4.2 Introduction  
Type 2 diabetes (T2D) is a complex disease, which occurs due to an increased level of postprandial 
glucose. This spike is caused by defective insulin transport of the elevated glucose for effective 
utilization by peripheral organs (such as muscle and adipose tissues) (Geijselaers et al., 2017; Nolan 
et al., 2015). Insulin resistance leads to chronic hyperglycaemia a precursor to anomalies in 
carbohydrate, protein and fat metabolism (Hardy et al., 2012).   
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Presently, over 422 million cases of diabetes have been recorded, which means 1 in 11 people in the 
world have diabetes and there will be an estimated increase by 2030 to 640 million cases (i.e. 1 in 10 
people) (Conway et al., 2018; WHO, 2016). This increase can be linked to factors such as change in 
diet, urbanization, sedentary lifestyles, aging and increasing population. There has been a global rise 
of diabetic cases as compared to the year 1980 where only 108 million cases were recorded (IDF, 
2015). In South Africa, the prevalence of diabetes increased from 5.5% to 9% during 2000 to 2009, 
making it the second highest mean of health care expenditure in the African region as a whole 
(Manyema et al., 2015). T2D remains the most prevalent type of diabetes and therefore the focus of 
this study is T2D.  
Many long-term and short-term complications are associated with the progression of T2D (Fonseca, 
2009) which include eye, kidney, nerve and heart problems. Diabetes can be controlled with the use 
of different types of treatment modalities, while the most common one is the use of synthetic oral 
hypoglycemic drugs. These drugs, though sometimes effective when used singly or in combination 
with other drugs, are associated with a number short- or long-term side effects such as nausea, weigh 
gain, lactic acidosis, gastrointestinal disturbances (Stein et al., 2013). Interestingly traditional 
medicine is able to play a role in the treatment of diverse diseases. Because, plants contain 
phytochemicals which are able to render synergistic effects in the treatment of diseases such as 
diabetes (Kooti et al., 2016). Several studies have highlighted the efficacy of medicinal plants in the 
treatment of diabetes (Choudhury et al., 2017; Mohammed et al., 2014). The vast array of land filled 
with medicinal plants gives more opportunities for researchers to carry out more studies with a view 
to harness the spread of diseases through the use of medicinal plants. 
Bridelia feruginea Benth (Euphorbiaceae) is a traditional medicinal plant commonly used in parts of 
Africa for the treatment of diabetes mellitus (Bakoma et al., 2014). The stem bark is boiled, and the 
water infusion is drunk to cure ailments such as diabetes, diarrhoea (Akuodor et al., 2012), arthritis 
(Olajide et al., 2012), boils and others (Olajide et al., 2012). The methanol leaves extract of B. 
ferruginea, was found in a recent study to possess   hypoglycaemic activity in glucose-intolerant rats 
(Njamen et al., 2012). The hypoglycaemic activity of the aqueous extract of the stem bark of this 
plant has also been investigated in both normal and alloxan-induced diabetic rats (Adewale and 
Oloyede, 2012). However, the anti-diabetic effect of the butanol fraction of the leaves of B. ferruginea 
has not been tested using a model that accurately mimics T2D in rats. Therefore, this study was 
conducted to comprehensively investigate the in vivo anti-diabetic mechanism of action of butanol 
fraction of B. ferruginea using a better T2D animal model. 
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6.4.3 Materials and methods 
Please refer to Chapter 2 for detailed materials and methods that affect B. ferruginea.   
6.4.4 Results 
The mean feed and fluid intake with weekly body weight changes of all animals were monitored all 
through the experimental period. The diabetic rats showed significantly (p < 0.05) higher feed and 
fluid consumption as well as lower body weight gains compared to the normal rats. Oral dosing of 
BFBF to the diabetic rats significantly (p < 0.05) decreased the fluid intake compared to the untreated 
diabetic rats (Figure 6.4.1). Feed intake was also reduced upon intervention with BFBF and 
metformin as seen in Figure 6.4.1.   
 
Figure 6.4.1: Mean feed and fluid intakes of different groups during the entire experimental period. 
Data are reported as the mean ± SD of seven animals. a-c Different superscript alphabets over the bars for a given parameter 
indicate significant difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic 
control, DBFL, Diabetic B. ferruginea low dose, DBFH, Diabetic B. ferruginea high dose, DBM, Diabetic metformin, DBG, 
Diabetic glibenclamide, NBF, Normal B. ferruginea high dose (toxicological control), 
Interestingly, animals in the DBFH and DBM group showed a better body weight gain than the low 












































Figure 6.4.2: Mean body weight change for all groups of experimental animals over the seven weeks 
experimental period. Data are reported as the mean ± SD of seven animals. a-cValues with different letters for a given 
week are significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, 
DBC, Diabetic control, DBFL, Diabetic B. ferruginea low dose, DBFH, Diabetic B. ferruginea high dose, DBM, Diabetic 
metformin, DBG, Diabetic glibenclamide, NBF, Normal B. ferruginea high dose (toxicological control), STZ, 
Streptozotocin. 
After STZ injection, the diabetic groups showed significantly higher blood glucose concentrations 
compared to the normal groups. However, as soon as treatment of the animals started the DBFL and 
the DBFH groups portrayed a dose-dependent and significantly lower (p < 0.05) blood glucose levels 
than the untreated group (DBC) throughout the entire intervention period (Figure 6.4.3).     
 
Figure 6.4.3: Weekly blood glucose concentrations in different animal groups during the intervention 
period. Data are reported as the mean ± SD of seven animals. a-dValues with different letters for a given week are 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, 
Diabetic control, DBFL, Diabetic B. ferruginea low dose, DBFH, Diabetic B. ferruginea high dose, DBM, Diabetic 
metformin, DBG, Diabetic glibenclamide, NBF, Normal B. ferruginea high dose (toxicological control), STZ, 
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The data for OGTT done on the last week (week 5) of the intervention period and the corresponding 
area under the curve (AUC) are shown in Figure 6.4.4. The glucose tolerance of DBFL and DBFH 
groups were significantly (p < 0.05) lower than the DBC and DBG group and even comparable to the 
metformin group (DBM). At the 120 min mark, the DBFH group exhibited a better glucose tolerance 
ability which was even lower than the 0-min blood glucose level. The total area under the curve 
(AUC) of DBFL and DBM groups were significantly lower than the other diabetic groups (DBC, 
DBFH, and DBG) (Figure 6.4.4) which signifies better tolerance of the glucose overload in the blood. 
 
Figure 6.4.4: Oral glucose tolerance test (OGTT) and corresponding area under the curve (AUC) of 
different animal groups in the last week of the intervention period. Data are reported as the mean ± SD of 
seven animals. a-eValues with different letters for a given time are significantly different from each other (Tukey’s-HSD 
multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, DBFL, Diabetic B. ferruginea low dose, 
DBFH, Diabetic B. ferruginea high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NBF, Normal B. 
ferruginea high dose (toxicological control), AUC, Area under the curve. 
The liver weight, relative liver weight and liver glycogen level of different animal groups are shown 
in Table 6.4.1. There was no significant difference in the liver weight of all animal groups, however, 
the relative liver weight of the normal groups (NC and NBF) were significantly (p < 0.05) lower than 
that of the diabetic groups. The DBFL group showed a significantly (p < 0.05) lower relative liver 
weight compared to the DBC group. The treatment with BFBF significantly increased the liver 
glycogen level compared to the untreated group (Table 6.4.1). 
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Table 6.4.1: The effects of different doses of BFBF on liver weight, relative liver weight and liver 
glycogen levels in the different animal groups at the end of the intervention period. 
Parameter NC DBC DBFL DBFH DBM DBG NBF 
Liver weights (g) 10.7±0.8 8.7±0.9 9.0±0.7 10.6±0.9 9.6±0.7 9.9±0.9 9.9±0.8 
Rel. liver weights 
(%) 
2.9±0.3a 3.8±0.2b 3.2±0.4b 4.4±0.5c 2.7±0.1a 2.4±0.1a 2.8±0.3a 
Liver glycogen 
(mg/g tissue) 
36.0±0.9e 11.8±1.1a 23.6±0.3c 31.8±0.1d 31.4±1.1d 21.8±0.8b 36.4±0.7e 
Results are expressed as mean ± SD (n=7). a-eDifferent superscript letters along a row for a given parameter indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). 
At the end of the experimental period after sacrificing the animals, the blood  samples were taken and 
the serum lipid profile of all the animals were taken and it is reported in Figure 6.4.5. The DBC group 
showed a significantly (p < 0.05) higher total and LDL-cholesterol compared to the normal groups. 
However, treatment with BFBF reduced the levels of these cholesterols as seen in the DBFL, DBFH 
and DBM groups, the DBG group showed a statistically similar result to DBC for total and HDL-
cholesterol. Interestingly, the DBFL group showed even lowed LDL-cholesterol than the normal 
group. On the other hand, the NC group showed a significantly (p < 0.05) higher amount of HDL-
cholesterol just like the other groups more than the DBC group. T2D-induction caused a significant 
(p < 0.05) elevation of serum triglycerides level which was reduced in the DBFH and DBM groups.  
 
Figure 6.4.5: Serum lipid profile of different animal groups at the end of the intervention period. Data 
are reported as the mean ± SD of seven animals. a-eValues with different letters for a given parameter 
significantly different from each other (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal 
control, DBC, Diabetic control, DBFL, Diabetic B. ferruginea low dose, DBFH, Diabetic B. ferruginea high 
dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NBF, Normal B. ferruginea high dose 
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Data of other serum indices of diabetic complications investigated are shown on Table 6.4.2. The 
induction of T2D using STZ intraperitoneal injection had no effect of serum ALT levels in all animals 
in all groups. Serum levels of ALP, AST and urea were increased in the DBC group compared to the 
NC and NBF groups. Interestingly, BFBF treatment significantly ameliorated the ALP, AST, urea 
and creatinine levels in the respective groups. 
Table 6.4.2: Serum biochemical parameters in different animal groups at the end of the experimental 
period.        
Parameter    NC   DBC  DBFL    DBFH   DBM    DBG    NBF 
AST (U/L) 49.5±5.6a   147±16.3e 
  
73.5±5.7bc 
59.5±9.7ab 102.5±12.5bd 85±8.8cd 50±14.3a 
ALT (U/L) 87.8±1.1   87.3±2.0   86.3±1.8    87±0.7  85.5±2.1  86.3±1.3     86±5.8 
ALP (U/L) 72.3±6.2a 308.3±44.8de 259.3±23cd 142±24ab  206.8±59.5bc   395.9±86.2e  68.3±13.9a 
Urea 
(mg/dL) 
52.6±4.8b   73.8±3.4c    56.5±8.8b 41.3±2.8a   51±5.8ab 71.5±3.9c 46.3±5.8ab 
UA 
(mg/dL) 
    0.78±0.43a   3.5±0.9c    2.2±0.3b     1.1±0.5ab   1.3±0.5ab    1.6±0.7ab 




118.9±14.7a 305.5±27.8d 250.9±35c 171.9±22.9b 113.9±17.7a 185.9±7.6b 153±22.3ab 
Results are expressed as mean ± SD (n=7). a-eDifferent superscript letters for a given parameter along a row indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, 
DBFL, Diabetic B. ferruginea low dose, DBFH, Diabetic B. ferruginea high dose, DBM, Diabetic metformin, DBG, 
Diabetic glibenclamide, NBF, Normal B. ferruginea high dose (toxicological control), AST, Aspartate aminotransferase; 
ALT, Alanine aminotransferase; ALP, Alanine phosphatase; UA, Uric acid; CK-MB, Creatinine kinase-myocardial band.   
Serum insulin levels were significantly (p < 0.05) higher in DBFH and normal groups compared to 
the remaining groups (Table 6.4.3). The HOMA-IR score in the NC group was significantly lower 
than that of the DBC and treatment with BFBF was able to reduce to HOMA-IR scores. In the other 
case, the HOMA-β scores of the DBC group was seen to be significantly lower than that of the NC 
groups and the DBFH group showed a moderate increase in HOMA-β scores. Serum fructosamine 
data also showed a difference in the DBC group compared to the NC. Interestingly, treatment with 






Table 6.4.3: Serum insulin, and fructosamine concentrations as well as calculated HOMA-IR and 
HOMA-β scores of different animal groups at the end of the experimental period. 
Parameter      NC DBC DBFL DBFH DBM DBG NBF 
Serum Insulin 
(pmol/L) 
65.2±1.1c 23.5±1.8a 46±3.9b 58.7±1.5c 59.8±6.7c 41.8±2.3b 62.8±3.5a 
Fructosamine 495.8±17.9a 990±10.4c 896.3±117.5c 575.8±11.6a 572.5±9.2a 743.6±37.4b 492±43.6a 
HOMA-IR 2.1±0.3a 14.0±0.3e 6.2±0.5d 4.9±0.1b 6.5±0.7d 5.2±0.3c 2.1±0.1a 
HOMA-β 100.3±1.7f 2.7±0.2a 7.0±0.6b 16.3±0.4d 11.9±1.3c 7.0±0.4b 95±4.6e 
Results are expressed as mean ± SD (n=7). a-eDifferent superscript letters for a given parameter along a row indicate the 
significance of difference (Tukey’s-HSD multiple range post hoc test, p < 0.05). NC, Normal control, DBC, Diabetic control, 
DBFL, Diabetic B. ferruginea low dose, DBFH, Diabetic B. ferruginea high dose, DBM, Diabetic metformin, DBG, 
Diabetic glibenclamide, NBF, Normal B. ferruginea high dose (toxicological control), HOMA-IR and HOMA-β; 
Homeostatic model assessment for IR (insulin resistance) and β (β-cell function).  
The pancreas was subjected to histopathological analysis Figure 6.4.6. Examination of the DBC 
pancreas showed a reduction or shrinkage of the pancreatic islets (red arrow). Microscopic 
examination of the normal (NC) pancreas sections showed the normal appearance of the pancreatic 
islets which looked lightly stained than the surrounding acinar cells (green arrow). The acinar cells 
are generated from pyramidal cells with basal nuclei and apical acidophilic cytoplasm. Induction of 
T2D caused a severe destruction to both the exocrine and endocrine components of the pancreatic 
islets in the DBC group (red arrow). The acinar cells appear swollen and vacuoles were seen in almost 
all acinar cells compared to the pancreas of NC group. The β-cells of pancreatic islets are almost 
entirely lost in the untreated STZ-injected rats (red arrow). Similar findings were seen in the DBG 
group (purple arrow). However, high dose (yellow arrow) of BFBF treatment rendered protection and 
regeneration abilities to the T2D-associated destruction of β-cells because atrophic alterations of the 
acinar cells were less severe and larger islets when low dose (grey arrow) could not show any such 









Figure 6.4.6: Histopathological images of the pancreas of different animal groups at the end of the 
experiment. NC, Normal control, DBC, Diabetic control, DBFL, Diabetic B. ferruginea low dose, DBFH, 
Diabetic B. ferruginea high dose, DBM, Diabetic metformin, DBG, Diabetic glibenclamide, NBF, Normal B. 
ferruginea high dose (toxicological control).  
6.4.5 Discussion 
Africa is home to many indigenous plants which have anti-diabetic activity. The cost, unavailability 
and unwanted side effects of common synthetic drugs makes medicinal plants of high importance in 
T2D-drug research. Medicinal plants showing anti-diabetic activities must possess glucose lowering 
effect and must be able to keep glucose levels close to normal at all times.   
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The T2D-induction model used in this study was carried out using two distinct pathological features 
of T2D. The first is induction of insulin resistance by high fructose diet (giving the animals 10% 
fructose for two weeks) and the second is induction of partial pancreatic β-cell destruction (a single 
intraperitoneal injection of 40 mg/kg bw STZ) (Wilson and Islam, 2012).   
Common physical manifestation of T2D includes polydipsia (frequent thirst), polyphagia (insatiable 
appetite), weight loss due to diarrhoea, lethargy, blurred vision, frequent urination and others (Kohei, 
2010). Successful induction of T2D in our experiment was confirmed by the induction of feed and 
fluid intake of the diabetic animals compared to the normal animals (Figure 6.4.1) and loss of body 
weight (Figure 6.4.2). The ability of these symptoms to improve significantly upon treatment with 
extracts suggests the anti-diabetic potential of this plant fraction.    
A main pathological feature of T2D is persistent high blood glucose level which was exhibited in the 
untreated diabetic (DBC) group all through the intervention period (Figure 6.4.3). Maintaining 
normal blood glucose level is the main goal of T2D treatment modalities so as to stop the diseases 
from progressing into major macrovascular complications (Asif, 2014). The ability of the high dose 
of the fraction (DBFH) to reduce blood glucose concentrations to almost normal level might be due 
to its enhancing glycogenolysis and cellular glucose uptake. 
A high dose (300 mg/kg bw) of the BFBF showed promising blood glucose lowering abilities (Figure 
6.4.3), improved glucose clearance (Figure 6.4.4), displayed insulin resistance alleviating properties 
(Table 6.4.3) and even demonstrated pancreatic β-cell protective abilities (HOMA-β and 
histopathological analysis). This can be explained better by suggesting that the fraction favoured 
insulin secretion, which then induced effective glucose uptake by the cells. The ability of the fraction 
to protect the β-cells of the pancreas after STZ-injection might be due to the antioxidant potential of 
the fraction which was reported in the last section (Section 6.3) since oxidative stress has been 
implicated to induce damage to the β-cell of the pancreas (Li et al., 2008).  
The reduction of liver glycogen level is another pathological feature of experimental induction of 
diabetes (Chaudhury et al., 2017). This observed reduction is caused by decrease in the action of 
glycogen synthase and glycogen phosphorylase (Adeva-Andany et al., 2016). Studies have reported 
on the ability of medicinal plants to stimulate glycogen production by increasing glycogenesis in the 
liver thereby potentiating anti-diabetic activities. Interestingly high glycogen levels seen in the DBFH 
group (Table 6.4.1) compared to the untreated group showed the anti-diabetic activity is not only 
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limited to insulin production, β-cell protection and increasing glucose uptake but also by improving 
the synthesis of liver glycogen level.  
Hyperlipidaemia is another feature of experimentally-induced T2D where elevation of serum insulin 
levels suggests increased risk of coronary heart disease and stroke in T2D (Gomes, 2013); a major 
complication of T2D that increases the mortality rate of patients (Einarson et al., 2018). Significantly, 
increased levels of serum total and LDL-cholesterol was seen in the DBC group compared to the 
normal group (Figure 6.4.5).  The serum HDL-cholesterol on the other hand was increased in the 
normal groups compared to the diabetic groups. Interestingly, the BFBF groups all had same HDL-
cholesterol levels as the normal and standard drug-treated groups. Hypertriglyceridemia (high serum 
triglyceride levels) is a suggested marker for coronary heart disease. Induction of T2D elevated the 
level of serum triglycerides, which was reduced in the BFBF treated groups shows the ability of the 
plant fraction to protect the heart against cardiac problems and atherosclerosis associated with T2D.A 
number of plant-based phytoconstituents have been reported to elicit hypolipidemic abilities in 
experimentally induced diabetes (Dhulasavant et al., 2010, Gaikwad et al., 2014). 
Data from other parameters of complications in T2D also showed a significant increase in AST, ALP, 
urea, uric acid and CK-MB. No significant change was seen amongst the serum ALT of all the animals 
in different groups. Insulin deficiency in T2D leads to increased serum levels of transaminase 
enzymes due to initiation of gluconeogenesis and ketogenesis (Ghosh and Suryawanshi, 2001). 
Increase levels of AST, ALP and ALT are markers of liver malfunction as a result of insulin 
deficiency. Interestingly, treatment with BFBF in our study significantly reversed the increased levels 
of these enzymes thereby signifying hepatoprotective ability of the fraction. 
Diabetic kidney disease is a major complication of T2D. Hyperglycaemia destroys the microvascular 
blood vessels thereby causing impaired renal activity and diabetic nephropathy. Studies have shown 
that high serum uric acid levels show the prognosis of chronic kidney disease in T2D (Kushiyama et 
al., 2014), which predicts an imbalance in uric acid production and excretion. Induction of T2D in 
our study caused an increased level of serum uric acid (Table 6.4.2), however, daily treatment with 
the fraction significantly reduced the uric acid levels, thereby showing the nephroprotective ability of 
the fraction in T2D complications. 
The presence of sitosterol a known phenolics in B. ferruginea might be responsible for the observed 
cardio, renal and hepatoprotective effect of the high dose of the butanol fraction as demonstrated in a 
study by Olaiya et al. (2015).    
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 In conclusion, the findings of this study indicate that oral administration of BFBF in male SD rats 
can reduce hyperglycaemia, diabetic complications and protect against STZ-induced damage to the 
pancreatic β-cell. The phyto-chemical constituents of B. ferruginea might be responsible for these 
pharmacological activities. We can therefore conclude that B. ferruginea is a non-toxic (even at a 
high dose) source of natural antioxidants that can be effectively used in the treatment of diabetes and 
its complications. However, a detailed molecular study should be done to better understand the 





THE ANTIOXIDANT AND ANTIDIABETIC ACTIVITIES OF BOERHAVIA 
DIFFUSA IN VITRO, EX VIVO AND IN SILICO 
7.1 Background 
Boerhaavia diffusa is a perennial, ground-spreading shrub (as long as 2000 m) found growing richly 
in unfertilized soil and is native to both India and Brazil and parts of Africa (Figure 7.1). The leaves 
are simple, thick, fleshy, hairy and oblong in shape. The small pinkish flowers with short stalk has 
both staminate and carpellate parts. The roots of B. diffusa are well developed, stout, fusiform and 
cylindrical in shape with yellowish brown colour. The stem is prostrate (creeping plant) in nature, 
succulent, slender and cylindrical in shape.  
 
Figure 7.1: Boerhavia diffusa Linn (Nyctaginaceae): Common names: Arowojeja (Yoruba, Nigeria), 
red spiderling, spreading hogweed (English). Adapted without permission from Indiamart (2009). 
7.1.1 Ethnobotanical uses 
B. diffusa is a super food used successfully in folk medicine, and the leaves are eaten in salad or 
sauces. In parts of Nigeria, the whole plant is eaten in curries and soups while the seeds and roots are 
used to make pancakes. Traditionally, B. diffusa is planted in gardens as snake and scorpion 
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repellents. The plant is used locally tied around a pregnant woman’s waist to induce labour, and when 
ground and mixed with honey it is used to treat conjunctivitis. In Ayurveda, B. diffusa is commonly 
used for treatment of jaundice, liver diseases, diabetes, edema, oliguria, anemia, inflammatory edema, 
diseases of the eye, and aging (Murti et al., 2010).  
7.1.2 Biological activities  
Some bioactive constituents have been isolated from the aerial parts of B.diffusa and they include 
ursolic acid, β-sitosterol, boeravinone, punarnavoside, alkaloids, sterols, sugars and flavones and a 
host of others (Chakraborti and Handa, 1989, Nayak and Thirunavoukkarasu, 2016; Pereira et al., 
2009,).     
A study reported that oral administration of leaf extract of B. diffusa at 200 mg/kg body weight (bw) 
elicited a significant reduction in lipid peroxidation with a concomitant induction of endogenous 
antioxidant enzymes like catalase, superoxide dismutase, reduced glutathione, glutathione peroxidase 
and S-transferase in the kidney and liver of alloxan-induced diabetic rats (Satheesh and Pari, 2004).  
B. diffusa root extract showed hepatoprotective ability in experimentally-induced hepatotoxicity in 
mice (Rajpoot and Mishra, 2011). Oral administration of the aqueous leaves extract of B. diffusa in 
normal and alloxan-induced diabetic rats showed a decrease in blood glucose levels and a significant 
rise in plasma insulin levels, which was even more significant than the effect of glibenclamide (a 
standard anti-diabetic drug) (Chude et al., 2001; Pari and Amarnath Satheesh, 2004; Satheesh and 
Pari, 2004). At a dose of 200 mg/kg bw for four weeks, the aqueous leaf extract of B. diffusa showed 
significant (p < 0.05) change in blood glucose concentration and activity of hepatic gluconeogenic 
enzymes (increase in hexokinase activity and decrease in glucose-6-phosphatase and fructose-1, 6- 
phosphatase activity) in both normal and alloxan induced diabetic rats (Pari and Satheesh, 2004). The 
chloroform extract of the leaves of this plant was tested on streptozotocin-induced type 2 diabetic rats 
and it also showed a dose-dependent reduction of blood sugar levels even comparable to the action 




7.2 Boerhaavia diffusa inhibits key enzymes linked to type 2 diabetes in vitro and in 
silico; and modulates abdominal glucose absorption and muscle glucose uptake 
ex vivo 
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Preface: This article reports the detailed in vitro antioxidant and anti-diabetic effects of the crude 
extracts from B. diffusa, which has been published in Journal of Biomedicine and Pharmacotherapy. 
7.2.1 Abstract 
The present study investigated the in vitro and ex vivo antioxidant, anti-diabetic and anti-obesogenic 
potentials of different solvent (ethyl acetate, ethanol and water) extracts from the aerial parts of 
Boerhaavia diffusa. The ferric reducing antioxidant power (FRAP), DPPH scavenging activity and 
the ameliorative effects of the extracts on Fe2+-induced oxidative injury was investigated both in vitro 
and ex vivo. The glucosidase and pancreatic lipase inhibitory potentials of the extracts were examined 
in vitro, while the effects of the ethanol extract on abdominal glucose intake and muscle glucose 
uptake were determined in freshly harvested tissues ex vivo. The extracts were subjected to Gas 
Chromatography-Mass Spectrometry (GC–MS) analysis to identify their possible bioactive 
components. The ethanol extract showed the most potent FRAP and DPPH radical scavenging 
activities compare to other extracts. All extracts increased catalase and SOD activities, and GSH 
levels in oxidative pancreatic injury. Both ethanol and aqueous extracts exhibited remarkable enzyme 
inhibitory activities, which was significantly higher than ethyl acetate extract and acarbose but was 
not comparable to orlistat. The ethanol extract portrayed a dose-dependent inhibitory effect on jejunal 
glucose uptake and enhancement of muscle glucose 
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uptake. 9-(4 methoxyphenyl) xanthene, xanthone and stigmasterol showed strong binding affinities 
for α-glucosidase and lipase enzymes tested. Data from this study suggest that aerial parts of B. diffusa 
(particularly the ethanol extract) may not only exhibit antioxidant potentials but may also mediate 
anti-lipidemic and anti-hyperglycemic effects via inhibiting fat and carbohydrate digestion as well as 
abdominal glucose intake and enhancing muscle glucose uptake. 
7.2.2 Introduction  
Diabetes mellitus (DM) is regarded as the most common endocrine disorder in humans. According to 
the World Health Organization (WHO, 2016), at least 1.5 million deaths in 2015 alone were directly 
caused by diabetes globally. Among the different occurrences of diabetes, type 2 diabetes (T2D) 
remains the most common, and major public health challenge of the 21st century (Canivell and Gomis, 
2014). It is described as a versatile and degenerative illness that is affiliated with several metabolic 
flaws and organ malfunction or damage (Pratley, 2013). The eminent pathogenic features of T2D 
include pancreatic beta cell impairment and insulinemia which ultimately results in defective insulin 
secretion and persistent hyperglycemia (Gilbert and Pratley, 2015). Insulin resistance is also 
associated with poor lipid metabolism, which aggravates metabolic syndrome and lipidemia in the 
progression of T2D (Kahn et al., 2014). 
In peripheral tissues like adipose and muscle tissues, insulin resistance is an indicator for inadequate 
cellular glucose uptake, which leads to hyperglycemia in T2D (Paneni et al., 2014, Pratley and Weyer, 
2001). Hyperglycemia-induced oxidative stress has been implicated in the symptoms, progression 
and complications of T2D (Röder et al., 2014, Tangvarasittichai, 2015). Persistent hyperglycemia is 
responsible for elevated levels of mitochondrial energy production, glucose oxidation, protein 
glycosylation and lipid peroxidation, which leads to an increased output of free radicals and reactive 
oxygen species (ROS) and eventually, oxidative stress (Gargari et al., 2011). The pancreas is one of 
the most vulnerable organs to oxidative stress, because of its low levels of free radical scavenging 
ability compared to other organs (Eleazu et al., 2013). Free radicals such as nitric oxide and hydroxyl 
radical are the potent culprit in the oxidative damage of pancreatic beta cells, which further worsens 
diabetic conditions (Eleazu et al., 2013).  
The use of traditional medicinal plants has been an effective approach in ameliorating oxidative stress, 
hyperglycemia and metabolic syndrome (Nistor BL et al., 2010). This is because of their rich 
therapeutic phytochemical constituents including phenolics, flavonoids, tannins, saponins, glycosides 
etc. (Eid and Haddad, 2014), which can potentiate several bioactivities including anti-oxidant, anti-
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hyperglycemic and anti-lipidemic activities. Additionally, medicinal plants are relatively accessible 
and affordable compared to commercial synthetic drugs and are void of most side effects associated 
with these commercial synthetic drugs (El-Houri et al., 2015). Amongst such plants is Boerhaavia 
diffusa L.  
B. diffusa (family: Nyctaginaceae) is a perennial creeping weed with spreading branches whose roots 
are tough and tapered (Nayak and Thirunavoukkarasu, 2016). The stem is woody, purplish, hairy 
and inspissates at the nodes. Its leaves are fleshy, hairy and green arranged in unequal pairs with 
minute pinkish-red flowers.  Its leaves, roots and the aerial parts are used in India in the treatment of 
kidney disorders, rheumatism, liver complaints and other diseases (Mishra et al., 2014). The leaf 
extracts have been reported to contain anti-hyperglycemic activities in various animal models 
(Prakash et al., 2015, Sharma et al., 2014). The root extract has also been reported to show no α-
amylase inhibitory activity (Prashanth D et al., 2001) but when it was used in combination with seeds 
of Silybum marianum it showed hepatoprotective abilities on animals with induced non-alcoholic 
fatty liver disease (Sachin et al., 2013). The extracts from the leaves and roots of this plant have also 
been tested on animal models to investigate their anti-hyperglycemic abilities and B. diffusa has also 
shown some inhibitory effects on carbohydrate absorption in experimental animals (Kanagavalli et 
al., 2015, Malhotra et al., 2014). Previous phytochemical studies on B. diffusa have indicated the 
presence of a wide range of phytochemicals such as essential oils, rotenoids, alkaloids, flavonoids, 
alkamide, and N-trans-feruloyltyramine, xanthones and phenolic compounds (Wajid et al., 2017, 
Olaoluwa et al., 2018, Agrawal et al., 2011, Do et al., 2013).  
 However, no study in the literature has reported on compounds found in the ethanol and aqueous 
extracts of the aerial parts or shown the ability of these compounds to effectively bind key anti-
diabetic (α-glucosidase) and anti-obesogenic enzyme (lipase). This shows that some studies on the 
anti-hyperglycemic and anti-lipidemic potentials of the aerial part of this plant and the possible mode 
of actions are still lacking. Hence, this study   examined the antioxidant potentials of B. diffusa aerial 
parts and its effect on carbohydrate and lipid digestion, intestinal glucose absorption and muscle 
glucose uptake using several in vitro and ex vivo experimental and computational models. 
7.2.3  Results 
The data showing the total phenolic content of the extracts as presented in Figure 7.2.1. A 
significantly higher (p < 0.05) phenolic content was observed in the ethanol extract compared to the 
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ethyl acetate and aqueous extract, when ethyl acetate extract showed significantly higher total 
phenolic content compared to the aqueous extract. 
 
Figure 7.2.1: Total phenolic contents of B. diffusa extracts. Data are reported as mean ± SD of three replicas. 
a-c Values with different letters above the bars for a given extract are significantly different from each other (p < 0.05, 
Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAc: Ethyl acetate extract. 
The FRAP results of the different solvent extracts are presented in Figure 7.2.2. All solvent extracts 
exhibited a dose-dependent reduction of Fe3+ radical, when ethanol extract showed a significantly 
higher (p < 0.05) activity than ethyl acetate and aqueous extracts and positive control, Trolox. 
 
Figure 7.2.2: Ferric reducing antioxidant power (FRAP) of B. diffusa aerial part extracts. Data are 
reported as mean ± SD of three replicas. a-c Values with different letter above the bars for a given concentration are 
significantly different from each other (p < 0.05, Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows). 
EtAC, Ethyl acetate; EtOH, Ethanol. 
The results of the DPPH radical scavenging activity of the different extracts B. diffusa aerial parts are 
presented in Figure 7.2.3 while their calculated EC50 (minimum extract concentration for 50% 













































































scavenging activities of DPPH, where the ethanol extract exhibited the most potent (p < 0.05) activity 
(EC50 = 9.92 ± 0.5 μg/mL). 
 
Figure 7.2.3: DPPH scavenging activity of B. diffusa aerial part extracts. Data are reported as mean ± SD 
three replicas. a-dValues with different letters above the bars for a given concentration are significantly different from each 
other (p < 0.05, Tukey’s HSD-multiple range post-hoc test, IBM SPSS for Windows). EtAC, Ethyl acetate; EtOH, Ethanol; 
AA, Ascorbic acid. 
Oxidative injury was successfully induced by incubation of the samples with FeSO4 as depicted by 
significantly (p < 0.05) lower catalase activity in the untreated group compared to the normal group 
(Figure 7.2.4). After treatment with varying doses of the extracts, there was noticeable increase in 
catalase levels (Figure 7.2.4 A) which shows the antioxidative potentials of B. diffusa. The ethanol 
and aqueous extracts of B. diffusa showed significantly higher (p < 0.05) catalase increasing activity. 
On induction of oxidative injury in the pancreas, the SOD activities were significantly (p < 0.05) 
reduced in the untreated group, treatment with varying doses of the extracts, showed marked increase 
in SOD activities (Figure 7.2.4 B). The ethanol and aqueous extracts exhibited higher activities 
compared with the ethyl acetate extract (Figure 7.2.4 B and Table 7.2.1).  
There was a reduction in the levels of reduced GSH upon induction of oxidative stress in the pancreas 
(Figure 7.2.4 C) but treatment with the different doses of the extracts led to significant (p < 0.05) 
increase in GSH level. This could further ascertain the antioxidative potentials of the extract in 
correlation with the in vitro results which have already been discussed above. The induction of 
oxidative injury in the pancreas caused significant (p < 0.05) increase in malondialdehyde (MDA) 
levels (Figure 7.2.4 D). All the extracts were able to reduce the MDA level, with the aqueous extract 















































Figure 7.2.4: Effect of extracts of B. diffusa aerial parts on (A) catalase activity, (B) SOD activity, 
(C) GSH level and (D) lipid peroxidation in oxidative pancreatic injury. Data are reported as mean ± SD of 
three replicas. *Significantly different from untreated sample and #Significantly different from normal sample (p < 0.05, 
Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). Normal = normal tissues, Untreated = tissues 
oxidatively injured but not treated. AA; Ascorbic acid 
The results of α-glucosidase and lipase enzymes inhibitory effects of B. diffusa extracts are presented 
in Figure 7.2.5 A and B respectively and their calculated EC50 values are shown in Table 7.2.1. All 
extracts exhibited concentration-dependent inhibition of α-glucosidase (Figure 7.2.5 A) and 
pancreatic lipase (Figure 7.2.5 B) inhibitory activities. Both ethanol and aqueous extract showed 
significantly (p > 0.05) more potent inhibitory activity compared to ethyl acetate extract, while the 
lipase inhibitory activity of the aqueous extract was significantly (p < 0.05) greater than that of the 
ethanol extract (Figure 7.2.5 B). There was no virtual difference on α-glucosidase inhibitory 
activities between the ethanol and aqueous extracts when compared with the positive control, 











































































































































Figure 7.2.5: (A) α-glucosidase, (B) Lipase inhibitory activity of aerial part extracts of B. diffusa. 
Data are reported as mean ± SD of three replicas. a-dDifferent letters over the bars for a given concentration for 
each extract are significantly different from each other (p < 0.05, Tukey’s-HSD-multiple range post-hoc test, 
IBM SPSS for Windows). EtAC, Ethyl acetate; EtOH, Ethanol. 
The data of the effects of the different concentrations of the ethanol on glucose absorption in harvested 
rat jejunum and glucose uptake in harvested rat psoas muscle are presented in Figure 7.2.6 A and B, 
respectively. Incubation of isolated rat jejunum with ethanol extract resulted in a significant (p < 0.05) 
and dose-dependent reduction in glucose absorption compared to the control (Figure 7.2.6 A). On 
the other hand, the ethanol extract significantly and dose dependently increased glucose uptake in rat 
psoas muscle (Figure 7.2.6 B). Glucose uptake at 200 and 250 mg/dL concentrations of ethanol 
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extracts was significantly (p < 0.05) higher than that of the control, 50, 100 and 150 mg/dL 
concentrations of ethanol extracts and metformin (Figure 7.2.6 B). 
 
Figure 7.2.6: Effect of the ethanol extract of the aerial part of B. diffusa on (A) glucose absorption in 
isolated rat jejunum and (B) glucose uptake in rat psoas muscle. Data are reported as mean ± SD of three 
replicas. a-cDifferent letters over the bars for a given concentration are significantly different from each other 
(p < 0.05, Tukey’s-HSD-multiple range post-hoc test, IBM SPSS for Windows). 
The GC–MS result (Figure 7.2.7) showed the presence of 9 and 3 compounds respectively from the 
ethanol and aqueous extracts of B. diffusa aerial parts. Their retention time (min), molecular formula, 
and mass spectra data (amu) are shown in Table 7.2.2. Figure 7.2.8 A–C shows the binding affinity 
of xanthone, 9-(4-methoxyphenyl) xanthene and stigmasterol to complexed α-glucosidase, while 
Figure 7.2.8 D–F shows the binding affinities of these compounds with lipase enzyme. 
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36.7±5.6e 5.21±1.0b 13.21±2.1d 7.34±1.1 d 16.42±2.5c 39.01±5.3c 134.39±9.2d ND 
Ethanol 9.92±0.5c 1.13±0.5a 2.05±0.1a 2.14±0.4b 11.83±1.0b 2.82±0.3b 17.434±3.1c 1.604±1.03 
Aqueous 25.70±1.1d 1.26±0.8a 5.72±1.0c 1.09±0.1a 5.71±0.4a 1.08±0.5a 5.79±2.9b ND 
Standard         
Ascorbic 
acid 
2.19±0.05a 1.01±0.04a 3.91±1.2b 3.65±0.7c 15.39±6.2c ND ND ND 
Trolox 5.79±0.4b ND ND ND ND ND ND ND 
Acarbose ND ND ND ND ND 36.27±1.84c ND ND 
Orlistat ND ND ND ND ND ND 0.03±0.12a ND 
DPPH-1,1-diphenyl-2-picrylhydrazyl radical, NO-nitric oxide radical, ND-not determined. Data are reported as mean ± SD 
values of three replicas. a-d Different letters stand for significantly different values from each other within a column (Tukey’s-
HSD multiple range post hoc test, p < 0.05): the same letters stand for non-significant difference. 
Table 7.2.2: Phytochemical compounds identified from the ethanol (F) and aqueous (BD) extracts of 
B. diffusa aerial parts by GC-MS 




Mass spectral data (amu) 
 Ethanol extract    
1 D-Limonene 6.09 C10H16 136 [M+] 
2 Tetradecanoic acid 15.58 C14H28O2 228 [M+] 
3 Phytol acetate 16.88 C22H42O2 278 [M+ - acyl - H2O] 
4 Xanthone 17.02 C13H8O2 196 [M+] 
5 Phytol 19.11 C20H40O 123, 71 (base peak) 
6 Octadecanoic acid 19.56 C18H36O2 284 [M+] 
7 9-(4-Methoxyphenyl) xanthene 22.40 C20H16O2 288 [M
+], 181 (base 
peak) 
8 Stigmasterol 28.99 C29H48O 412 [M+] 
9 Sitosterol 29.78 C29H50O 414 [M+] 
     
 Aqueous extract    
10 Dodecanoic acid methyl ester 12.82 C13H26O2 87, 74 (base peak) 
11 Tetradecanoic acid methyl ester 15.17 C15H30O2 143, 87, 74 (base peak) 




Figure 7.2.7: Structures of the compounds isolated from the ethanol (F) and aqueous (BD) extracts 
of B. diffusa aerial parts. 









 Ethanol extract   
1 D-Limonene -7.2 6.51 
2 Tetradecanoic acid -3.5 7.30 
3 Phytol acetate -3.4 7.13 
4 Xanthone -9.8 2.35 
5 Phytol -8.5 3.12 
6 Octadecanoic acid -4.7 6.25 
7 9-(4-Methoxyphenyl) xanthene -10.3 4.52 
8 Stigmasterol -10.9 2.05 
9 Sitosterol -8.8 5.26 
    
 Aqueous extract   
10 Dodecanoic acid methyl ester -6.7 3.7 
11 Tetradecanoic acid methyl ester -8.2 2.1 













 Ethanol extract   
1 D-Limonene -4.5 4.20 
2 Tetradecanoic acid -5.4 4.11 
3 Phytol acetate -6.2 4.52 
4 Xanthone -10.3 3.30 
5 Phytol -8.4 3.52 




8 Stigmasterol -11.8 3.14 
9 Sitosterol -7.9 4.44 
 
 Aqueous extract   
10 Dodecanoic acid methyl 
ester 
-6.7 5.11 
11 Tetradecanoic acid methyl 
ester 
-8.2 4.42 









Figure 7.2.8: 3D structure showing the interacting residues (hydrogen bonding and hydrophobic) of 
extracts with highest binding affinities around binding pocket of (A) and (D) Xanthone (B) and (E) 
9-(4-Methoxyphenyl) xanthene and (C) and (F) Stigmasterol to complexed α-glucosidase and Lipase 
respectively 
7.2.4 Discussion 
The derangement in lipid metabolism in diabetic conditions is one of the major influencing factors in 
the complications associated with diabetes especially T2D (Odegaard and Chawla, 2012) and 
oxidative stress is a known culprit (Fowler, 2008). Different parts of B. diffusa plants have been 
shown to exhibit antioxidant and anti-hyperglycemic potentials both in vivo and in vitro (Prakash et 
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al., 2015, Sharma et al., 2014, Prashanth D et al., 2001) but the possible anti-lipidemic potentials and 
mode of action behind their antioxidative and anti-hyperglycemic potentials remains elusive. Our 
present study revealed that different solvent extract (particularly, ethanol extract and aqueous extract) 
of B. diffusa aerial part exhibited not only antioxidant activities but anti-lipidemic and anti-
hyperglycemic potentials via inhibiting lipid and carbohydrate digestion and abdominal glucose 
intake as well as enhancing muscle glucose uptake. 
It is well documented that plants rich in polyphenols can boost antioxidant activity of the plasma, 
thus limiting the effects of oxidative stress associated diseases such as T2D (Zhang and Tsao, 2016, 
Kanner et al., 2017). The presence of polyphenols in all studied extracts of the aerial parts of B. 
diffusa (Figure 7.2.1) gives credence to its role in the traditional treatment of various ailments, 
particularly the ethanol extract with the highest phenolic content. 
Scavenging free radicals has been demonstrated as an ameliorative effect against oxidative stress 
(Shon et al., 2007). The DPPH scavenging and total reducing power of the extracts, portray an anti-
oxidative effect. These activities depict a therapeutic potential against oxidative complications 
particularly in T2D, where oxidative stress has been linked to the pathogenesis and progression of 
T2D (Erukainure et al., 2017a). 
Fe2+-induced oxidative stress in the rat pancreatic homogenates led to an increased generation of 
superoxide, hydrogen peroxide, and hydroxy radicals. Diverse methods have been used to reduce the 
damage caused by oxidative stress   and the most potent of all is the use of natural endogenous 
antioxidants (Gil et al., 2017). The protective ability of catalase and SOD has been reported, SOD 
catalyzes the dismutation of superoxide to hydrogen peroxide and catalase in turn catalyzes the 
conversion of the resulting hydrogen peroxide to water and molecular oxygen (Liu and Kokare, 2017). 
The reduced catalase and SOD levels seen in the untreated groups (Figure 7.2.4 A and B) occurred 
as a result of oxidative injury caused by incubation with FeSO4. The ability of the extracts, especially 
the ethanol and aqueous extracts, to increase the activities of these enzymes in the treated groups 
portrays their antioxidant abilities. 
A reduction in the GSH levels has been reported in cases of pancreatic β-cell dysfunction which could 
ultimately lead to the complications of T2D (Tiwari et al., 2013). At the cellular level, GSH is a direct 
marker of oxidative stress and has been described as a first line of defence against oxidative damage 
(Erukainure et al., 2017a, Gil et al., 2017). The reduced levels of GSH seen in the untreated groups 
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indicates an occurrence of oxidative damage and this was increased upon incubation with the extracts 
(Figure 7.2.4 C). 
Lipid peroxidation has been well reported to occur due to iron overload and if the residual hydrogen 
peroxide is not removed by catalase leads to a build-up of hydroxy radicals through the Fenton 
reaction (Andrews, 1999, Rajpathak et al., 2009). These radicals cause lipid peroxidation on the cell 
membrane thereby leading to the production of reactive moieties such as acrolein, 4-hydroxynonenal, 
4-oxononenal and MDA (Saddala et al., 2013). High MDA levels have been reported in cases of T2D 
(Saddala et al., 2013). After incubation with FeSO4, there was an increase in levels of MDA which 
portrays an occurrence of lipid peroxidation (Figure 7.2.4 D). Treatment with the extracts was able 
to reduce the levels of MDA, an indication of the ability of the extract to reduce the level of lipid 
peroxidation in the tissues. This also relates with the ability of the extracts to increase the activity of 
catalase and SOD, and GSH levels thereby portraying the anti-peroxidative ability of the plant. 
Lipase and α-glucosidase are major enzymes in the breakdown of dietary lipids and carbohydrates. 
The effective inhibition of these enzymes can control the postprandial rise in blood glucose as well 
as minimize the accumulation of fat as seen in obese-T2D patients (Dalar et al., 2015, Wu et al., 
2013). The inhibitory effect of the extracts on these enzymes (Figure 7.2.5 A and B) demonstrates a 
delayed breakdown of carbohydrates and lipids in the intestine, thereby reducing the amount of 
glucose and fatty acids in the blood stream (Erukainure et al., 2017a). Thus, demonstrating an anti-
hyperglycemic and antilipolytic potential of B. diffusa aerial parts. This is further portrayed by the 
inhibition of glucose absorption in isolated intestinal tissues incubated with B. diffusa ethanol extract 
(Figure 7.2.6 A), also reducing the amount of glucose in the blood stream. Dietary glucose resulting 
from carbohydrate breakdown is rapidly absorbed in the small intestine, especially in the first quarter 
jejunal and duodenal regions (Rider et al., 1967, Riesenfeld et al., 1980). Its rapid absorption results 
in elevated blood glucose which could be detrimental, especially in diabetic individuals if not 
normalized (Hassan et al., 2010). Thus, the delayed carbohydrate digestion and concomitant 
inhibition of intestinal glucose absorption by B. diffusa extracts may validate its folkloric use in the 
treatment of diabetes and its complications. Similar effects have been reported for phenolics 
compounds (Toma et al., 2014, Inthongkaew et al., 2017), thus these activities may also be attributed 
to the total phenolic content of the extracts (Figure 7.2.1). 
Skeletal muscle plays an important role in the regulation of glucose homeostasis and carbohydrate 
metabolism (Sinacore and Gulve, 1993). They are particularly rich in GLUT-4 which aids glucose 
uptake (Satoh, 2014). Defects in muscle glucose uptake have been attributed to the pathogenesis of 
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insulin resistance (Sinacore and Gulve, 1993, Satoh, 2014), and is thus a major contributor to 
hyperglycemia. Stimulation of muscle glucose uptake regardless of insulin level has been recognized 
as a major therapy for glycemic control in T2D (Pereira et al., 2017). Thus, the increased glucose 
uptake in muscles incubated with B. diffusa ethanol extract (Figure 7.2.6 B) further indicates an anti-
hyperglycemic activity of the plant and its potential to modulate hyperglycemia. 
The presence of various bioactive compounds in the aerial part of the plant justifies the use of this 
plant in the treatment and management of various ailments. Thus, the phytoconstituents analysed by 
GC–MS gives a comprehensive presentation of the pharmaceutical and therapeutic potential of the 
plant. Previous studies on the leaves and root of the plant showed the presence of diverse 
phytochemical s which have been shown to possess anti-hyperglycemic abilities (Agrawal et al., 
2011, Shanmugapriya and Maneemegalai, 2017). The presence of xanthones and their derivatives in 
the ethanol extract of the aerial part of B. diffusa has been reported in this study (Figure 7.2.7, Table 
7.2.2). Xanthones have been shown to possess hypoglycemic abilities (Taher et al., 2016).  
Limonene also seen in the ethanol extract (Table 7.2.3) has been documented to act as an antioxidant 
by lowering oxidative stress in streptozotocin-induced diabetic rats (Bacanlı et al., 2017). The ethanol 
extract showed the presence of stigmasterol in the GC–MS analysis; interestingly, the role of 
stigmasterol in the fight against diseases such as cancer and diabetes has also been reported (Ramu et 
al., 2016). Plant sterols and esters have also been reported to possess potent anti-hyperglycemic and 
anti-obesogenic abilities (Hallikainen et al., 2011, Gylling et al., 2014). The observed anti-
hyperglycemic and anti-obesogenic abilities of B. diffusa could be as a result of the synergistic effect 
rendered by these constituents identified by GC–MS.  
Molecular docking studies were performed to gain further insight to the inhibition potentials of 
ethanol and aqueous extract. Docking result revealed ethanol and aqueous extracts showed inhibition 
potentials with 9-(4 methoxyphenyl) xanthene, xanthone and stigmasterol having highest binding 
affinities compared to other compounds. This is also evident in the hydrogen bond interactions 
(Tables 7.2.3 and 7.2.4) with amino acid residues. Similar protocol was performed by Bharatham, 
Bharatham, Park and Lee (Bharatham et al., 2008). For stigmasterol with the highest binding affinity, 
the amino acid residues are: ASN54, ASP57, GLU 58, ARG 84 and GLY 83. Comparing the 
inhibitory potential of compounds between α-glucosidase and lipase, Figure 7.2.8 A–C and D–F 
revealed that 9-(4 methoxyphenyl) xanthene and stigmasterol had the strongest binding affinities of -
12.7 and 11.8 kcal/mol respectively for lipase. The high binding energy of stigmasterol and 9-(4 
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methoxyphenyl) xanthene is very likely due to the hydroxyl and methoxy groups as well as 
hydrophobic interactions (Bharatham et al., 2008). The binding mode analysis of the compounds with 
some amino acid residues provides important information of catalytic site which is essential for 
proposing the catalytic mechanism. 
7.2.5 Conclusions 
These results demonstrate the antioxidant and antidiabetic activities of the aerial parts of B. diffusa as 
shown by its free radical scavenging, and carbohydrate and lipid digesting enzymes inhibitory 
activities. These activities can be attributed to the total phenolic content and identified bioactive 
compounds, particularly in the ethanol extract. The ability of the ethanol extract to inhibit small 
intestinal glucose absorption as well as stimulate muscle glucose uptake, further portrays the 





GENERAL DISCUSSION AND CONCLUSIONS 
8.1 General discussion 
In recent times, increase in mortality, morbidity and amputations in Africa has occurred due to the 
rise in diabetes mellitus. Sedentary lifestyle, dietary habits and urbanization have encouraged the 
spread of this disease (IDF, 2017). Microvascular and macrovascular complications linked to diabetes 
increase mortality in Africa and other parts of the world. A number of synthetic drugs are currently 
available for treatment of this disease, but the high cost and unwanted side effects makes them less 
desirable to people living with diabetes. In most undeveloped parts of Africa, people rely on 
traditional medicine as a means of avoiding the heavy monetary burden due to using expensive drugs. 
However, so many locals are more appreciative of traditional medicine since they claim, “it has been 
in use since the time of our fore-fathers”. The plants used in this study are plants which are used in 
traditional medicine for treatment of diabetes mellitus and they include: Alstonia boonei, Acalypha 
wilkesiana, Crassocephalum rubens, Bridelia ferruginea and Boerhaavia diffusa. The claims of most 
locals on the efficacy of these plants in treating diabetes led to the need to ascertain and confirm their 
hypothesis. Thus, this study was undertaken to give a sound scientific proof for future exploration of 
these plants in the pharmaceutical industry either in the crude form or as standard formulations for 
treatment of diabetes mellitus and its associated complications. This study was also done to identify 
the potent bioactive constituents responsible for anti-diabetic action and most importantly, to 
ascertain the level of toxicity of these plants at different doses, thereby enlightening the locals who 
still depend on traditional medicine for the treatment of diseases.  
To fully perform a detailed screening on these plants, the leaves, stem bark and root barks of A. 
boonei, A. wilkesiana and B. ferruginea were used while the aerial parts of C. rubens and B. diffusa 
were exploited. The first screening test done using these plant parts was to investigate the in vitro and 
ex vivo antioxidant potential of these plants since diabetic complications and etiology abounds due to 
actions of oxidative stress (Asmat et al., 2016). The crude extract (within a plant) with the best activity 
was selected for further analysis. 
Alstonia boonei was the first plant studied in this research. After various in vitro and ex vivo 
antioxidant and antidiabetic study on the crude extracts, the ethanol extract of the leaves was chosen 
for fractionation (Section 3.2). Four fractions were obtained after fractionation and the butanol 
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fraction in particular showed the best inhibition of key enzymes linked to type 2 diabetes and also 
showed potent glucose absorption inhibition in the small intestine together with induction of glucose 
uptake in peripheral tissues (Section 3.3). However, results for the in vivo assay showed the low dose 
(150 mg/kg bw) as more effective in eliciting glucose lowering and organ protection than the high 
dose (300 mg/kg bw) (Section 3.4). This could be due to the reported toxicity of a high dose of this 
fraction (Olanlokun and Olorunsogo, 2018). The low dose of the fraction also showed a better 
oxidative stress alleviating potential than the higher dose, which further verifies the toxicity of this 
fraction at a higher dose. The GC-MS analysis revealed the presence of potent phyto-phenols like 2-
hydroxy-1-(hydroxymethyl) ethyl hexadecanoate, which was predominantly present in the butanol 
and aqueous fraction. Interestingly, this compound has been reported to possess antioxidant and 
hypocholesterolemic activity (Jegadeeswari et al., 2012; Tyagia and Argawak, 2017). Considering 
the results from this study, it is suggested that further screening be done using a low dose of the 
fraction to fully verify the efficacy of the plant in alternate therapies for treatment of diabetes. 
Acalypha wilkesiana was the second plant to be investigated. The in vitro antioxidant activity of the 
extracts from different plant parts of A. wilkesiana was first done coupled with the free radical 
scavenging activity in Fe2+-induced oxidative pancreatic injury (Section 4.2). The ethanol extract of 
the root bark showed potent antioxidant effect in the ex vivo study. The crude ethanol extract obtained 
from the stem bark and root bark also showed promising -glucosidase and -amylase inhibitory 
potential (Section 4.3). GC-MS analysis revealed the presence of biologically active plant phenols 
such as xanthones and sterols which have been reported to elicit anti-diabetes activity (Ghosh et al., 
2015, Takato et al., 2017). 
Crassocephalum rubens the next plant investigated is a traditional leafy vegetable eaten as a salad in 
parts of Africa. Only solvent extracts from the aerial parts were investigated, and no fractionation was 
done due to the unavailability of the plant in large quantity. In vitro and ex vivo antioxidant and anti-
diabetic activity revealed the aqueous extract as the most potent extract (Section 5.2). No study in the 
literature has reported the presence of bioactive constituents in any part of C. rubens, so this study is 
the first of its kind to detect the presence of bioactive compounds in the leaves of this plant. LC-MS 
analysis of the aqueous extract revealed the presence of phytochemicals like sanguisorbic acid 
dilactone (an ellagitannin), 8-methoxy-6,7-methylenedioxycoumarin, 3,4-methylenedioxybenzoic 
acid, all of which have potent antioxidant and antidiabetic activity (García-Villalba et al., 2015; Tan 
et al., 2017, Tk, 2012, Venugopala et al., 2013). To further verify the antioxidant and antidiabetic 
potential, these bioactive constituents were docked with key antidiabetic (-glucosidase and lipase) 
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and antioxidants (superoxide dismutase, catalase and glutathione reductase) using in silico molecular 
docking techniques. Interestingly, sanguisorbic acid dilactone showed highest binding energies for 
all the enzymes tested, which could provide valuable information towards proposing the catalytic 
mechanism of these compounds (Section 5.2). Although LC-MS assay identified some 
phytochemicals present, there is need to isolate and characterize a pure compound before we can be 
sure of the bioactive constituents. The aqueous extract (since it showed best activity) was subjected 
to in vivo analysis using a type 2 diabetic animal model (Section 5.3). Interestingly the extract retained 
its anti-diabetic activity in a dose-dependent manner with no toxicity seen; this confirms an earlier 
report on the toxicity of C. rubens (Adjatin et al., 2013a). It was also able to ameliorate diabetes-
induced oxidative stress thereby rendering cardiac, renal and hepatoprotective effects in 
complications of diabetes (Section 5.4). In general, C. rubens could play a promising role in area of 
drug research.  
For Bridelia ferruginea, the crude ethanol extract of the leaves and root bark showed the best 
antioxidant and anti-diabetic activity (Section 6.2). The ethanol extract of the leaves was 
consequently fractionated, while the butanol fraction was discovered to show best results for the in 
vitro antioxidant and antidiabetic models (Section 6.3). The fraction also demonstrated potent anti-
diabetic effects and seems to do this via different mechanisms. This might be a result of the synergistic 
effects of the bioactive constituents present in the plant. GC-MS analysis of the extracts showed the 
presence of 32 compounds most of which were phenols. β-amyrin and -amyrin acetate found in this 
plant are known pentacyclic triterpenes found distributed in plants and have been reported to have 
diverse biological properties like anti-inflammatory, anti-microbial, cytotoxic, and trypanocidal 
activity amongst others (Vázquez et al., 2012). The anti-diabetic properties of these triterpenes have 
also been established (Nair et al., 2014; Santos et al., 2012). 4-phenylbenzophenone and lupenone 
identified in our study have also been reported to exhibit promising anti-diabetic activity (Lin et al., 
2009; Xu et al., 2014). Interestingly, β-amyrin, 4-phenylbenzophenone and lupenone had the highest 
binding energies for -glucosidase, -amylase and lipase enzymes respectively, which justified the 
biological properties of the compounds. With the observed anti-diabetic potential of the leaves of this 
plant, it can be recommended for further screening for possible usage as an anti-diabetic herbal drug, 
which could consequently be made available for public consumption.   
Boerhaavia diffusa was the last plant investigated. The aerial part of the plant was subjected to in 
vitro, ex vivo and in silico antioxidant and anti-diabetic assays.  Both ethanol and aqueous extracts 
exhibited remarkable enzyme inhibitory activities, which were significantly higher than ethyl acetate 
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extract and acarbose but was not comparable to orlistat. The ethanol extract portrayed a dose-
dependent inhibitory effect on jejunal glucose uptake and enhancement of muscle glucose uptake in 
isolated normal rat tissue (Section 7.2). 9-(4 methoxyphenyl) xanthene, xanthone and stigmasterol 
showed strong binding affinities for α-glucosidase and lipase enzymes using in silico molecular 
docking analysis. Due to the observed antioxidant and anti-diabetic activity of this plant, B. diffusa 
should be recommended to be eaten in soups and salads of individuals with high blood glucose levels.  
 
Figure 8.1: Pictures of the plants used in this study with their mechanism of action. a) Alstonia 
boonei, b) Acalypha wilkesiana c) Crassocephalum rubens, d) Bridelia ferruginea, e) Boerhaavia 
diffusa, TPC, Total phenol content, EtOH ext, Ethanol extract, ABBF, Alstonia boonei butanol 
fraction, GC-MS, Gas chromatography-mass spectroscopy, CRAQ, Crassocephalum rubens aqueous 
extract, LC-MS, Liquid chromatography-mass spectrometry, AP, Aerial parts, BFBF, Bridelia 





Figure 8.2: Schematic diagram showing the possible mechanisms of action of the investigated plants 
and their phytochemicals.  
8.2 General conclusions  
Three out of the five medicinal plants used in this study have exhibited promising anti-diabetic 
activity in all the models tested, even similar to the standard drug metformin and sometimes better 
than the action of glibenclamide. Except for one plant at a high dose, these plants did not show signs 
of toxicity for most of the parameters measured in this investigation. These findings are important for 
the relevant government agencies, pharmaceutical industries, scientific community and local people 
suffering from diabetes because it might open an avenue for the development of viable and cost 
effective anti-diabetic drugs.  
8.3 Recommendations  
The next step for confirmation of the anti-diabetic activity of these plants should entail human-based 
cell culture studies followed by a detailed clinical-trial studies in human subjects with diabetes 
mellitus. The identified bioactive compounds should be subjected to a thorough in vivo anti-diabetic 
study with the most effective fractions determined in this study. This may eventually lead to 
development of novel anti-diabetic drugs. However, toxicological studies in human-based cell lines 
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Bacanlı M, Anlar HG, Aydın S, Çal T, Arı N, Bucurgat ÜÜ, Başaran AA, Başaran N (2017). d-
limonene ameliorates diabetes and its complications in streptozotocin-induced diabetic rats. 
Food and Chemical Toxicology, 110, 434-442. 
Bahadoran Z, Mirmiran P, Azizi F (2013). Dietary polyphenols as potential nutraceuticals in 
management of diabetes: a review. Journal of Diabetes & Metabolic Disorders, 12, 1-9. 
Bahar E, Akter K-M, Lee G-H, Lee H-Y, Rashid H-O, Choi M-K, Bhattarai KR, Hossain MMM, Ara 
J, Mazumder K (2017). β-Cell protection and antidiabetic activities of Crassocephalum 
crepidioides (Asteraceae) Benth. S. Moore extract against alloxan-induced oxidative stress 
via regulation of apoptosis and reactive oxygen species (ROS). BMC complementary and 
alternative medicine, 17, 1-12. 
Bailey CJ, Day C (2004). Metformin: its botanical background. Practical diabetes, 21, 115-117. 
Bajaj S, Khan A (2012). Antioxidants and diabetes. Indian journal of endocrinology and metabolism, 
16, 267-271. 
Baker MJ, Trevisan J, Bassan P, Bhargava R, Butler HJ, Dorling KM, Fielden PR, Fogarty SW, 
Fullwood NJ, Heys KA (2014). Using Fourier transform IR spectroscopy to analyze 
biological materials. Nature protocols, 9, 1771-1791. 
Bakoma B, Berké B, Eklu-Gadegbeku K, Agbonon A, Aklikokou K, Gbeassor M, Creppy EE, Moore 
N (2013). Acute and sub-chronic (28 days) oral toxicity evaluation of hydroethanolic extract 




Bakoma B, Berké B, Eklu-Gadegbeku K, Agbonon A, Aklikokou K, Gbeassor M, Moore N (2014). 
Effect of Bridelia ferruginea Benth (Euphorbiaceae) ethyl acetate and acetone fractions on 
insulin resistance in fructose drinking mice. Journal of ethnopharmacology, 153, 896-899. 
Bakoma B, Eklu-Gadegbeku K, Agbonon A, Aklikokou K, Bassene E, Gbeassor M (2011). 
Preventive effect of Bridelia ferruginea Benth against high-fructose diet induced glucose 
intolerance, oxidative stress and hyperlipidemia in male Wistar rats. J Pharmacol Toxicol, 3, 
249-257. 
Balamurugan R, Duraipandiyan V, Ignacimuthu S (2011). Antidiabetic activity of γ-sitosterol isolated 
from Lippia nodiflora L. in streptozotocin induced diabetic rats. European journal of 
pharmacology, 667, 410-418. 
Bamforth CW, Muller R, Walker M (1993). Oxygen and oxygen radicals in malting and brewing: a 
review. journal of the American Society of Brewing Chemists, 51, 79-88. 
Barnes R. (2015). Blood Sugar Regulation [Online]. Available: 
http://sciencethemlkway.blogspot.com/2015/12/blood-sugar-regulation.html [Accessed 06 
November 2018 2018]. 
Barouch LA, Berkowitz DE, Harrison RW, O’donnell CP, Hare JM (2003). Disruption of leptin 
signaling contributes to cardiac hypertrophy independently of body weight in mice. 
Circulation, 108, 754-759. 
Baynes JW (1991). Role of oxidative stress in development of complications in diabetes. Diabetes, 
40, 405-412. 
Baynest HW (2015). Classification, pathophysiology, diagnosis and management of diabetes 
mellitus. Journal of Diabetes Metabolism, 6, 1-9. 
Benzie IF, Strain J (1999). [2] Ferric reducing/antioxidant power assay: Direct measure of total 
antioxidant activity of biological fluids and modified version for simultaneous measurement 
of total antioxidant power and ascorbic acid concentration. Methods in enzymology. Elsevier, 
15-27. 
Benzie IF, Strain JJ (1996). The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant 
power”: the FRAP assay. Analytical biochemistry, 239, 70-76. 
Bhandari MR, Jong-Anurakkun N, Hong G, Kawabata J (2008). α-Glucosidase and α-amylase 
inhibitory activities of Nepalese medicinal herb Pakhanbhed (Bergenia ciliata, Haw.). Food 
Chemistry, 106, 247-252. 
235 
 
Bharatham K, Bharatham N, Park KH, Lee KW (2008). Binding mode analyses and pharmacophore 
model development for sulfonamide chalcone derivatives, a new class of α-glucosidase 
inhibitors. Journal of Molecular Graphics and Modelling, 26, 1202-1212. 
Bhat M, Kothiwale SK, Tirmale AR, Bhargava SY, Joshi BN (2011). Antidiabetic properties of 
Azardiracta indica and Bougainvillea spectabilis: in vivo studies in murine diabetes model. 
Evidence-Based Complementary and Alternative Medicine, 2011, 1-9. 
Bhattacharyya A, Chattopadhyay R, Mitra S, Crowe SE (2014). Oxidative stress: an essential factor 
in the pathogenesis of gastrointestinal mucosal diseases. Physiological reviews, 94, 329-354. 
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012). Oxidative stress and antioxidant 
defense. World Allergy Organization Journal, 5, 9-19. 
Bloodsworth A, O’donnell VB, Freeman BA (2000). Nitric oxide regulation of free radical–and 
enzyme-mediated lipid and lipoprotein oxidation. Arteriosclerosis, thrombosis, and vascular 
biology, 20, 1707-1715. 
Bonadonna RC, Bonora E, Del Prato S, Saccomani MP, Cobelli C, Natali A, Frascerra S, Pecori N, 
Ferrannini E, Bier D (1996). Roles of glucose transport and glucose phosphorylation in 
muscle insulin resistance of NIDDM. Diabetes, 45, 915-925. 
Boora F, Chirisa E, Mukanganyama S (2014). Evaluation of nitrite radical scavenging properties of 
selected Zimbabwean plant extracts and their phytoconstituents. Journal of Food Processing, 
2014, 1-7. 
Bortolon LNM, Triz LDPL, De Souza Faustino B, De Sá LBC, Rocha DRTW, Arbex AK (2016). 
Gestational diabetes mellitus: new diagnostic criteria. Open Journal of Endocrine and 
Metabolic Diseases, 6, 13-19. 
Bouguerra R, Alberti H, Salem LB, Rayana CB, Atti J, Gaigi S, Slama CB, Zouari B, Alberti K 
(2007). The global diabetes pandemic: the Tunisian experience. European journal of clinical 
nutrition, 61, 160-165. 
Brewer GJ (2007). Iron and copper toxicity in diseases of aging, particularly atherosclerosis and 
Alzheimer’s disease. Experimental Biology and Medicine, 232, 323-335. 
Brunken U. SM, Dressler S., Janssen T., Thiombiano A. & Zizka, G. . (2008). West African plants - 
A Photo Guide. [Online]. Forschungsinstitut Senckenberg, Frankfurt/Main, Germany. 
Available: www.westafricanplants.senckenberg.de. [Accessed 7th November 2018]. 
Burkill HM, Dalziel JM (1985). The useful plants of west tropical Africa. Edition 2. Vol. 1: families 
AD, Australia, Royal Botanic Gardens 
236 
 
Büssing A, Stein G, Herterich-Akinpelu I, Pfüller U (1999). Apoptosis-associated generation of 
reactive oxygen intermediates and release of pro-inflammatory cytokines in human 
lymphocytes and granulocytes by extracts from the seeds of Acalypha wilkesiana. Journal of 
ethnopharmacology, 66, 301-309. 
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003). β-cell deficit and 
increased β-cell apoptosis in humans with type 2 diabetes. Diabetes, 52, 102-110. 
Canivell S, Gomis R (2014). Diagnosis and classification of autoimmune diabetes mellitus. 
Autoimmunity reviews, 13, 403-407. 
Cefalu WT (2009). Inflammation, insulin resistance, and type 2 diabetes: back to the future? Diabetes, 
58, 307-308. 
Cerf ME (2013). Beta cell dysfunction and insulin resistance. Frontiers in endocrinology, 4, 1-12. 
Cernea S (2011). The role of incretin therapy at different stages of diabetes. The review of diabetic 
studies: RDS, 8, 323-338. 
Chakraborti K, Handa S (1989). Antihepatotoxic activity of Boerhaavia diffusa. Indian drugs, 27, 
161-166. 
Chance B, Maehly A (1955). [136] Assay of catalases and peroxidases. Methods in enzymology, 2, 
764-775. 
Chang CL, Lin Y, Bartolome AP, Chen Y-C, Chiu S-C, Yang W-C (2013). Herbal therapies for type 
2 diabetes mellitus: chemistry, biology, and potential application of selected plants and 
compounds. Evidence-Based Complementary and Alternative Medicine, 2013, 1-33. 
Chase HP, Hoops SL, Archer PG, O'brien D (1989). Insulin-dependent Diabetes. Jama, 261, 1155-
1160. 
Chaudhury A, Duvoor C, Dendi R, Sena V, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, 
Montales MT (2017). Clinical review of antidiabetic drugs: Implications for type 2 diabetes 
mellitus management. Frontiers in endocrinology, 8, 1-12. 
Chauhan D, Shrivastava A, Patra S (2014). Diversity of leafy vegetables used by tribal peoples of 
Chhattisgarh, India. Int. J. Curr. Microbiol. App. Sci, 3, 611-622. 
Chawla A, Chawla R, Jaggi S (2016). Microvasular and macrovascular complications in diabetes 
mellitus: distinct or continuum? Indian journal of endocrinology and metabolism, 20, 546-
551. 
Chen H-L, Lan X-Z, Wu Y-Y, Ou Y-W, Chen TC, Wu W-T (2017). The antioxidant activity and 
nitric oxide production of extracts obtained from the leaves of Chenopodium quinoa Willd. 
BioMedicine, 7, 24-28. 
237 
 
Cheng Z, Ren J, Li Y, Chang W, Chen Z (2003). Establishment of a quantitative structure–activity 
relationship model for evaluating and predicting the protective potentials of phenolic 
antioxidants on lipid peroxidation. Journal of pharmaceutical sciences, 92, 475-484. 
Chime SA, Ugwuoke E, Onyishi I, Brown S, Onunkwo G (2013). Formulation and evaluation of 
Alstonia boonei stem bark powder tablets. Indian journal of pharmaceutical sciences, 75, 
226-230. 
Chiu C-J, Taylor A (2011). Dietary hyperglycemia, glycemic index and metabolic retinal diseases. 
Progress in retinal and eye research, 30, 18-53. 
Cho N, Shaw J, Karuranga S, Huang Y, Da Rocha Fernandes J, Ohlrogge A, Malanda B (2018). IDF 
Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. 
Diabetes research and clinical practice, 138, 271-281. 
Choe E, Min DB (2006). Chemistry and reactions of reactive oxygen species in foods. Critical 
Reviews in Food Science and Nutrition, 46, 1-22. 
Choi K, Kim Y-B (2010). Molecular mechanism of insulin resistance in obesity and type 2 diabetes. 
The Korean journal of internal medicine, 25, 119-129. 
Choudhury H, Pandey M, Hua CK, Mun CS, Jing JK, Kong L, Ern LY, Ashraf NA, Kit SW, Yee TS 
(2017). An update on natural compounds in the remedy of diabetes mellitus: A systematic 
review. Journal of Traditional and Complementary Medicine, 8, 361-376. 
Chowdhury P, Soulsby M (2002). Lipid peroxidation in rat brain is increased by simulated 
weightlessness and decreased by a soy-protein diet. Annals of Clinical & Laboratory Science, 
32, 188-192. 
Chude M, Orisakwe O, Afonne O, Gamaniel K, Vongtau O, Obi E (2001). Hypoglycaemic effect of 
the aqueous extract of Boerhavia diffusa leaves. Indian Journal of Pharmacology, 33, 215-
216. 
Chukwuma CI, Mopuri R, Nagiah S, Chuturgoon AA, Islam MS (2017). Erythritol reduces small 
intestinal glucose absorption, increases muscle glucose uptake, improves glucose metabolic 
enzymes activities and increases expression of Glut-4 and IRS-1 in type 2 diabetic rats. 
European Journal of Nutrition, 57, 2431-2444. 
Chung SS, Ho EC, Lam KS, Chung SK (2003). Contribution of polyol pathway to diabetes-induced 
oxidative stress. Journal of the American Society of Nephrology, 14, S233-S236. 
Cobb J, Dukes I (1998). Recent advances in the development of agents for the treatment of type 2 
diabetes. Annual reports in medicinal chemistry, 33, 213-222. 
238 
 
Conway BN, Han X, Munro HM, Gross AL, Shu X-O, Hargreaves MK, Zheng W, Powers AC, Blot 
WJ (2018). The obesity epidemic and rising diabetes incidence in a low-income racially 
diverse southern US cohort. PloS one, 13, e0190993. 
Costacou T, Evans RW, Orchard TJ (2011). High-density lipoprotein cholesterol in diabetes: is higher 
always better? Journal of clinical lipidology, 5, 387-394. 
Craft BD, Kerrihard AL, Amarowicz R, Pegg RB (2012). Phenol‐based antioxidants and the in vitro 
methods used for their assessment. Comprehensive Reviews in Food Science and Food 
Safety, 11, 148-173. 
Crook M (2004). Type 2 diabetes mellitus: a disease of the innate immune system? An update. 
Diabetic Medicine, 21, 203-207. 
Dal S, Sigrist S (2016). Protective effect of antioxidants consumption on diabetes, hepatic and 
vascular complications. Diseases, 3, 1-51. 
Dalar A, Uzun Y, Mukemre M, Turker M, Konczak I (2015). Centaurea karduchorum Boiss. from 
Eastern Anatolia: Phenolic composition, antioxidant and enzyme inhibitory activities. 
Journal of Herbal Medicine, 5, 211-216. 
Dansi A, Adjatin A, Adoukonou-Sagbadja H, Faladé V, Yedomonhan H, Odou D, Dossou B (2008). 
Traditional leafy vegetables and their use in the Benin Republic. Genetic Resources and Crop 
Evolution, 55, 1239-1256. 
Dansi A, Vodouhè R, Azokpota P, Yedomonhan H, Assogba P, Adjatin A, Loko Y, Dossou-Aminon 
I, Akpagana K (2012). Diversity of the neglected and underutilized crop species of 
importance in Benin. The scientific world journal, 2012, 1-19. 
De Felice FG, Ferreira ST (2014). Inflammation, defective insulin signaling, and mitochondrial 
dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer 
disease. Diabetes, 63, 2262-2272. 
De Luca V, Salim V, Atsumi SM, Yu F (2012). Mining the biodiversity of plants: a revolution in the 
making. Science, 336, 1658-1661. 
Defronzo RA (2011). Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 
2 diabetes. Diabetes Care, 34, 789-794. 
Defronzo RA (2015). Pathogenesis of type 2 diabetes mellitus. International Textbook of Diabetes 
Mellitus. 4th ed. Chichester (UK): Wiley Blackwell, 371-400. 
Defronzo RA, Tripathy D (2009). Skeletal muscle insulin resistance is the primary defect in type 2 
diabetes. Diabetes care, 32, S157-S163. 
239 
 
Derubertis FR, Craven PA (1994). Activation of protein kinase C in glomerular cells in diabetes: 
mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes, 43, 
1-8. 
Devendra D, Liu E, Eisenbarth GS (2004). Type 1 diabetes: recent developments. BMJ: British 
Medical Journal, 328, 750-754. 
Dewanjee S, Maiti A, Sahu R, Dua TK, Mandal V (2011). Effective control of type 2 diabetes through 
antioxidant defense by edible fruits of Diospyros peregrina. Evidence-Based Complementary 
and Alternative Medicine, 2011, 1-7. 
Dhulasavant V, Shinde S, Pawar M, Naikwade N (2010). Antihyperlipidemic activity of 
Cinnamomum tamala Nees. on high cholesterol diet induced hyperlipidemia. Int J Pharm 
Tech Res, 2, 2517-2521. 
Diplock AT (1997). Will the ‘good fairies’ please prove to us that vitamin E lessens human 
degenerative disease? Free radical research, 27, 511-532. 
Do TML, Truong AV, Vo TN, Pinnock TG, Pratt LM, Guillaume D, Nguyen KPP (2013). New 
derivatives from the aerial parts of Boerhaavia diffusa L.(Nyctaginaceae). Phytochemistry 
Letters, 6, 544-551. 
Du X-L, Edelstein D, Dimmeler S, Brownlee M (2001). Hyperglycemia inhibits endothelial nitric 
oxide synthase (enos) acitivity by altering post-translational modification at the Akt site  
Diabetes, 108, 1341-1348. 
Du X-L, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000). 
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine 
pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 
glycosylation. Proceedings of the National Academy of Sciences, 97, 12222-12226. 
Duraipandiyan V, Ayyanar M, Ignacimuthu S (2006). Antimicrobial activity of some ethnomedicinal 
plants used by Paliyar tribe from Tamil Nadu, India. BMC complementary and alternative 
medicine, 6, 1-7. 
Eddouks M, Chattopadhyay D, De Feo V, Cho WC (2012). Medicinal plants in the prevention and 
treatment of chronic diseases. Evidence-Based Complementary and Alternative Medicine, 
2012, 1-3. 
Edelman SV, Polonsky WH (2017). Type 2 diabetes in the real world: the elusive nature of glycemic 
control. Diabetes care, 40, 1425-1432. 
240 
 
Egloff M-P, Marguet F, Buono G, Verger R, Cambillau C, Van Tilbeurgh H (1995). The 2.46. ANG. 
Resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl 
phosphonate. Biochemistry, 34, 2751-2762. 
Eid HM, Haddad PS (2014). Mechanisms of action of indigenous antidiabetic plants from the Boreal 
Forest of Northeastern Canada. Advances in Endocrinology, 2014, 1-11. 
Einarson TR, Acs A, Ludwig C, Panton UH (2018). Prevalence of cardiovascular disease in type 2 
diabetes: a systematic literature review of scientific evidence from across the world in 2007–
2017. Cardiovascular diabetology, 17, 1-19. 
El-Houri RB, Mortier J, Murgueitio MS, Wolber G, Christensen LP (2015). Identification of PPARγ 
agonists from natural sources using different in silico approaches. Planta medica, 81, 488-
494. 
El-Kamali HH (2009). Medicinal plants in east and central Africa: challenges and constraints. 
Ethnobotanical Leaflets, 13, 364-369. 
Eleazu CO, Eleazu KC, Chukwuma S, Essien UN (2013). Review of the mechanism of cell death 
resulting from streptozotocin challenge in experimental animals, its practical use and 
potential risk to humans. Journal of Diabetes & Metabolic Disorders, 12, 1-7. 
Ellman GL (1959). Tissue sulfhydryl groups. Archives of biochemistry and biophysics, 82, 70-77. 
Enechi O, Oluka HI, Ugwu PO (2014). Acute toxicity, lipid peroxidation and ameliorative properties 
of Alstonia boonei ethanol leaf extract on the kidney markers of alloxan induced diabetic rats. 
African Journal of Biotechnology, 13, 678-682. 
Erukainure OL, Mopuri R, Oyebode OA, Koorbanally NA, Islam MS (2017a). Dacryodes edulis 
enhances antioxidant activities, suppresses DNA fragmentation in oxidative pancreatic and 
hepatic injuries; and inhibits carbohydrate digestive enzymes linked to type 2 diabetes. 
Biomedicine & Pharmacotherapy, 96, 37-47. 
Erukainure OL, Oyebode OA, Sokhela MK, Koorbanally NA, Islam MS (2017b). Caffeine–rich 
infusion from Cola nitida (kola nut) inhibits major carbohydrate catabolic enzymes; abates 
redox imbalance; and modulates oxidative dysregulated metabolic pathways and metabolites 
in Fe 2+-induced hepatic toxicity. Biomedicine & Pharmacotherapy, 96, 1065-1074. 
Espineli DL, Agoo EMG, Del Fierro RS, Shen C-C, Ragasa CY (2014). Cytotoxic and antimicrobial 
compounds from Cinnamomum cebuense Kosterm.(Lauraceae). Pharmaceutical Chemistry 
Journal, 48, 598-602. 
241 
 
Espinosa RR, Inchingolo R, Alencar SM, Rodriguez-Estrada MT, Castro IA (2015). Antioxidant 
activity of phenolic compounds added to a functional emulsion containing omega-3 fatty 
acids and plant sterol esters. Food chemistry, 182, 95-104. 
Eze E, Mohammed A, Musa K, Tanko Y, Isa A (2012). Effect of ethanolic leaf extract of" 
Mucunapruriens"(fabaceae) on lipid profile in alloxan-induced diabetic wistar rats. British 
Journal of Pharmacology and Toxicology, 3, 102-109. 
Ezeani C, Ezenyi I, Okoye T, Okoli C (2017). Ocimum basilicum extract exhibits antidiabetic effects 
via inhibition of hepatic glucose mobilization and carbohydrate metabolizing enzymes. 
Journal of intercultural ethnopharmacology, 6, 22-28. 
Farag M, Ahmed WJ, Foud I, Mohammed MS (2016). The Role of Medicinal Plants in the Treatment 
of Type-2 Diabetes. Advanced Journal of Pharmacie and Life science Research, 2, 1-8. 
Farese RV, Sajan MP, Standaert ML (2005). Insulin-sensitive protein kinases (atypical protein kinase 
C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Experimental 
biology and medicine, 230, 593-605. 
Farook SM, Atlee WC, Karimulla S, Davey MS (2011). Assessment of antidiabetic potential of 
Caesalpinia digyna Rottler root extract in streptozotocin induced diabetic rats. International 
Journal of Pharmaceutical Sciences and Research, 2, 675-684. 
Farzaei F, Morovati MR, Farjadmand F, Farzaei MH (2017). A mechanistic review on medicinal 
plants used for diabetes mellitus in traditional Persian medicine. Journal of evidence-based 
complementary & alternative medicine, 22, 944-955. 
Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G (2011). The role 
of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro-and macrovascular 
complications: avenues for a mechanistic-based therapeutic approach. Current diabetes 
reviews, 7, 313-324. 
Fonseca VA (2009). Defining and characterizing the progression of type 2 diabetes. Diabetes care, 
32, S151-S156. 
Forbes JM, Cooper ME (2013). Mechanisms of diabetic complications. Physiological reviews, 93, 
137-188. 
Ford ES (2005). Risks for all-cause mortality, cardiovascular disease, and diabetes associated with 
the metabolic syndrome: a summary of the evidence. Diabetes care, 28, 1769-1778. 
Forouhi NG, Wareham NJ (2010). Epidemiology of diabetes. Medicine, 38, 602-606. 
242 
 
Fotie J, Bohle DS (2006). Pharmacological and biological activities of xanthones. Anti-Infective 
Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Infective 
Agents), 5, 15-31. 
Fowler MJ (2008). Microvascular and macrovascular complications of diabetes. Clinical diabetes, 
26, 77-82. 
Francisqueti FV, Chiaverini LCT, Santos KCD, Minatel IO, Ronchi CB, Ferron AJT, Ferreira ALA, 
Corrêa CR (2017). The role of oxidative stress on the pathophysiology of metabolic 
syndrome. Revista da Associação Médica Brasileira, 63, 85-91. 
Fu Z, R Gilbert E, Liu D (2013). Regulation of insulin synthesis and secretion and pancreatic Beta-
cell dysfunction in diabetes. Current diabetes reviews, 9, 25-53. 
Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, Ma C, Fontanillas 
P, Moutsianas L, Mccarthy DJ (2016). The genetic architecture of type 2 diabetes. Nature, 
536, 41-47. 
Fukai T, Ushio-Fukai M (2011). Superoxide dismutases: role in redox signaling, vascular function, 
and diseases. Antioxidants & redox signaling, 15, 1583-1606. 
Furtado LM, Somwar R, Sweeney G, Niu W, Klip A (2002). Activation of the glucose transporter 
GLUT4 by insulin. Biochemistry and Cell Biology, 80, 569-578. 
Gach K, Długosz A, Janecka A (2015). The role of oxidative stress in anticancer activity of 
sesquiterpene lactones. Naunyn-Schmiedeberg's archives of pharmacology, 388, 477-486. 
Gaikwad BS, Krishna Mohan G, Sandhya Rani M (2014). Phytochemicals for diabetes management. 
Pharmaceutical Crops, 5, 11-28. 
García-Villalba R, Espín JC, Aaby K, Alasalvar C, Heinonen M, Jacobs G, Voorspoels S, KoivumäKi 
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